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Many eukaryotic proteins are attached to the cell membrane via Glycosylphosphatidyl-
inositol (GPI) anchors that are added post-translationally to the C-terminus of proteins. These 
complex structures contain a highly conserved carbohydrate core, variable number of 
phosphate residues and lipid chains. The functions of GPI-anchored proteins (GPI-APs) are 
widespread, including participation in signal transduction, immune response regulation, lipid 
raft partitioning and prion disease pathogenesis. However, the effect of the GPI-anchor itself 
in these processes still remains unclear. Due to their high complexity and metabolic expense, 
a function beyond membrane anchoring has been anticipated.  
GPI-APs are not accessible in a homogeneous form and high amounts by isolation from 
natural sources, making investigation of the GPI effects on the function and structure of the 
protein difficult. Some progress has been made in the field of total GPI synthesis and small 
GPI-anchored peptides are now accessible by chemical synthesis, but these strategies are 
limited regarding peptide length by the scope of solid-phase peptide synthesis (SPPS). So far, 
no method is available for the routine generation of homogeneous GPI-APs for structural or 
biological studies.  
In this work, different semi-synthetic, intein-based methods have been investigated and 
established for the generation of homogeneous GPI-anchored proteins, Figure 1. The first 
method, Expressed Protein Ligation (EPL, a), utilizes the GyraseA intein from 
Mycobacterium xenopi for the generation of protein α-thioesters which are then ligated to 
cysteine-containing GPI-anchors. The second method, Protein Trans-Splicing (PTS, b) uses 
the naturally split DnaE intein from Nostoc punctiforme. For PTS, proteins of interest are 
expressed in E. coli as fusion proteins with the larger N-terminal split intein fragment Npu
N
, 
whereas the shorter (39 amino acids) C-terminal fragment Npu
C
 is synthesized by SPPS and 
ligated to a cysteine-containing GPI-anchor. Subsequently both fragments are combined and 
trans-splicing takes place initiated by association of the fragments and folding into a full 
intein structure, ligating both exteins together with a native peptide bond. This method 
requires the introduction of some extra amino acid residues which are essential for the 
splicing reaction.  
Both EPL and PTS were successfully established for the anchoring of eGFP as a model 
protein to biotin and a GPI anchor containing the full pseudo-pentasaccharide core structure, 
phosphates, and a simplified monolipid chain. Application of these strategies to the semi-
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synthesis of the naturally GPI-anchored proteins Thy-1 and prion protein (PrP) showed, 
however, that thioester generation is inefficient under denaturing conditions, making the EPL 
strategy less useful for our purpose. PTS on the other hand was efficient under denaturing 
conditions, although slower. In comparison to the natural conditions, this strategy suffered 
from insufficient availability of the synthetic GPI-coupled peptide due to a high synthetic 
effort required for its synthesis.  
Therefore, a third semi-synthetic, intein-based method was developed: One-Pot-Ligation 
(OPL, c). In OPL, the same fusion proteins required for PTS can be used, but they are 
combined with a mutated C-terminal fragment, Npu
C
(AA), in which two essential amino acid 
residues are exchanged for alanines, rendering the C-terminus of the split intein function-less. 
Instead, with this system, a protein intermediate can be captured and protein thioesters can be 
generated in situ by the additions of external thiol reagents, with subsequent ligation of Cys-
GPI in a one-pot manner. This strategy was successfully applied for anchoring both soluble 
and denatured proteins (eGFP, Thy-1, PrP and IL-2) to biotin, dimannose and mono- and 
bilipidated GPI-anchors. It is more versatile towards the generation of GPI-AP libraries, 
however exhibited some immature protein thioester hydrolysis which could largely be 
overcome by the use of more stable thiols.  
 
Figure 1. Retrosynthetic Analysis of the Semi-Synthesis of GPI-Anchored Proteins using intein-based 
strategies. a) Expressed Protein Ligation (EPL), b) Protein Trans-Splicing (PTS), c) One-Pot-Ligation 
(OPL).  
Additional challenges arose from characterization of these highly complex protein-
carbohydrate-lipid conjugates, carrying multiple charges, in LC-MS. Although progress could 
be made towards this goal, a complete characterization was not achieved for each protein.  
Initial structural characterization of the obtained GPI-APs was performed for eGFP-GPI 
using circular dichroism (CD). This study showed that using any of the three methods 




Viele eukaryotische Proteine sind mittels Glycosylphosphatidylinositol (GPI) Ankern an der 
Zelle verankert, die post-translational an den C-terminus des Proteins angehängt werden. 
Diese komplexen Strukturen beinhalten einen hochkonservierten Kohlenhydratkern, variable 
Zahl an Phosphatresten sowie Lipidketten. GPI-verankerte Proteine (GPI-APs) haben sehr 
diverse Funktionen, unter anderem sind sie beteiligt an der Signaltransduktion, 
Immunantwortregulation, Lipid-Raft-Partitionierung sowie der Pathogenese von 
Prionenkrankheiten. Der Effekt des GPI-Ankers selbst auf diese Prozesse ist jedoch immer 
noch unklar. Aufgrund ihrer hohen Komplexität und metabolisch aufwendigen Herstellung in 
der Zelle geht man von einer über die reine Membranverankerung hinausgehenden Funktion 
aus.  
GPI-APs können nicht in homogener Form und großen Mengen durch Isolation aus 
natürlichen Quellen gewonnen werden, was die Erforschung des Effekts des GPI-Ankers auf 
die Funktion und Struktur von Proteinen erschwert. Durch erzielte Fortschritte auf dem 
Gebiet der Totalsynthese von GPIs können mittlerweile kleine GPI-verankerte Peptide 
chemisch hergestellt werden. Diese Strategien werden jedoch durch die Möglichkeiten der 
Festphasen-Peptidsynthese (SPPS) in Bezug auf die Peptidlänge limitiert. Bisher sind keine 
Methoden für die routinemäßige Herstellung homogener GPI-APs für strukturelle und 
biologische Studien verfügbar.  
In dieser Arbeit wurden verschiedene semi-synthetische, intein-basierte Methoden für die 
Herstellung homogener GPI-verankerter Proteine untersucht und etabliert, Abbildung 1. Die 
erste Methode, Expressed Protein Ligation (EPL, a), nutzt das GyraseA-Intein aus 
Mycobacterium xenopi für die Herstellung von Protein-α-Thioestern, die dann mit Cystein-
tragenden GPI-Ankern ligiert werden. Die zweite Methode, Protein-Trans-Splicing (PTS, b), 
nutzt das natürliche gespaltene Intein DnaE aus Nostoc punctiforme. Für PTS werden die 
Zielproteine als Fusionsproteine mit dem größeren N-terminalen Fragment, Npu
N
, des 
gespaltenen Inteins in E. coli exprimiert, während das kürzere (39 Aminosäuren lange) C-
terminale Fragment Npu
C
 mittels SPPS synthetisiert wird, gefolgt von Ligation zu einem 
Cystein-tragenden GPI-Anker. Anschließend werden beide Fragmente kombiniert und die 
durch Assoziation initiierte Trans-Splicing-Reaktion findet statt durch Faltung der Fragmente 
in eine komplette Inteinstruktur und mit dem Ergebnis der Ligation beider Exteine. Diese 
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Methode erfordert die Insertion einiger zusätzlicher Aminosäuren in das Endprodukt, die für 
die Splicing-Reaktion essentiell sind.  
Beide Methoden, EPL und PTS, wurden erfolgreich etabliert für die Verankerung von eGFP 
als Modellprotein an Biotin sowie an einen GPI-Anker, der die vollständige 
Pseudopentasaccharid-Kernstruktur, Phosphate und eine vereinfachte Monolipidkette enthält. 
Die Anwendung dieser Strategie auf natürliche GPI-verankerte Proteine Thy-1 und Prion-
Protein (PrP), die nur in unlöslicher Form erhalten werden konnten, zeigte allerdings, dass die 
Thioesterbildung unter denaturierenden Bedingungen ineffizient ist, was die EPL-Strategie 
für unsere Ziele wenig nützlich macht. PTS war hingegen effizient unter denaturierenden 
Bedingungen, wenn auch langsamer als unter nativen Bedingungen; jedoch stellte die 
unzureichende Verfügbarkeit der notwendigen synthetischen GPI-gekoppelten Peptide ein 
Problem dar, die aus einem hohen synthetischen Aufwand für deren Generierung resultierte.  
Daher wurde eine dritte semi-synthetische, intein-basierte Methode entwickelt: One-Pot-
Ligation (OPL, c). Für OPL können die gleichen Fusionsproteine genutzt werden wie für 
PTS, sie werden jedoch mit einem mutierten C-terminalen Fragment, Npu
C
(AA), kombiniert, 
in welchem zwei essentielle Aminosäuren gegen Alanine ausgetauscht wurden, wodurch der 
C-terminus des gespaltenen Inteins für ein Trans-Splicing funktionslos wird.  
 
 
Abbildung 1. Retrosynthetische Analyse der Semi-Synthese GPI-verankerter Proteine mittels intein-
basierter Strategien. a) Expressed Protein Ligation (EPL), b) Protein Trans-Splicing (PTS), c) One-Pot-
Ligation (OPL).  
 
Stattdessen werden generierte Protein-Intermediate in diesem System durch die Zugabe 
externer Thiol-Reagenzien in situ zu Protein-Thioestern umgewandelt, gefolgt von der 
Ligation zu Cys-GPI in einem Topf. Diese Strategie wurde erfolgreich angewendet, um 
sowohl lösliche als auch unlösliche Proteine (eGFP, Thy-1, PrP und IL-2) zu Biotin, 
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Dimannose, sowie mono- und bilipidierten GPI-Ankern zu ligieren. Sie ist vielfältiger 
anwendbar für die Generierung von Bibliotheken von GPI-APs, zeigte jedoch ein gewisses 
Ausmaß an vorzeitiger Protein-Thioester-Hydrolyse, was aber durch die Nutzung stabilerer 
Thiol-Reagenzien zu großen Teilen überwunden werden konnte. 
 
Eine zusätzliche Herausforderung in dieser Arbeit stellte die Charakterisierung dieser 
hochkomplexen Protein-Kohlenhydrat-Lipid-Konjugate mit mehreren unterschiedlichen 
Ladungen in LC-MS dar. Obwohl hier große Fortschritte erzielt werden konnten, konnte eine 
vollständige Charakterisierung nicht für jedes Protein erreicht werden.  
Erste Untersuchungen der Struktur von eGFP-Ligationsprodukten unter Nutzung von 
Zirkulardichroismus (CD) zeigten, dass bei Nutzung keiner der drei verwendeten Strategien 











APC     Antigen presenting cell 
APS     Ammonium persulfate 
BCA     Bicinchoninic Acid 
bp     base pair 
BSA     Bovine Serum Albumin  
CBD     Chitin Binding Domain 
CD     Cluster of differentiation 
CD      Circular Dichroism 
CJD     Creutzfeldt-Jakob-disease 
CoA     Coenzyme A 
CV     Column Volume 
Da     Dalton 
DAC     Diammonium hydrogen citrate 
DHAP    2,5-Dihydroxyacetophenon 
DHB     2,5-Dihydroxybenzoic acid 
DIC     Diisopropylcarbodiimide 
DNA    Deoxyribonucleic acid 
dNTPs    deoxynucleotides (any base) 
DTT     Dithiothreitol 
ECL     Enhanced Chemiluminescence 
EDTA    Ethylenediaminetetraacetic acid 
ER endoplasmic reticulum 
ESI-QTOF-MS Electrospray Ionization – Quadrupole – Time Of Flight 
Mass Spectrometry 
FA     Formic Acid 
FPLC    Fast Protein Liquid Chromatography 
fw     forward 
Glc     Glucose 
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GlcN    Glucosamine 
GlcNAc    N-acetylglucosamine 
GPI     Glycosylphosphatidylinositol 
GPI-AP    GPI-anchored protein 
HABA    4'-hydroxyazobenzene-2-carboxylic acid 
HRP     Horseradish peroxidase 
IFN     Interferon 
IgG     Immunoglobulin G 
IL     Interleukin 
IMPACT Intein-Mediated Purification with an Affinity Chitin-
binding Tag 
i.e.     id est 
Int     Intein 
IPTG    Isopropyl-β-D-thiogalactopyranosid 
mAb     Monoclonal antibody 
MALDI-TOF-MS Matrix-assisted Laser Desorption / Ionization – Time Of 
Flight mass spectrometry 
Man     Mannose 
MESNA    Sodium 2-Mercaptoethanesulfonate 
MMBA    4-(Mercaptomethyl)benzoic acid 
MMP    Methyl 3-mercaptopropionate 
MPAA     4-Mercaptophenylacetic acid 
Nd:YAG laser   Neodymium-doped yttrium aluminum garnet laser 
NK cells    Natural killer cells 
Npu     Nostoc punctiforme 
NTA     Nitrilotriacetic acid 
OD600    Optical Density at 600 nm 
o/n     overnight 
PBS(-T)    Phosphate buffered saline (with 0.1% Tween 20) 
PEG     Polyethylene glycol 
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PGAP    Post-GPI-attachment to proteins 
PIG     Phosphatidylinositol glycan 
PMSF    Phenylmethylsulfonyl fluoride 
POI     Protein of interest 
PrP     Prion protein 
PTS     Protein-Trans-Splicing 
PVDF    Polyvinylidene difluoride 
rev reverse 
RP-HPLC Reverse Phase High Performance Liquid 
Chromatography  
rpm     rounds per minute 
RT     room temperature 
SA     Sinapinic acid 
SDS-PAGE    Sodiumdodecylsulfate Polyacrylamide gel 
electrophoresis 
SEC     Size Exclusion Chromatography  
SeMBA    4-(Selenomercaptomethyl)benzoic acid 
TCGF    T-cell growth factor 
TCEP    Tris(2-carboxyethyl)phosphine 
TEMED    N,N,N',N'-Tetramethylethylendiamin 
TBS(-T)    Tris-Buffered Saline (with 0.1% Tween 20)  
TFA     Trifluoroacetic acid  
TIC     Total Ion Count 
TIPS     Triisopropylsilane  
tR     Retention time 
TSE     Transmissible spongiform encephalopathy 
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In living organisms, all information is stored in DNA within the cell. According to the 
central dogma of molecular biology,
1,2
 this information flows from DNA to RNA in a process 
called transcription that is followed by the flow from RNA to protein via translation,
2
 Figure 
1.1. Both are directly template-driven processes in which one linear structure is converted into 
another linear structure, even though two different alphabets are used: on one hand the set of 
the nucleobases in DNA and RNA (adenine, thymine/uracil, guanine and cytosine) and on the 
other hand the set of 20 proteinogenic amino acids. Both alphabets are connected to each 
other via the genetic code.
3
 With four bases and 20 amino acids present in the standard 
repertoire, three bases are at least needed to code for one amino acid (4
2
 = 16 is not sufficient, 
4
3
 = 64 possible translations), forming a codon. The genetic code is non-overlapping, 
degenerate and almost universal,
2,4,5
 meaning that some amino acids are encoded by more 
than one codon.  
 
 
Figure 1.1. The Central Dogma of Molecular 
Biology: DNA is transcribed into mRNA, which is 
then translated into proteins. Higher variety is 
achieved by the addition of posttranslational 
modification (PTMs) to proteins, such as 





In prokaryotic organisms the transfer of 
information from DNA to mRNA and to 
protein is mostly linear, just as shown in 
Figure 1.1, although PTMs exist also in 
prokaryotes.
6
 In eukaryotes, however, 
different variations can occur within these 
processes. At the DNA level (or 
epigenetics level), DNA modifications 
such as methylation can influence gene 
expression without altering the genome 
itself by the formation of the chromatin 




At the mRNA, or post-transcription level, 
mRNA splicing can take place.




Pre-mRNA is directly transcribed from the template DNA of protein-coding genes 
containing introns (intragenic region) in between exons (expressed region). Introns are 
removed utilizing Watson-Crick base-pairing between the intron and an snRNA in the 
spliceosome, generating mature mRNA.
8
 A variation of mRNA splicing is alternative 
splicing, where some exons can be skipped due to weaker exon signals at some sites or 




 Post-Translational Modifications 1.1
Additionally to the sequence-based diversity, epigenetic regulation and mRNA splicing, 
post-translational modifications (PTMs) of proteins confer an even higher degree of 
complexity to the proteome of a cell (Figure 1.1), increasing the number of protein species by 
two to three orders of magnitude compared to the number expected from the genome.
10-13
 
These modifications expand the functional scope of the proteome, especially regarding 
activity, conformation and localization of proteins, as well as interactions with other 
proteins.
11,13,14




A post-translational modification is defined as a covalent modification of an amino acid 
residue in the protein chain.
13,16
 It can be conferred either by enzymatic attachment of 
functional groups or other fragments, by chemical reactions breaking the peptide backbone of 
the peptide, i.e. by proteases or autocatalytic cleavage,
10
 or by spontaneous chemical reactions 
via the encounter of a reactive metabolite.
17
 These modifications can occur directly after 
translation next to the ribosome, in special cell organelles, or even outside of the producing 
cell. In comparison to gene expression, the post-translational modification of proteins is less 
tightly regulated,
12
 making it faster and more dynamic to changes in the environment.
18
 PTMs 
are therefore often used as disease markers.
11
 However, due to the vast diversity of PTMs, 
elucidation of their structure and function is difficult.
12
 Nowadays, characterization of PTMs 
is mostly achieved by western blot or mass spectrometric methods, i.e. MS-based proteomics 
and LC-MS/MS techniques.
14,18,19
 The localization of most PTMs is defined by recognition 
sites called sequons, of which generally not all are used at all times. This means that PTMs 








The most common PTMs include phosphorylation, acetylation, glycosylation, 
ubiquitination, hydroxylation, methylation, lipidation and proteolysis of proteins,
6,10-13,16
 
although many more exist.
14,15,19
 Protein phosphorylation takes place at Ser/Thr/Tyr residues, 
is mediated by protein kinases
13
 and is often part of switching protein activity on or off,
16
 and 
signaling by inducing changes in protein conformation.
12
 It is a reversible PTM, as protein 
phosphatases can cleave off the phosphate added by the kinases.
11
 Protein acetylation 
describes the reversible transfer of an acetyl group from acetyl-CoA mainly to lysine residues 
by lysine acetyltransferases. Acetylation can be reversed by lysine deacetylases, thereby 
representing a dynamic and reversible mechanism for transcription regulation.
13
 It alters the 
charge distribution in a protein
10
 and has been found to be involved in various diseases.
11
 In 
ubiquitination, the 76-residue protein ubiquitin is attached to lysine residues in a three-step 
process. It is a PTM involved in proteasomal degradation of proteins which are no longer 
needed,
13
 and in apoptosis regulation.
20
 Lipidation is another diverse PTM that is also very 
difficult to analyze due to the lack of suitable antibodies.
13
 The two most common lipidations 





 and S-palmitoylation at cysteine residues, in which 
acyltransferases attach the lipid from a C16 fatty acyl CoA donor to the cysteine residue.
10,11
 







 Protein Glycosylation  1.1.1
One of the most common and most important PTMs is glycosylation, which involves the 
attachment of carbohydrate structures to proteins.
13
 Protein glycosylation takes place in the 
ER and the golgi apparatus and is performed by glycosyltransferases that attach the 
carbohydrates to Ser/Thr/Tyr residues in the case of O-glycosylation, or to the Asn in the 
Asn-X-Ser/Thr/Tyr motif (X is any amino acid except for proline) giving the more prevalent 
and often more complex N-glycosylation.
10,13,14
 Glycosylation is a non-template-dependent 
process
13
 that leads to significant microheterogeneity of the resulting structures.
21
 The 
complexity of the glycans is especially due to carbohydrate branching, the presence of 
different possible anomeric linkages and the presence of modifications in the glycans such as 
phosphates, sulfates,
22
 Figure 1.2.  




Proteins found in secretory pathways, and on the cell surface are often glycosylated. 
Glycosylation plays a role in protein folding and quality control.
13,23
 Additionally, 
glycoproteins are also involved in important biological processes such as fertilization, 





Figure 1.2. Overview of the types of glycoproteins and other glycosylated structures in cells.  (Figure 




 GPI-Anchors and Glypiation 1.1.2
A very complex PTM is the attachment of glycosylphosphatidylinositol (GPI) anchors to the 
C-terminus of proteins, named glypiation.
26-28
 In total ca. 0.5 – 1% of all eukaryotic proteins 
carry a GPI-anchor.
26,27
 Since their discovery in the 1980ies,
29
 at least 150 proteins have been 
found to be glypiated in humans.
30
 The primary function of the GPI is the anchoring of 
proteins to the outer leaflet of the cell membrane via their C-terminus.
26,31,32
 However, GPI-
anchored proteins (GPI-APs) have diverse functions and participate in many important 
biological processes including cell adhesion, complement regulation, signal transduction and 
are often receptors.
29,30,33-35
 Additional to membrane anchoring, the role of the GPI anchor 








The GPI anchor contains a highly conserved core structure consisting of a 
phosphoethanolamine, a trimannoside, a glucosamine and an inositol phospholipid. This 
structure can also carry additional carbohydrate units, phosphorylations and lipid chains, 
resulting in heterogeneous structures,
27,32,36,38,39 









Figure 1.3. Structure of a Glycosylphosphatidylinositol (GPI) anchored glycoprotein. (Figure by Daniel 
Varón Silva, 2013
40
, modified).  
     
GPI-APs are often associated with membrane microdomains rich in cholesterol and 
sphingolipids, called lipid rafts.
33,41,42
 These microdomains are separate, ordered structures 
within the laterally disordered cell membrane that may facilitate interactions between proteins 
and lipids with other proteins by clustering them in close proximity to each other.
26,32,33,41
 GPI 
molecules are also found freely on the cell membrane, not attached to a protein, especially on 
protozoan parasites. In Plasmodium falciparum, the parasite causing malaria infection, the 





The biosynthesis of GPIs and GPI-APs is a very complex process involving at least nine 
enzymatic steps. For this, the gene products of 22 PIG (phosphatidyl inositol glycan) genes 
and four PGAP (post-GPI attachment to protein) genes are required, Figure 1.4 a. 
Biosynthesis of GPI precursors begins on the cytoplasmic side of the endoplasmic reticulum 
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the growing GPI-pseudodisaccharide precursor is flipped to the luminal side of the ER by 
enzymes that still need to be identified.
30
 The protein to be glypiated is localized to the ER via 
an N-terminal signal peptide. Subsequently, the GPI is elongated further and is finally 
attached to a protein en bloc by GPI transamidase in a transamidation reaction, replacing a C-
terminal GPI attachment signal peptide, Figure 1.4 b.
28,30,32,43,44
 This process takes place 
within less than one minute from protein localization to the ER.
45
 As a final step, the GPI-AP 
is transported to the golgi apparatus by protein complexes. Structural remodeling of glycan 









Figure 1.4. Biosynthesis of the GPI anchor and transfer to the C-terminus of a protein. a) Biosynthetic 
pathway of GPI anchor assembly, flip and protein attachment including all participating enzymes, b) Two signal 
sequences are required for protein glypiation: an N-terminal ER-localization signal and a C-terminal GPI 
attachment signal that is replaced by the GPI en bloc by GPI transferase (GPI-T). (Figures from Kinoshita, 2008
30
).  
 Chemical Synthesis of GPI Anchors 1.1.4
In order to elucidate the function of the GPI anchor, access to pure, homogeneous material 
is crucial. Due to their high complexity and difficult isolation, the chemical synthesis of GPI 
anchors has become the method of choice. However, the synthesis is challenging
34
 and only in 
the two last decades, some routes have been developed for a convergent synthesis of different 
GPI anchors using a relatively small set of building blocks.
47,48
 Generally, these methods 




involve a convergent or a linear assembly of a fully protected GPI-glycan, which is modified 
at a late stage by incorporation of the lipid chains and phosphorylations.  
 
 Relevance of GPI-Anchors and GPI-Anchored Proteins in Disease 1.1.5
GPI-anchored proteins are known to be involved in several diseases and lack of GPI anchors 
is lethal in yeast and in mammals.
26,46,49
 Additional to the infection with parasites, the most 




Prion diseases are a group of protein borne illnesses that are characterized by a misfolding 
of the physiological form of the prion protein, PrP
c
, into the scrapie form PrP
Sc
. Since this 
misfolding seems to be transmissible between proteins, it is anticipated that the GPI anchor 
together with the localization in lipid rafts is crucial for progressing of prion pathogenesis.
46
  
PNH is caused by acquired mutations in the PIGA gene in a single hematopoietic stem cell 
and its progeny, rendering them unable to assemble the GPI anchor, as biosynthesis is 
abrogated in the first step.
46,49
 The absence of GPI-biosynthesis leads to a lack of GPI-
anchored CD59 protein (a complement inhibitor) on red blood cells and thus to uncontrolled 
hemolysis mediated by the complement system, inducing the disease.
46,50
  
 Malaria, Chagas disease and toxoplasmosis are infectious diseases caused by the parasites  
Plasmodium falciparum,  Trypanosoma cruzi and Toxoplasma gondii which are transmitted 
by different routes and affect large populations, especially in developing countries.
46,51
  
GPIs are also abundant in parasite, and their potential use as diagnostics has been 




 Natural GPI-Anchored Proteins  1.1.6
Approximately 0.5-1% of eukaryotic proteins are glypiated.
26,27
 Some of the most well-
known proteins among them are CD52, CD59, Thy-1 (CD90), the prion protein and the P. 
falciparum Merozoite Surface Protein family. A short overview over their functions and 








CD52 (Campath-1 antigen) 
CD52 is a short (12 amino acid) GPI-anchored glycoprotein that is widely expressed on the 
surface of immune cells (lymphocytes, natural killer (NK) cells, macrophages and others).
54
 
Due to its large sialylated N-glycan, CD52 is negatively charged and it may function as an 
anti-adhesive molecule on the cell surface, increasing cell mobility. The GPI-anchor of CD52 
is cleavable by Phospholipase C, releasing soluble CD52 protein that may act as an immune 
regulator.
55
 It is not completely understood, however, how CD52 is involved in physiology.
54
 
Since the beginning of synthetic studies regarding GPI-APs, CD52 has been a target of wide 





CD59 (MAC-Inhibitory Protein)  
CD59 is a GPI-anchored complement regulatory protein which protects the cell from 
uncontrolled complement-mediated lysis.
58
 It is expressed in high levels on cells of each 
tissue type and is structurally similar to snake neurotoxins. Defects in GPI biosynthesis induce 
a defective expression of this protein that can lead to Paroxysmal Nocturnal Hemoglobinuria 
and other acquired conditions.
46
 Additionally, CD59 is involved in the infection with and 





Thy-1 (Thymocyte Differentiation Antigen 1) 
Thy-1, or CD90, is a conserved, heavily glycosylated GPI-anchored cell surface protein 
(30% carbohydrate content) with a single V-like immunoglobulin domain, rendering it the 
smallest member of the immunoglobulin protein family.
60,61
 It was the first protein for which 
the structure of the GPI-anchor was elucidated.
62
 It is known as a T-cell marker and is most 
abundant on murine T-cells. However, the physiological functions of Thy-1 protein are still 
not completely understood.
62,63
 Thy-1 is not only found on T-cells, but also in nervous tissue 
and is possibly involved in fear inhibition.
64
 This protein also plays a role in different types of 
cancer, especially in chemo-resistance, cancer cell proliferation and metastasis. In some 
cancers, however, it also has a tumor suppressing function. The mode of action strongly 
depends on the tumor microenvironment and the signaling mechanisms present in the cancer 
cells. Due to these implications, Thy-1 is interesting as a cancer biomarker or could possibly 








MSP1 (Merozoite Surface Protein 1)  
Malaria is an infectious disease caused by the apicomplexan parasite Plasmodium 
falciparum that was responsible for an estimated 216 million cases and 655,000 deaths in 
2010.
51,66
 The parasite is transmitted to the human host via the bite of mosquitoes as vectors. 
Following inoculation in the human blood, the parasite invades the liver (so-called liver-
stage) where it reproduces, causing infected hepatocytes to burst.  Then, the released parasites 
infect the host’s red blood cells, entering the blood stage of infection, Figure 1.5. In this stage, 
the MSP1 protein, a GPI-anchored protein present on malaria merozoites, plays an important 
role during infection.
67
 MSP1 is expressed in merozoites as a large (195 kDa) glycoprotein. 
During infection of red blood cells, the protein undergoes proteolytic processing by subtilisin 
1 and 2 proteases, leaving only a small GPI-anchored fragment (MSP119) on the parasite 
surface.
67,68
 MSP119 binds to the red blood cell, initiating contact between parasite and cell.
67
 
Therefore, MSP1 has been an interesting therapeutic target for malaria treatment
69











Prion Protein  
Probably the most notorious example among GPI-anchored proteins is the prion protein, 
which is responsible for different kinds of transmissible spongiform encephalopathies (TSEs) 
and the Creutzfeldt-Jakob disease (CJD) affecting the nervous system of humans and many 






 Differently from initial expectations, the prion protein was found to induce these 
diseases solely via protein-based mechanisms.
72-74
 The term prion was coined by Stanley 
Prusiner in 1982 and is derived from proteinaceous and infectious particle (represented by the 
ending –on, from the greek word for particle).72,73 
This “protein only” hypothesis is widely accepted now. Prion pathogenesis is reported to be 
the effect of a conformational conversion of the physiological, normal form of the prion 
protein (PrP
C





misfolding can be transferred from the PrP
Sc
 to a PrP
C
 according to the “refolding” or 







 undergoes a conformational change into PrP
Sc
. Otherwise, a high 
energy barrier prevents this transformation. An alternative model of prion pathogenesis is the 
“seeding” or nucleation-polymerization model (Figure 1.6 b). According to this model, 
several monomeric PrP
Sc
 molecules can form a highly ordered seed that recruits PrP
C
, induces 
its misfolding and causes aggregation to form amyloids. The formation of these aggregates 
stabilizes the PrP
Sc
 form. Fragmentation of these structures can lead to replication of the so-
called prions.
75
   
 
 









 differ structurally and in their biochemical properties. While PrP
C
 consists 
mainly of α-helical structures with a long, flexible N-terminal tail, is soluble and sensitive to 




digestion by proteinase K digestion, PrP
Sc
 has a structure containing mostly β-sheets, is 
protease resistant and prone to aggregation (Figure 1.7).
73,76
 As the misfolding events seem to 
take place in lipid rafts where many GPI-anchored protein cluster,
33
 it is assumed that the 
GPI-anchor plays an important role in prion propagation and pathogenesis. The membrane 
composition also seems to play an important role in this process, namely the cholesterol 
content, which is an important component of lipid rafts. The GPI-anchor enhances lateral 
protein mobility between cells, a factor that could enable PrP
Sc










The amyloids formed in the process of prion pathogenesis can aggregate in the brain and 
lead to cell death. This process creates a sponge-like structure in the brain, causing 
neurodegenerative symptoms that eventually lead to death.
78
 A cure is currently not available 
for any of the prion diseases.
79,80
 As the physiological function of the prion protein is still not 
completely understood,
73,76
 effort towards the understanding of this fatal disease and its 




 Therapeutic Proteins 1.1.7
Linking naturally non-GPI-anchored proteins to GPIs might facilitate their targeting, 
trafficking and membrane localization using the ability of GPI-APs to spontaneously insert 
into lipid bilayers.
27,81,82
 Nowadays, therapeutic proteins are administered by injection, a 




method that is not favorable for most patients.
83
 Therefore, new administration ways are 
necessary. Protein glypiation has been suggested as a potential modification for therapeutic 
proteins, such as antibodies or cytokines, as it could improve their effectiveness and in vivo 
half-life and at the same time enable lower dosage, resulting in fewer adverse effects or less 
frequent administration.
84
 Two possible examples for small therapeutic proteins are described 
below.  
 
Interleukin-2 (IL-2), also known as T-cell growth factor (TCGF), is a peptide hormone 
involved in immune stimulation and regulation. It is secreted by activated T-cells, stimulating 
proliferation and differentiation of B- and T-cells as well as of cytotoxic and NK cells. It can 
also act as an immune regulator by promoting homeostasis of regulatory T-cells, maintaining 
self-tolerance.
85
 IL-2 is currently used under the name Aldesleukin for treatment of renal cell 
carcinoma (it is approved in Germany, Austria and Switzerland as Proleukin by Novartis).
86
 
Here, the immunostimulatory effect of IL-2 is exploited.  
In a study published in 2002,
87
 Ji and coworkers fused IL-2 to a GPI anchor which was 
achieved by including a GPI-signal sequence in melanoma cells (B16F0 cell line). It was 
shown that the protein localized to the tumor cell membrane, resulting in high local 
concentrations of IL-2 and inhibited melanoma cell growth. This higher activity and 
localization would enable lower dosage and reduce the severe adverse effects which are 
common in systemic administration of IL-2.  
 
Interferon-α2a (IFN-α2a) is the most prominent member of the cytokine group of 
interferons. Interferons are produced in response to viral infection, conferring resistance to 
virus replication to non-infected cells by activating genes which inhibit viral translation and 
degrade viral RNA.  
Additionally, they activate dendritic cells, macrophages and NK cells, which leads to the 
killing of infected cells.
88,89
 Interferons are used to treat viral infections, such as HIV and 
hepatitis B and/or C.
83,90
 The main problem of interferons as therapeutic proteins is their short 
half-life time in the blood, making frequent injections necessary to maintain an effect. 
Following a similar strategy to IL-2, GPI-anchoring of IFN-α2a may be a potential approach 
in order to increase its half-life in cells.  
  




 Protein Semi-Synthesis 1.2
Nowadays there is a high demand for proteins in research and medicine.
91
 Most commonly, 
proteins are obtained by isolation from natural sources or by expression in mammalian cell 
lines, yeast cells or bacterial cells, i.e. by utilizing protein biosynthesis pathways. This has the 
advantage of relatively easy access to biomolecules of any size. However, these methods have 
some limitations like the difficult or impossible installation of site-specific modifications, 
even if mutagenesis methods are applied.
92
 For many modified and unmodified proteins, 
isolation from biological samples methods often results in heterogeneous products, rendering 
exact investigation of the function of specific modifications difficult.
12,13
 Purely chemical 
methods, on the other hand, often offer good control over the site of modification but are 
limited regarding the yield and size of the proteins that can be obtained.
93
  
Protein semi-synthesis, defined as the generation of a (modified) protein from a synthetic 
and a recombinant or native part,
94
 is an emerging field. A variety of methods are under 
investigation including chemical protein synthesis using Expressed Protein Ligation (EPL), 
cell free expression and genetic code expansion using amber suppression, to name a 
few.
5,92,95-100
 Bioorthogonal chemistry is another option to introduce site-specific 
modifications or labels to proteins. However these methods often introduce non-natural 
connections between protein and modification.
95,101
 Another possibility to generate proteins 




 Inteins and Protein Trans-Splicing 1.2.1
Inteins are protein domains capable of cleaving themselves out of flanking protein 
sequences in a folding dependent, autocatalytic, enzyme-like manner, without requiring any 
cofactors or energy in the form of ATP, and linking the flanking residues with a natural 
peptide bond.
102,104
 Analogous to mRNA splicing, where introns are spliced out of the RNA 
sequence to leave only the exons (the mature mRNA), the intein cleavage is called protein 
splicing.
103
 Accordingly, protein splicing is a form of post-translational protein processing.  
Inteins were first discovered in the early 1990s upon the finding that the final protein 
product of a yeast ATPase gene (TFP1/VMA1) was much shorter than expected, however, 
cDNA and mRNA were found to be exactly as expected. Inteins were first described by 
Hirata et al. and Kane et al. in 1990.
105,106
 Inteins are mainly found in endonucleases and 




proteins involved in DNA replication and repair. They exist as large and mini inteins, both of 
which contain the splicing domain. The large inteins consist of the splicing domain and an 
endonuclease homing domain which has the role to support lateral transfer of the intein 
between genomes.
102
 This way inteins are replicated within genomes, and since they have no 
known use for the host organism, they can be considered selfish.
107,108
 Inteins are found in all 
kingdoms of life
103,109
 and are present in proteins with diverse biological functions, for 
example metabolic enzymes, proteases, but mainly in enzymes participating in DNA 
replication and repair.
110
 The enzyme-like mode of action of the protein splicing reaction can 
be described by a four-step mechanism, Figure 1.8.  
 
Figure 1.8. Protein Splicing Mechanism. The protein splicing mechanism is a four-step process starting with 
activation of the N-terminal splice junction by an N-S (or O) acyl shift, giving a thioester intermediate (2). In 
step 2, a nucleophilic residue from the C-terminal splice junction attacks the thioester, resulting in a branched 
thioester intermediate (3). Next, intein cleavage is performed by asparagine cyclization, leading to excision of 
the intein (5). Intermediate (4) finally undergoes a spontaneous rearrangement resulting in the formation of a 




In the protein splicing reaction, initially the side chain group of a conserved Cys or Ser 
residue in the intein N-terminal splice junction attacks the carbonyl group of the first extein 
residue inducing an N-to-S/O acyl shift, resulting in formation of a (thio)ester intermediate. In 




the second step, a trans(thio)esterification by a nucleophilic attack of the side chain of a 
conserved Cys or Ser residue in the C-terminal splice junction takes place, giving a thioester 
intermediate. In the following step, the C-terminal asparagine of the intein undergoes a 
cyclization reaction, the intein is excised out of the protein sequence upon succinimide 
formation, and the two exteins are linked together with an ester bond. The final step is a 
spontaneous rearrangement, in which a peptide bond is formed via an S/O-to-N acyl shift 
between both exteins.
94,102,104,107
 It has been shown that some inteins require only the first 






Most inteins show low sequence homology and only the terminal regions and some internal 
motifs required for activation of the peptide bond to be broken in the first step are 
conserved.
112
 The structure of inteins is similar to hedgehog proteins. It contains 12-14 β-
sheets forming a U-shape, having the catalytic center in the center of the U on the ends of two 
neighboring sheets. The splice area forms a separate domain.
110
 The complex formed by the 




Trans Inteins and Protein Trans-Splicing 
In 1998, so called trans or split inteins were simultaneously discovered in nature and 
developed artificially.
112
 While the classical intein described above splices in cis, i.e. within 
its own protein molecule, the fragments of a trans intein are expressed on different positions 
in the genomes and splice exteins from two distinct proteins to give one final protein. The 
first naturally split intein discovered was the SspDnaB intein from the cyanobacterium 
Synechocystis species.
112
 Whereas cis inteins have been found in all kingdoms of life, split 
inteins have mainly been identified in different cyanobacteria and archeae.
102
 It seems likely 
that split inteins have evolved from formerly complete inteins that got divided.  
Split inteins use the same mechanism as cis inteins with an additional initial step involving 
the association of both intein fragments.
94,114
 The intein fragments have very distinct pI 
values, i.e. the fragments of the Nostoc punctiforme intein have pI 4.4 for Npu
N
 and pI 9.7 for 
Npu
C
, due to which the multi-step split intein folding mechanism is initiated via electrostatic 
interactions of the two fragments (capture). Subsequently, the so far unstructured intein 
fragments become stabilized in a “collapse” mechanism, Figure 1.9. The N-intein alone has 
an extended shape, which seems to collapse upon binding of the C-terminal fragment. The 




surface between both intein fragments is mainly hydrophobic, which helps in the stabilization 
of the complex.
113
 Once it is assembled, the intein complex is very stable and shows very low 





Figure 1.9. Schematic view of the „Capture and Collapse“ folding mechanism of naturally split inteins. 
The N-intein (blue) consists of two lobes, a structured Npu
N
1 and an unstructured Npu
N
2. Only when the N-intein 
is in close proximity to the C-intein (red), the intrinsically disordered fragment collapses due to an electrostatic 
capture. This association results in the readily folded complete split intein complex in which both termini are 




The use of protein trans-splicing (PTS) has several advantages over the use of NCL and 




, the reaction rates are very high compared 
to the other selective chemical reactions and no free thiols re required as catalysts.
116
 Protein 
trans-splicing is not limited by the size of the fragments, which can be expressed 
recombinantly. Nevertheless, the smallest known C-terminal intein fragment (Int
C
 of Npu 
intein) consists of only 36 amino acids, which is accessible by solid phase peptide synthesis. 
Furthermore, PTS is less concentration dependent than NCL, which relies on random collision 
of the fragments in the reaction mixture.
117
 The cysteine residues flanking the intein 
fragments on both sides need to be present in reduced form for the splicing reaction.  
 
Split Intein from Nostoc punctiforme 
The best characterized split inteins are from cyanobacterial sources.
118
 The split intein from 
the filamentous cyanobacterium Nostoc punctiforme, NpuDnaE intein, is the fastest split 
intein known. The t1/2 of its trans-splicing reaction is reported to be ~1 min at 37°C. The 
reaction conditions needed for PTS (Protein trans-splicing) are gentle and very close to 
physiological conditions and therefore, PTS is possible even in live cells.
116
 The NpuDnaE 









Applications and Biological Role of Inteins 
Inteins have multiple applications in protein chemistry and biotechnology, such as the 
generation of self-cleaving affinity tags for protein purification, novel ligation systems for 
protein semi-synthesis, segmental labeling of proteins for NMR analysis,
104
 the generation of 
tag-less proteins and protein thioesters,
117
 the segmental construction of proteins or the 
selective modification of proteins. Non-native exteins are accepted but splicing rates can vary 
significantly depending on the respective extein.
110,118
 Inteins can also be used for protein 
labeling (fluorophores etc.) with the advantage that the biological function of the proteins is 
not changed as in most other protein labeling methods.
116
 No advantage for the host is known,  
although inteins are often found in essential proteins.
110
 Therefore, inteins are considered 
selfish protein elements.
107,108
   
 
 Expressed Protein Ligation 1.2.2
Native chemical ligation is a widely used technique for the chemoselective reaction of two 
unprotected peptide fragments, one carrying a C-terminal α-thioester, the other one having an 
N-terminal cysteine residue.
119,120
 After forming a thioester-linked intermediate in a 
chemoselective transthioesterification, the reaction proceeds with a rapid S-to-N acyl shift, 
ligating both peptides together with a native amide bond, Figure 1.10.  
 
 
Figure 1.10. Native Chemical Ligation between two unprotected peptides. Peptide 1 has a C-terminal 
thioester and peptide 2 has a free N-terminal cysteine. The peptides undergo a transthioesterification reaction, 
forming a thioester-linked intermediate. This step is followed by an S-to-N acyl shift, ligating both fragments 
together via a native peptide bond.  




The NCL strategy is limited by the access to only small protein fragments. Due to the 
technical limitations of solid phase peptide synthesis (SPPS), only peptides with a maximum 
size of 50-60 amino acids are generally accessible. An expanded variation of the native 
chemical ligation reaction is the expressed protein ligation (EPL), in which one or several of 
the fragments to be ligated are of recombinant origin.
99,120-122
 Using recombinant protein 
expression, larger proteins and protein fragments can be generated.
120,121
 Thus, by using EPL, 
the main limitation of NCL can be overcome. The chemical routes to generate peptide 
thioesters generally involve the use of protection groups and are not well applicable to large 
recombinant proteins. Therefore, for recombinant proteins a different strategy was necessary 
for the generation of reactive peptide-α-thioesters. The protein-splicing activity of inteins 
(self-excising protein elements), which is known to involve a thioester intermediate, can be 
applied to generate recombinant protein-α-thioesters.120,121,123 This technique relies on the 
capture of the formed protein thioester intermediate by thiols, involving a trans-
thiosterification reaction. This is followed by a native chemical ligation reaction, ligating the 
Cys-bearing peptide fragment to the recombinant protein thioester, Figure 1.11.    
 
Figure 1.11. Expressed Protein Ligation (EPL). A protein thioester is formed with the using a C-terminally 
de-functionalized intein that is bound to an affinity matrix. A thiol reagent is added to capture the thioester 
intermediate formed due to the de-functionalization of the intein. The purified protein thioester can then be 
ligated to a peptide fragment with an N-terminal cysteine residue (Figure from Muir, 2003
120
).  




Thioesters are base-labile and prone to hydrolysis.
123,124
 Johnson & Kent (2006)
125
 and Reif 
et al. (2014)
124
 performed screenings to find the optimal thiol reagent for thioester formation 
and protein ligation. Generally aryl thiols, such as thiophenol or 4-mercaptophenylacetic acid 
(MPAA), are more reactive than alkyl thiols, such as ethanethiol or 2-mercaptoethane 
sulfonate sodium salt (MESNA). On the other hand, alkyl thioesters are more stable and 
easier to handle. MESNA has a good balance regarding stability and reactivity is the most 
commonly used thiol reagent for EPL.
122,125
 However, using MESNA, the thioester formation 
as well as the ligation reaction are slow, requiring several days to go to ~90 % completion.
126
 
Therefore, NCL and EPL can be improved using a thiol exchange, as described by Dawson et 
al. in 1997.
127
 Thioesters are generated using a less reactive thiol to obtain a stable thioester 
that can be purified and stored. During the ligation this thioester can be converted to a more 
reactive species by the addition of a more reactive aryl thiol.  
Using the phenyl thioester generated with thiophenol or MPAA, the expressed protein 
ligation reaction has been shown to obtain reaction up to 90% completion within 2 h.
125
 
However, thiophenol and its variant MPAA are also significantly prone to hydrolysis.
124
 
showed that using 4-(mercaptomethyl)benzoic acid (MMBA) the respective thioester is 
formed in an equally short time and only trace amounts of side products were formed, 
indicating low levels of hydrolysis. These characteristics suggest MMBA as a useful thiol for 
the formation of the protein thioester and for protein ligation.  
 
 Semi-Synthesis of GPI-Anchored Proteins – State of the Art  1.2.3
GPI-anchored proteins are a significant target for protein semi-synthesis. The isolation of 
these modified proteins generally results in mixtures of glycoforms and low yields and their 
total chemical synthesis faces several hurdles including availability of large peptides by 
synthetic methods. So far, there is a lock of suitable semi-synthetic methods for the generation 
of pure and homogeneous GPI-anchored proteins. A main challenge remains the access to 
sufficient amounts of homogeneous GPI-anchors. Chemical synthesis of these glycolipids is 
very challenging as multiple components (carbohydrates, lipids and phosphates) are involved, 
as described before in 1.1.4.
34,47,48
 The high variability of the structure of the carbohydrate 
portion and the different lipid chains that can be present, including the presence of 
unsaturated lipids and ceramides makes GPI synthesis even more challenging.
34
 Some 




progress has been recently made towards both types of GPI modifications in our group,
47,128-
130
 however there are still many challenges to obtain these molecules.  
Due to the amphiphilic character, the handling of GPI anchors is difficult. Therefore, the 
(semi-)synthesis of GPI-anchored peptides and proteins has been mostly evaluated using GPI 
fragments, analogues or mimics with apparently similar molecular properties.
34,131,132
 In early 
studies, very simple GPI mimics, protein models and unnatural linkages were employed to 
connect GPI analogues to peptides and proteins.
133
 However, the large difference between 
these models and the natural structures makes it difficult to elucidate the function of the GPI 
anchor itself in its native state on the protein’s C-terminus.  
Total chemical synthesis, mostly by Native Chemical Ligation (NCL), has been an option 
for the synthesis of small peptides carrying GPI-analogues.
119,134
 This strategy requires the 
generation of peptide thioesters, for example via peptide hydrazides and can be used without 
limitation such as solubility of the starting molecules.
135,136
  One of the first reports in this 
field was the study of Tanaka et al. (2003)
56
 in which NCL was used to generate Cys-GPI-
analogues (Cys-dimannose) and peptide thioesters (CD52 peptide). Another study addressing 
the synthesis of GPI-anchored CD52 peptide was conducted by Xue et al. in 2003.
57
 In this 
study, the two C-terminal amino acids of CD52 were ligated to a GPI mimic containing the 
carbohydrate core structure and a single C16 acyl chain linked to the glycan without 
phosphate.  
 
Expressed Protein Ligation  
As described in 1.2.2, Expressed Protein Ligation (EPL) is commonly used for the semi-
synthesis of (glyco-)proteins, and is also applied for studies for the generation of GPI-APs by 
some groups, an overview over the most successful ones is given in the following.  
The Bertozzi group investigated the effect of PEG linkers in comparison to glycans of 
various lengths on the properties of eGFP protein. In a first report dealing with the attachment 
of GPI mimics to a larger protein, Paulick et al. (2007)
137
 produced synthetic GPI analogues 
with PEG linkers of different lengths attached to none, one or two mannoses. These mimics 
were ligated to eGFP. The phosphoethanolamine-inositol-glucosamine moiety was replaced 
by a simple PEG linker, but two C16-chain lipids were present in the mimic (C16). In the EPL 
reaction, an excess of GPI analogues was applied. The modified eGFPs were purified by 
extraction with Triton X-114 as detergent and the effect on protein mobility was investigated. 
It was found that the GPI mimic can prevent protein-membrane interactions by enhancing 
protein mobility, probably due to higher rigidity in the presence of higher number of sugars.  




Olschewski et al. (2007)
132
 reported the semi-synthesis of the Prion Protein (PrP 90-231) 
fragment with GPI mimics. Lipidated peptides were used as GPI mimics to facilitate 
membrane targeting. The peptides were equipped with a fluorescent label for detection 
purposes and a PEG-linker in place of the glycan. Purified proteins were obtained in 18-30% 
yield, with 60% yield in the EPL reaction. However, due to the lack of natural material to 
compare them it is difficult to know to which extent these mimics can represent a GPI-anchor 
in biological studies.  
The same group reported the semi-synthesis of a GPI-anchored PrP using the expressed PrP 
90-231 fragment that was ligated to a monolipidated Cys-GPI (Becker et al., 2008).
131
 
Reaction with the crude GPI (1.5 eq.) at pH 7.8 gave the product in 50% yield. The product 
was purified by RP-HPLC and characterized in LC-ESI-MS, which was reported to be a 
difficult process due to the amphiphilic nature of the compound that delivered an MS 
spectrum of low quality. Furthermore, the insertion of the purified PrP-GPI into membranes 
(SUV) was demonstrated. This partial sequence of PrP, however is missing the N-terminal 
region (23-89), which has been described to be responsible for the aggregating properties of 
the Prion Protein.  
 
Protein Trans-Splicing 
Only few reports describe the use of PTS to generate GPI-APs. Olschewski et al. (2007)
132
 
applied also the PTS strategy for the semi-synthesis of PrP fragments with lipidated peptides 
as GPI mimic in 25% yield after purification by HPLC. Furthermore, they also performed 
PTS with lipidated peptides already inserted in liposomes.  
Another report involving PTS for generation of a glypiated protein was reported by the 
Mootz group (Dhar & Mootz (2011)
138
). In this report, the Npu
C
 intein fragment was 
expressed in yeast, carrying a GPI signal sequence to obtain a glypiation in vivo prior to its 
use in PTS with eGFP-Npu
N
 in live cells. Using this strategy it was possible to show 
localization of the GPI-AP on the cell membrane. However, the GPI anchor attached in the 
yeast culture is likely not homogeneous and it is not obvious on which residue of the protein 
the GPI was attached as analysis in mass spectrometry was not performed.  
 
Sortase A 
Sortases are transpeptidases of bacterial origin that naturally transfer proteins to the 
bacterial cell wall.
139
 Some groups employed these enzymes for the chemoenzymatic 
generation of GPI-APs. Sortase A (SrtA) from Staphylococcus aureus recognizes a LPXTG 




peptide sequence near the C-terminus of a protein, cleaving the bond between the Thr and 
Gly, which causes residues in the active site to generate a reactive thioester between Thr of 
the substrate protein and a Cys residue of SrtA. Subsequently, it transfers the Thr residue of 
the protein to another substrate protein, or to a synthetic peptidoglycan, especially to 
fragments having a polyglycine at the N-terminus.
38,81,139
  
The Guo group has reported progress using Sortase A for generation of GPI-APs. In Guo et 
al. (2009)
81
, a Cys-Phosphate-Mannose could first not be ligated to a peptide, probably due to 
the phosphate group that might alter the nucleophilicity of the amino group. Upon addition of 
two extra Gly residues the N-terminus, product formation was observed. The same GPI-
analogue including the two Gly residues was coupled by Wu et al. (2010)
38
 to attach a partial 
sequence of the MUC1 glycopeptide with three glycans and the signal peptide LPKTG. In a 
following report, Wu et al. (2013)
140
 successfully attached eGFP to a GPI derivative 
containing the GPI core glycan structure, a C18-llipid chain, and phosphate linkages having a 
GG dipeptide. Due to the Sortase mechanism, however, the final product carries the 
recognitions sequence LPATGG between the C-terminus of eGFP and the GPI.  
 
Other Methods to Obtain GPI-APs 
GPI Glycan-Peptide Conjugates (CD52 peptide) were obtained by Traceless Staudinger 
Ligation in Zhu & Guo (2017).
141
 A Staudinger reaction was carried out between a peptide 
phosphinoester and a GPI glycan azide, Figure 1.12. This region- and chemoselective reaction 
was expected to give peptides naturally linked to GPI glycan mimics (containing one to three 
mannose residues). The reactions were performed in DMF and a DMF-water mixture (1:1) 
using a fully protected peptide. The CD52 attached to a single mannose and to a trimannose 
were obtained at 40°C after 1 day reaction in 96% and 78% yield, respectively. The big 
advantage of this process is its independency of any sequence requirements as the other 
methods. However, the use of fully protected peptides renders this method useless for the 
ligation of bigger, recombinant proteins.  
 
Figure 1.12. Traceless Staudinger Ligation for the generation of GPI-peptide analogues. (Figure from 
Zhu & Guo, 2017
141
).  




A purely biological option to obtain GPI-APs is the direct expression of the GPI-APs in 
mammalian expression systems such as yeast or other eukaryotic cell lines. In Marbach et al. 
(2013)
142
 PrP was obtained with a native-like glycosylation and glypiation pattern and 
localized to the yeast plasma membrane via a GPI anchor. However, they observed 
unexpected insoluble expression of the protein without GPI anchor. eGFP-GPI was also 
expressed using GPI signal sequences and was found to localize to the cell membrane. High 
protein expression yields in yeast are given as the main advantage of this method. However, 
the lack of characterization of the GPI attached to the protein and of a proper determination of 
the yields of a single product show that this method cannot become a general strategy for the 
production of GPI-APs. Furthermore, the GPI-glycan attached to the proteins will depend on 
the glycosylation machinery of the expression host, and could differ from the natural form, 
like it is the case for yeast and the PrP.  
Expression in mammalian systems has rarely been used for the generation of GPI-APs.
143
 
This, of course, delivers completely natural products, however, the homogeneity cannot be 
controlled.
12,13
 Expression in insect cells has also been reported (Shams-Eldin et al., 2008
144
), 
which, however suffers from the same problems as mammalian systems.   
Most of the methods described above yield unnatural products in one way or the other for 
many proteins.
34
 NCL and EPL involve the addition of at least one extra Cys residue, if this is 
not the C-terminal residue of the target protein as it is the case for MSP1 and Thy-1 proteins. 
An additional strategy is the desulfurization strategy, which can be used to convert a cysteine 
to an alanine residue after ligation.
119
 Furthermore, the synthesis of Cys-GPIs is not trivial and 
the use of SrtA yields products bearing a pentapeptide with unclear implications on the 
structure and biological functions of the proteins.  
Unexplored methods such as the use of GPI transamidase (GPI-T) can be an interesting tool 
to ligate GPIs to proteins, since this would deliver truly natural GPI-APs.
34
 However, it is a 
very complex enzyme made up of five subunits, which would hamper its application in this 
challenging task.   




 Aim of the Work 1.3
The development of strategies for the production of homogeneous GPI-anchored proteins is 
required to decipher the role of this post-translational modification in eukaryotic proteins.  
In order to obtain proteins to decipher the role the GPIs, the aim of this thesis was the 
development of semi-synthetic strategies to obtain GPI-APs using inteins.  
First, native chemical ligation will be applied for the attachment of chemically synthesized 
GPIs having a cysteine residue to the C-terminus of recombinant proteins. The proteins will 
be obtained as active protein thioesters by an intein-based strategy using the Mycobacterium 
xenopi Gyrase A intein. Following intein cleavage, the released protein of interest having a C-
terminal thioester will be investigated in reactions with GPIs of different structures. A second 
strategy to be investigated will involve the use of protein trans-splicing. Here, the naturally 
occurring split intein from Nostoc punctiforme (NpuDnaE) will be used for the reaction.
145
 
Recombinant fusion proteins, consisting of the protein of interest and the N-terminal part of a 
split intein, will be obtained by recombinant expression and will be reacted to the chemically 
synthesized C-terminal intein part, which will be coupled to a GPI.  
Recombinant expression in E. coli strains will be used to obtain the fusion proteins of the 
POIs with the inteins. This commonly used bacterial expression system generally yields high 
protein amounts relatively easily and it will ensure that the proteins will be present in a 
homogeneous, non-glycosylated form. For establishing the methods, eGFP will be used as a 
model protein and fusion partner for the inteins. The expression of this protein is known to be 
possible in E. coli in a soluble form and it is easy to follow in purification and reactions due to 
its intrinsic fluorescence.  
As soon as EPL and PTS methods are established for eGFP, the established strategies will 
be applied to obtain other proteins coupled to GPI-anchors, creating a GPI-AP library, which 
can then be used for structural or activity-related studies in order to elucidate further 
biological functions of the GPIs.  
 
In addition to protein ligation and in order to be able to follow the progress of the reactions, 
suitable methods for detection will be evaluated and established. Methods such as LC-MS 
analysis of intact GPI-APs and western blot using anti-GPI antibodies have so far not been 
used for the characterization of this type of molecule. It is anticipated that ionization of these 
complex molecules might present a challenge due to the molecular diversity and complexity.   




2 Materials and Methods 
 Chemicals, Buffers and Consumables 2.1
 Chemicals 2.1.1
If not stated otherwise, chemicals were purchased from Carl Roth (Karlsruhe, Germany), 
AppliChem (Darmstadt, Germany), Sigma-Aldrich (St. Louis, USA) or VWR (Radnor, USA). 
All amino acids were purchased from IRIS Biotech (Marktredwitz, Germany) or 
Novabiochem (Darmstadt, Germany). Deionized water was obtained by purification with a 
Milli-Q purification system (Merck Millipore, Billerica, USA).  
 
Chemical Name Supplier 
Acrylamide 4K solution 30 %   AppliChem (Darmstadt, Germany) 
BSA       Life Technologies (Darmstadt, Germany)  
Deoxycholate, Na-salt    Roth (Karlsruhe, Germany)  
D-desthiobiotin     Sigma-Aldrich (St. Louis, USA) 
DIC (N,N’-Diisopropylcarbodiimide)  Iris Biotech (Marktredwitz, Germany)  
IPTG (Isopropyl β-D-1-thiogalactopyranoside) Roth (Karlsruhe, Germany) 
MESNA (Sodium 2-Mercaptoethanesulfonate) Sigma-Aldrich (St. Louis, USA) 




MMP (Methyl 3-mercaptopropionate)  Sigma-Aldrich (St. Louis, USA) 
MPAA (4-Mercaptophenylacetic acid)  Sigma-Aldrich (St. Louis, USA) 
Octyl β-D-glucopyranoside    Santa Cruz Biotechnology (Dallas, USA)  
Oxyma      Iris Biotech (Marktredwitz, Germany)  
Thiourea      Sigma-Aldrich (St. Louis, USA) 
TIPS (Triisopropylsilane)    Sigma-Aldrich (St. Louis, USA) 
 Consumables  2.1.2
Product Supplier 
1 kb Plus DNA Ladder     Invitrogen (Carlsbad, USA) 
Chitin Resin 50% Slurry    NEB (Ipswith, USA)  







 Chromatography Columns  Bio-Rad (Hercules, USA) 
InstantBlue Stain     Expedeon (Cambridgeshire, UK)  
Microtiter plates, clear, flat bottom   Sarstedt (Nümbrecht, Germany) 
Mini-PROTEAN® TGX™ Precast Gels   Bio-Rad (Hercules, USA) 
Any-kD, 15-well  
“NucleoBond” Xtra Midi Plasmid DNA Kit  Macherey-Nagel (Düren, Germany) 
“NucleoSpin” Plasmid Purification Kit   Macherey-Nagel (Düren, Germany) 
Pierce™ BCA Protein Assay Kit   ThermoFisher Scientific (Waltham, USA) 
Pierce™ ECL Western Blotting Substrate  ThermoFisher Scientific (Waltham, USA) 
PolyPrep
®
 Chromatography Columns  Bio-Rad (Hercules, USA)  
Ponceau S solution     AppliChem (Darmstadt, Germany) 
Precision Plus Protein™ Dual Color Standard Bio-Rad Laboratories (Hercules, USA) 
PVDF-Star Transfer Membrane 0.45 µm   AppliChem (Darmstadt, Germany)  
“QIAquick” Gel Extraction Kit   QIAGEN (Hilden, Germany) 
QuickStart Bradford 1x Dye Reagent  Bio-Rad (Hercules, USA) 





50% suspension  iba (Göttingen, Germany)  
Thin Blot Paper     Bio-Rad (Hercules, USA)  
ZipTip
®
 Pipette Tips    Merck (Darmstadt, Germany) 
 
 Media & Buffers 2.1.3
Medium name Ingredients 
Luria Broth (LB-Medium) 10 g/l Tryptone  
10 g/L NaCl  
5 g/L yeast extract 
 
All media components were dissolved in 0.9 L/L dH2O, autoclaved and filled up to 1 L with 
sterile water.  
For LB-agar plates, media components and 15 g/L agar-agar were dissolved in the required 
amount of water, autoclaved, cooled to < 50°C before the respective antibiotics were added 




(generally 100 µg/mL ampicillin or kanamycin) and aliquots of ca. 20 mL were poured into 
sterile plastic petri dishes. The plates were allowed to cool before storing at 4°C.  
 
Buffer name Ingredients 
Buffer W (StrepTactin Wash Buffer) 100 mM Tris/HCl pH 7.5 
150 mM NaCl 
1 mM EDTA 
 
Buffer E (StrepTactin Elution Buffer) Buffer W (pH 7.5) 
+ 2.5 mM desthiobiotin 
 
Buffer R (StrepTactin Regeneration Buffer) Buffer W (pH 7.5) 
+ 1 mM HABA 
 
EPL Buffer (for Expressed Protein Ligation) 20 mM Tris/ HCl, pH 7.5 
500 mM NaCl 
50 – 200 mM thiol reagent added freshly      
before use 
 
His-Tag Equilibration Buffer 50 mM Tris/HCl pH 8.0 
500 mM NaCl 
30 mM Imidazole (can be 10 – 40 mM) 
optional 6-8 M urea 
 
His-Tag Elution Buffer 50 mM Tris/HCl pH 8.0 
500 mM NaCl 
500 mM Imidazole 
optional 6-8 M urea 
 
PBS Buffer 10 mM phosphate, pH 7.4 (Na2HPO4 & 
KH2PO4) 
137 mM NaCl 
0.27 mM KCl 





TAE Buffer 1x 40 mM Tris Acetate, pH 8.3 
1 mM ETDA 
 
TBS Buffer 50 mM Tris/HCl pH 7.6 
150 mM NaCl 
 
Splicing buffer (modified from 
145
) 50 mM Tris/HCl pH 7.0     
300 mM NaCl 
optional 6 M urea 
 
SDS-PAGE Running Buffer 1x 25 mM Tris, pH 8.8 
192 mM Glycine 
10% w/v SDS 
 
SDS-PAGE Sample Buffer 4x 10% w/v SDS 
50 mM TCEP 
20% Glycerol 
0.2 M Tris/HCl pH 6.8 
0.05% bromophenol blue 
 
Native PAGE Sample Buffer 2x 62.5 mM Tris/HCl pH 6.8 
40% glycerol 
0.1% bromophenol blue 
 
SEC Running Buffer 50 mM Tris/HCl pH 7.5 
700 mM NaCl 
 
Western Blot Transfer Buffer 1x 25 mM Tris, pH 8.8 
192 mM Glycine 
15 – 20% Methanol freshly added 
 
 




Diazotation Buffer 6 M GdmCl 
200 mM Na2HPO4, pH 3.0 
20 mM NaNO2 
 
NCL Buffer (for Native Chemical Ligation) 6 M GdmCl 
100 mM Na2HPO4, pH 7.0 
100 eq. thiol (MMBA, MPAA, MMP) 
5 eq. TCEP per Cys residue 
Lysis Buffer B1
146
 500 mM NaCl, pH 8.5 
2 mM EDTA 
20 µM PMSF 
0.1 mM TCEP 
Washing Buffer IB
146
 1 mg/mL Na-deoxycholate, pH 8.5 
2 mM EDTA 
0.2 mg/mL lysozyme 
Denaturation Buffer (modified after
146
) 8 M urea, pH 8.0 
2 mM EDTA 
1 mM TCEP 
 
 Synthetic Molecules for Ligation 2.2
Four synthetic molecules were used for optimization of the ligation reactions and 
preparation of C-terminally modified proteins: Cys-biotin (Scheme 2.1), Cys-dimannose 
(Scheme 2.2) and the mono- and bilipidated GPIs (Scheme 2.3 and Scheme 2.4).  
These molecules were synthesized by members of the GPI- and Glycoproteins research 
group of the Biomolecular Systems Department of the MPIKG, Potsdam. The molecules were 
modified with a cysteine residue for ligation to the proteins.  
 
Scheme 2.1. Structure of Cys-biotin. A simple model compound for ligation optimization and easy detection.  
 




Scheme 2.2. Structure of Cys-dimannose. This molecule contains two mannoses as well as the phosphate 




Scheme 2.3: Structure of monolipidated, biphosphorylated GPI. This is the model GPI anchor used in 
most experiments for method development and optimization. It contains the glycan core structure of all GPI 
molecules and a simplified lipid moiety having an alkyl chain attached to a phosphate. It contains the natural 




Scheme 2.4. Structure of bilipidated, biphosphorylated GPI. This structure is the most simple bilipidated 
GPI molecule, containing the complete pseudopentasaccharide, phosphate and a bilipid.  
 




 Plasmids, Clones and Primers 2.3
Different E. coli strains were used for the production of proteins. TOP10 cells were used for 
cloning since this strain is recombination deficient and has high transformation efficiency. 
BL21 (DE3) Star cells were mostly used for protein expression as this strain is suitable for use 
of the T7 promoter and offers enhanced mRNA stability. Some proteins were expressed using 
Rosetta cells, or Origami cells which provide a better environment for the folding of difficult 
proteins.  
Plasmids were ordered from GenScript (Piscataway, USA) with optimized codons for 
expression in E. coli, if not stated otherwise. Primers were designed using DNAStar 
Lasergene software (Madison, USA) and ordered from GenScript as well. pTXB1 vector was 
purchased from NEB (Ipswich, USA). Primers are listed in Table 2.1.  
 
Table 2.1. List of primers used in this work.  
No.  Plasmid name Fusion protein Origin Clones 
1 pVS071 ST-eGFP-Npu
N
 provided by Prof. 
Henning Mootz, 
University of Münster 
TOP10 
BL21 (DE3) Star 
2 pVS41 ST-Npu
C
-eGFP-His6 provided by Prof. 
Henning Mootz, 
University of Münster 
TOP10 









created via subcloning TOP10 







 created via subcloning TOP10 






IFNα2a-NpuN-His6 GenScript TOP10 
BL21 (DE3) Star 
 Rosetta 








-His6 GenScript TOP10 










BL21 (DE3) Star 
Rosetta 
 
 Antibodies and Enzymes 2.4
Antibody Supplier 
Strep-MAB-Classic, HRP-Conjugate  iba (Göttingen, Germany) 
Mouse-anti-biotin, HRP-Conjugate Cell Signaling Technology (Danvers, 
USA) 
Mouse-anti-His antibody    Invitrogen (Carlsbad, USA) 
Goat anti-Mouse IgG, HRP-Conjugate Jackson ImmunoResearch Laboratories 
(West Grove, USA)  
Mouse anti-GPI made in-house by Dr. Reka Kurucz and 
Dr. Maria Antonietta Carillo 
 
Enzyme Supplier 
Antarctic Phosphatase New England Biolabs (Ipswich, USA) 
ConA Lectin Sigma Aldrich (St. Louis, USA)  
Phusion High-Fidelity DNA Polymerase  Thermo-Fisher Scientific(Waltham, USA) 
T4 DNA Ligase  New England Biolabs (Ipswich, USA) 
Taq Polymerase  New England Biolabs (Ipswich, USA) 
Restriction Enzymes:  New England Biolabs (Ipswich, USA) 
     EcoRV, HindIII, NdeI, PvuII, SapI 
 
Protease Supplier 
Trypsin, Sequencing Grade Roche (Rotkreuz, Switzerland)  




 Chromatography Columns  2.5
Column Supplier 
C4 Jupiter 50 x 2.1 mm, 300 Å   Phenomenex (Torrance, USA)  
C4 Jupiter 150 x 10 mm, 300 Å   Phenomenex (Torrance, USA) 
C8 ProPack 50 x 3 mm    YMC (Kyoto, Japan) 
C18 Hydrosphere 50 x 3 mm   YMC (Kyoto, Japan) 
C18 Hydrosphere 150 x 10 mm   YMC (Kyoto, Japan) 
Synergi 4 µm Fusion-RP 250 x 4.6mm  Phenomenex (Torrance, USA) 
Synergi 4 µm Fusion-RP 250 x 21.2 mm  Phenomenex (Torrance, USA) 
HisTrap FF 5 mL     GE Healthcare (Little Chalfont, UK) 
HisTrap HP 1 mL     GE Healthcare (Little Chalfont, UK) 
Superdex 30 pg HiLoad 16/600   GE Healthcare (Little Chalfont, UK) 
Superdex 75 pg HiLoad 16/600   GE Healthcare (Little Chalfont, UK) 
Superdex peptide 10/300 GL   GE Healthcare (Little Chalfont, UK) 
Yarra SEC-2000 300 x 4.6 mm   Phenomenex (Torrance, USA) 
 
 Software 2.6
Software Name Publisher 
Biopharmalynx     Waters (Milford, USA) 
ChemDraw Professional 16   PerkinElmer (Waltham, USA) 
ChemStation     Agilent (Santa Clara, USA) 
DNAStar Lasergene 9    DNAStar (Madison, USA)  
FlexControl & FlexAnalysis   Bruker Daltonics (Bremen, Germany)  
ImageJ      NIH (Open Source, http://imagej.ni.gov/ij) 
MassLynx      Waters (Milford, USA) 
MS Office       Microsoft (Redmond, USA) 
Origin Pro      Originlab (Northampton, USA) 
PurityChrom     Knauer (Berlin, Germany) 
 






Autoclave HICLAVE HG-80   HMC (Haar, Germany)    
Avanti J-E centrifuge with JA-10 and JA-  Beckman-Coulter (Brea, USA) 
25.50 rotors 
Benchtop Orbital Shaker MaxQ™ Thermo Scientific (Waltham, USA) 
Bio-Rad Electrophoresis System   Bio-Rad Laboratories (Hercules, USA) 
Circular Dichroism Spectrometer Chirascan Applied Photophysics (Leatherhead, UK) 
Electrophoresis Power Supply Power Pack Basic Bio-Rad Laboratories (Hercules, USA)  
ESI-QTOF Xevo G2-XS with Acquity   Waters (Milford, USA) 
H-class UPLC  
FPLC Knauer Azura    Knauer (Berlin, Germany) 
HPLC Knauer Azura preparative system  Knauer (Berlin, Germany) 
HPLC Waters 600 System with Waters  Waters Corporation (Milford, USA) 
 4187 Dual λ Absorbance Detector 
Herasafe KS Biological Safety Cabinet Thermo Scientific (Waltham, USA) 
HPLC Agilent 1100    Agilent (Santa Clara, USA) 
Imager G:Box Chemi-XXX6   Syngene (Cambridge, UK) 
Incubator       Memmert (Schwabach, Germany) 
Lyophilizer Alpha 2-4 LDplus   Christ (Osterode am Harz, Germany) 
MALDI-TOF Autoflex Speed MS   Bruker Daltonics (Bremen, Germany) 
Microplate Reader SpectraMax M5  Molecular Devices (San José, USA)  
NanoPhotometer NP80    Implen (Munich, Germany)  
pH meter pHenomenal 1100L   VWR (Radnor, USA) 
Tabletop centrifuge MiniSpin   Eppendorf (Hamburg, Germany) 
Tabletop centrifuge Multifuge X3R  Heraeus (Hanau, Germany)  
Tabletop centrifuge Micro Star 17R  VWR (Radnor, USA) 
Waterbath VWB 6     VWR (Radnor, USA)    
ThermoMixer C     Eppendorf (Hamburg, Germany)  
Vortex Genie 2     Scientific Industries (Bohemia, USA) 
 




 Methods  2.8
 Molecular Biology Methods 2.8.1
DNA restriction digests 
Restriction enzymes were purchased from New England Biolabs (Ipswich, USA).  
Digestions were set up according to the manufacturer’s instructions using the provided 
buffers. For test digestions, usually 1 µg DNA was digested using 1 µL restriction enzyme in 
1x restriction buffer (total volume 20 µL) at 37°C for 1 h. Digestions were analyzed in 
agarose gel electrophoresis.  
For preparative digestions, usually 5 – 20 µg DNA were digested with 1.5 µL restriction 
enzyme in 1x restriction buffer (total volume 50 µL) at 37°C for 1 h. Bands were excised 
under UV Light using a scalpel.  
Enzymes were inactivated by heating at 65°C for 15 minutes.  
 
Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate DNA fragments corresponding to their 
size for analytical as well as preparative purposes. 1% agarose (w/v) was dissolved in TAE 
buffer, melted in the microwave and poured into a Biozym gel tray. DNA-Dye NonTox 
(AppliChem) was used as loading buffer and staining solution. Gel electrophoresis was 
performed at 110 V. GeneRuler 1 kb Plus DNA Ladder (Fermentas) was used as a size 
marker.  
For analytical agarose gel electrophoresis, 200 ng – 1 µg DNA was loaded into the gel 
wells. The bands were visualized and documented using an UV gel documentation device 
(INTAS, Göttingen, Germany).  
In order to prevent DNA from damage by UV-light, for preparative agarose gel 
electrophoresis 5 µL of the preparative reaction were mixed with 1 µL DNA-Dye NonTox 
and loaded into a well as reference lane. In the next well, the remaining 45 µL + 8 µL dye 
were loaded. Following electrophoresis, the preparative lane was excised from the gel 
completely. Then, the DNA in the reference band was visualized as mentioned before and the 
position of the desired fragment’s positions was marked. Afterwards, the excised lane was 
placed again next to the gel and the fragment was cut out at the respective height. It was 
checked if all DNA had been cut out by shortly switching on the UV-light.  
 




DNA Preparation  
Plasmid DNA Isolation from E. coli cells 
Plasmid DNA was isolated from E. coli cells using “NucleoSpin” Plasmid Purification Kit 
(Macherey-Nagel, Düren, Germany) according to the manufacturers’ instructions.  
 
Generation of DNA stocks 
Bigger amounts of plasmid DNA were isolated using the “NucleoBond” Xtra Midi Plasmid 
DNA purification Kit from Macherey-Nagel following the manufacturer’s instructions.  
 
DNA Ligation 
Vectors were opened using appropriate restriction enzymes. The restriction sites were 
treated with alkaline phosphatase (New England Biolabs, Ipswich, USA) in order to prevent 
self-ligation. DNA fragments were ligated into the treated vectors using T4 DNA Ligase 
(New England Biolabs, Ipswich, USA) in the respective buffer on ice overnight (0°C to room 
temperature). 50 – 100 ng vector DNA was used and the required amount of insert DNA was 
calculated using equation (1). Vector-to-insert ratios of 1:3 to 1:5 were used.  
 
 
𝐴𝑚𝑜𝑢𝑛𝑡(𝑓𝑟𝑎𝑔𝑚𝑒𝑛𝑡) [𝑛𝑔] =  





a – depending on the ratio of vector:insert. a = 3 for ratio 1:3 
 
The ligation reactions were inactivated by heating at 65°C for 20 min. The ligated vectors 
were purified using agarose gel electrophoresis as described above. 
 
DNA Isolation from Agarose Gel Pieces 
Restricted DNA fragments and vectors were isolated from excised agarose gel pieces using 
the “QIAquick” Gel Extraction Kit from QIAGEN (Hilden, Germany) according to the 
manufacturer’s instructions.  
 
DNA Quantification 
DNA concentrations were determined by measuring the absorbance at 260 nm using a NP80 
NanoPhotometer (Implen, Munich, Germany) against TAE buffer as reference. DNA purity 




was assessed using the ratio of OD260/OD230 (expected to be 2.0-2.2) and OD260/OD280 (at 
~1.8 the sample is considered pure).  
 
Blue-White Screening 
In order to assess ligation success Blue-White-Screening was used to detect recombinant 
DNA in clones. The fragment of interest was ligated into a vector containing the gene for β-
galactosidase in the multiple cloning site (pBluescript). Following transformation into 
competent cells (TOP10 or DH5α), the cells were streaked onto LB-agar plates with X-gal 
and IPTG and incubated at 37°C overnight. Blue colonies indicate an intact β-galactosidase 
gene (i.e. no successful ligation): the functional enzyme converts X-Gal into 5,5'-dibromo-
4,4'-dichloro-indigo, a bright blue insoluble pigment. White colonies indicate successful 
ligation: here the β-galactosidase gene has been disrupted by the fragment of interest which 
was inserted in the multiple cloning site, no functional enzyme can be formed and X-Gal is 
not converted into the blue pigment.  
 
 
Figure 2.1: Blue-White Screening is used to check whether a DNA fragment of interest was successfully 
ligated into the vector. This picture shows an LB-agar plate presenting blue as well as white colonies. 
 
PCR – Polymerase Chain Reaction 
Preparative and Colony PCR were carried out using a Thermoblock C (Eppendorf, 
Hamburg, Germany).  
 
Preparative PCR 
PCR was applied to generate sufficient amounts of DNA sequences out of existing plasmids 
for cloning. Therefore, Phusion High-Fidelity DNA Polymerase (Thermo-Fisher Scientific, 
Waltham, USA) (a highly accurate enzyme) was. Forward and reverse primers were designed 
according to the desired starting and ending points, as well as required restriction sites. Each 
PCR reaction (50 µL) contained 1x HF Phusion Buffer, 200 µM dNTPs, 0.5 µM fw primer, 




0.5 µM rev primer, 1 – 10 ng template DNA and 1 U Phusion DNA Polymerase. The PCR 
program used was:  
- Start: 5 min, 95°C 
- 30 cycles of 30 s, 95°C, 30 s, 45 – 50°C (depending on the primers used), 60 s / 1 kb 
template, 68°C 
- Finish: 5 min, 68°C 
The resulting DNA fragment was analyzed in agarose gel electrophoresis.  
 
Colony PCR 
For identification of clones containing a desired insert, colony PCR was used. Since here the 
resulting amplified DNA was not going to be used in further experiments, Taq Polymerase 
(New England Biolabs, Ipswich, USA) was used as it is very fast, but error-prone. For colony 
PCR, single colonies were picked and resuspended in 100 µL sterile dH2O. 1 µL of this cell 
suspension was used as template.  
Each PCR reaction (50 µL) contained 1x Taq Polymerase Buffer, 200 µM dNTPs, 0.2 µM 
T7 fw primer, 0.2 µM T7 Term primer and 1.25 U Taq Polymerase.  
The PCR program used was:  
- Start: 3 min, 95°C 
- 30 cycles of 30 s, 95°C, 30 s, 50°C, 60 s / 1 kb template, 68°C 
- Finish: 5 min, 68°C 
The fragment size was checked via agarose gel electrophoresis. The remaining cell 
suspension of a correct clone was streaked on a LB-agar plate with the respective antibiotic 
and incubated at 37°C overnight.  
 
DNA Sequencing 
DNA samples were sent to MWG-Biotech (Eberberg, Germany) for sequencing in order to 
check the correctness.  
 
Competent Cells 
For the preparation of chemically competent cells, a 2 mL LB preculture of the desired cells 
was grown (i.e. TOP10, BL21 (DE3) Star, or others) at 37°C overnight, shaking at 220 rpm. 
The next day, 200 mL of LB medium was inoculated with the preculture and grown to an 
OD600 of 0.4 – 0.6 at 37°C, 150 rpm. As soon as the culture reached the required OD600 it was 
cooled down on ice for 15 minutes in order to stop the growth and cool the bacteria down. 




From now on, cells were kept on ice wherever possible. The cells were harvested by 
centrifugation in a Beckman Avanti Centrifuge at 3000 x g for 10 minutes. The cell pellet was 
resuspended in 10 mL of 100 mM CaCl2 solution and incubated on ice for 1 h. Following 
centrifugation and incubation, these steps were repeated once. Afterwards, the pellet was 
resuspended in 2 mL of 100 mM CaCl2 containing 15% (v/v) glycerol and incubated on ice 
for 30 minutes. Aliquots of 200 µL were transferred quickly into precooled reaction tubes, 
and frozen immediately in a dry ice / ethanol bath. Competent cells were stored at – 80°C.  
To test transformation efficiency, a test transformation was performed using 50 pg of 
pUC18 vector.  
 
Heat Shock Transformation 
An aliquot of 50 – 100 µL of chemically competent cells was thawed slowly on ice. 1 – 
2 µL of DNA were added to the cell suspension, and incubated on ice for 30 minutes. Cells 
were heat shocked in a 42°C water bath for 30 seconds, and rested on ice for 1 – 2 minutes. 
1 mL of pre-warmed LB medium was added to the cells and they were incubated at 37°C for 
1 h (30 minutes in case of Amp-resistance gene, 1 h for Kan-resistance), shaking vigorously. 
Cells were centrifuged in an Eppendorf Minispin centrifuge at 3000 rpm, 2 minutes. After 
removal of the supernatant, the cells were resuspended and plated onto an LB-agar plate 
containing the required antibiotic. The plates were incubated at 37°C overnight and checked 
for colonies the next day.  
Following the cloning steps, cryo stocks of all clones were prepared by transferring 1 mL of 
a saturated overnight culture of the respective clone into RotiStore Cryo Vials (Roth, 
Karlsruhe, Germany), shaking it 5 times and removing the liquid. The cryo stocks were then 
stored at -80°C.  
 
 Bacteria Cultivation and Protein Expression 2.8.2
Cultivation of Bacteria for Protein Expression 
Generally, cryo stocks were streaked on a LB-agar plate containing the appropriate 
antibiotic for the respective clone using a spreader rod and incubated at 37°C overnight. The 
next day, a liquid preculture (10 – 50 mL LB medium with the appropriate antibiotic) was 
inoculated with one fresh colony using an inoculation loop and incubated at 37°C overnight, 
shaking at 220 rpm. If not stated otherwise, the main cultures were inoculated to a starting 




OD600 of 0.05 in baffled 2 L shake flasks (Roth, Karlsruhe, Germany) filled with max. 0.5 L 
LB medium with the respective antibiotic. The cultures were grown to the late exponential 
growth phase (i.e. OD600 of ca. 0.6 – 0.8) and the recombinant protein expression was induced 
with 0.1 – 1 mM IPTG. The induction concentrations as well as expression temperatures were 
optimized for each clone individually between 12°C and 37°C. Following expression, the 
cells were harvested by centrifugation at 10.000 x g. The cleared medium was discarded.  
 
Measurements of Optical Density 
In order to assess bacterial growth, optical density at 600 nm (OD600) was measured against 
fresh LB medium as reference using half-micro plastic cuvettes with NP80 Nanophotometer 
(Implen, Munich, Germany). If values above OD600 of ~1 were observed or expected, the cell 
broth was diluted with LB medium, to keep values below 1.  
 
 Protein Purification 2.8.3
Cell lysis 
After harvesting, the bacterial cells were resuspended in a lysis buffer suitable for the first 
following purification step. If not stated otherwise, protease inhibitors have been included in 
the buffers. A first lysis was achieved by incubation with 0.25 – 0.5 mg/mL lysozyme for 
30 min – 1 h at 30°C, or at 15 – 18°C overnight. Subsequently, the suspension was sonicated 
on ice using Digital Sonifier (Branson), with amplitude 20 – 40%, using pulses and pauses of 
10 – 30 sec. Special care was taken to avoid heating of the samples. Finally, the suspension 
was centrifuged at 24,400 x g for 1 h at 4°C.  
Depending on protein solubility, the resulting supernatant was subjected to further 
purification methods, or the cell pellet was solubilized using 6 – 8 M urea.  
 
Affinity Chromatography 
In this work several affinity tags have been applied for the purification of proteins using 
affinity chromatography. The methods are listed below, sorted according to the tag used.  
 
Strep-tag 
The strep-tag II is an eight amino acid (Trp-Ser-His-Pro-Gln-Phe-Glu-Lys) tag that can be 
used at the N- or C-terminus of proteins for detection or purification using StrepTactin
® 






 For purification, the clarified and filtered (0.2 µm using a syringe filter) cell lysate in 
buffer W was loaded to StrepTactin
®
 resin according to the manufacturer’s instructions, 
washed with 10 – 15 CV of buffer W, before eluting the protein of interest using 6 x 0.5 CV 
of buffer E. The fractions including flow-through and wash fractions were analyzed on SDS-
PAGE. Fractions containing the protein of interest were pooled and dialyzed in order to 




For His-tag affinity purification the protein of interest is fused to six neighboring His 
residues at its N- or C-terminus.
148,149
 The protein of interest can be bound to a Ni
2+
 NTA 
(nitrilotriacetic acid) resin by metal chelation (see Figure 2.2) whereas host proteins flow 





Figure 2.2: Schematic depiction of the interaction of the His6-tag with Ni
2+
-NTA resin. Four valencies of the 
nickel ion are interacting with the immobilized NTA resin while the remaining two valencies are interacting with 




For purification of fusion proteins from cleared cell lysate, HisTrap™ FF crude 5 mL 
columns (GE Healthcare, Little Chalfont, UK) preloaded with Ni
2+
 ions were used in a 
Knauer Azura FPLC system. Once column was equilibrated with HisTrap Equilibration buffer 
(containing 10 – 30 mM imidazole), up to 8.5 mL clarified lysate were loaded using a 10 mL 
sample loop and a manual injection valve. The flow-through (20 mL) was collected in a 50 
mL falcon tube before the column was washed with 10 CV (collected in a 50 mL falcon tube). 
Subsequently, the bound fusion protein was eluted by a gradient from 10 – 30 mM imidazole 




to 500 mM imidazole over 5 CV. The fractions including flow-through and wash fractions 
were analyzed on SDS-PAGE. Fractions containing the protein of interest were pooled and 
dialyzed in order to remove imidazole, or subjected to further purification steps as required 
(i.e. size exclusion chromatography). 
 
Chitin Binding Domain with simultaneous protein thioester formation 
The chitin binding domain (CDB) is commonly used in combination with a modified intein, 
rendering it a self-cleaving affinity tag.
123,152
 It is included in the commercially available 
IMPACT (Intein-Mediated Purification with an Affinity Chitin-binding Tag) system (NEB, 
Ipswich, USA) for purification of the intein fusion constructs via a chitin resin (also NEB). 
Different vector systems exist, having the intein-CBD domain either on the N- or the C-
terminus. The pTXB1 vector used in this work gives a fusion protein with the protein of 
interest fused at its C-terminus to the MxeGyrA intein from Mycobacterium xenopi and the 
CBD. If DTT or β-mercaptoethanol is used for intein cleavage, the whole tag will just be 
removed and the thiol hydrolyzed. The purification via CDB can however also be used with 
simultaneous intein cleavage and protein thioester formation by using more stable thiol 
reagents such as MESNA.  
In a typical purification, a gravity flow column is prepared with the chitin resin slurry (50% 
in ethanol); generally a column with CV = 1.5 mL was used for 100 mL culture volume. After 
washing the resin with 5 CV dH2O and equilibration with buffer W (pH 7.5, 2 x 5 CV), the 
clarified lysate was loaded to the column (10 mL). The flow-through was collected. The 
column was washed with 3 x 10 CV buffer W (collected). Subsequently, the intein cleavage 
was induced by flushing the column with 3 CV cleavage buffer (buffer W + 50 mM thiol, pH 
7.0), closing the column and incubating at room temperature for 16 – 40 h (depending on the 
thiol used). The pure protein thioester was eluted with 6 x 0.5 CV buffer W, pH 7.0. The 
fractions including the flow-through and wash fractions were analyzed in SDS-PAGE. 
Fractions containing the protein thioester (usually elution fractions No. 2 – 5) were pooled 
and subjected to size-exclusion chromatography on a Superdex peptide 10/300 GL column 
(GE Healthcare, Little Chalfont, UK) for removal of unreacted thiol.  
 
Size Exclusion Chromatography 
Size Exclusion Chromatography (SEC) was generally applied as a polishing step in protein 
purification, i.e. following an initial capturing step. In SEC, proteins are separated by size 
rather than by any interaction with the stationary phase. Smaller proteins and other molecules 




can enter into the pores of the stationary phase material which usually consists of small 
porous polymer beads such as agarose or sepharose with different pore sizes. Therefore, 
smaller molecules are retained longer during the run and elute later than larger proteins.  
Depending on the purpose and the molecular size, different SEC columns were used. The 
separations were carried out using a Knauer Azura FPLC System:  
- Superdex 75 pg HiLoad 16/600 for proteins (CV = 120 mL)  
- Superdex 30 pg HiLoad 16/600 for peptides (CV = 120 mL)  
- Superdex peptide 10/300 GL for peptides or for desalting of proteins (CV = 24 mL)  
 
Generally, all samples were centrifuged at 13.3 k rpm and / or filtered through a 0.2 µm 
syringe filter prior to loading on SEC columns. Maximum 1.5 mL of sample containing 0.5 – 
10 mg protein was loaded onto the Superdex 75 column.  
 
RP-HPLC 
Reverse-Phase High Performance Liquid Chromatography (RP-HPLC) was also used for 
protein purification in some cases. HPLC is based on the principles of distribution (reversed 
phase) and adsorption (normal phase) of the analyte on the stationary phase. In the case of 
RP-HPLC the stationary phase generally consists of a porous, often silica-based material 
which is surface-modified with non-polar alkyl chains (most commonly C18, C8 and C4 
chains). The mobile phase is in this case most commonly a combination of water and 
acetonitrile or methanol. Generally, the analyte is first bound to the stationary phase at a low 
concentration of acetonitrile (ACN) or methanol before it is eluted by a linear gradient of the 
respective solvent. When RP-HPLC is used with proteins, the retention of the proteins 
depends mainly on their hydrophobicity. Low percentages of organic acids are often used in 
order to decrease the pH, rendering the proteins positively charged and enhancing the 
separation and peak shape.
153
  
For protein purification, a Phenomenex Jupiter C4 column (10 x 150 mm, 5 µm particle 
size, pore size 300 Å) was used which is specifically designed for the separation of 
hydrophobic proteins.
154
 Separations were performed on a Waters 600 system (Controller and 
Pump) with a Waters 2487 Dual λ Absorbance Detector and a flow rate of 4 mL/min. 
Gradients were optimized starting from a standard gradient of 10 to 70% acetonitrile (ACN) 
in water with 0.1% TFA in 30 minutes for a good separation of the protein of interest from 
any contaminants. Up to 10 mg of protein was injected using a manual injection valve with a 
2 mL sample loop. Fractions were collected manually according to the absorption observed 




and analyzed in MALDI-TOF-MS in order to identify fractions containing the protein of 
interest in high purity. The respective fractions were then combined, frozen and lyophilized.  
 
Protein Concentration Determination 
Protein concentrations were generally determined using Pierce BCA Protein Assay Kit 
(Thermo Scientific, Waltham, USA) according to the manufacturer’s instructions (microplate 
procedure). If use of BCA assay was not possible due to thiol compounds present in the 
solution, QuickStart Bradford 1x Dye Reagent (Bio-Rad (Hercules, USA) was used by mixing 
100 µL dye with 100 µL protein sample in a 96-well plate and measuring the absorption at 
595 nm using Microplate Reader SpectraMax M5 (Molecular Devices, San José, USA).  
 
 Peptide Synthesis and Native Chemical Ligation 2.8.4
Synthesis of peptide hydrazides using automated SPPS 
Peptide synthesis was performed in collaboration with GPI-group members Dr. Dana 
Michel and Antonella Rella by Fmoc-SPPS (Solid Phase Peptide Synthesis) using a CEM 
Microwave Peptide Synthesizer (Liberty Blue).  
NovaPEG Wang resin (Novabiochem) with a substitution of 0.63 mmol/g was used for 
peptide synthesis in 0.1 mmol scale (250 mg resin). After introducing a hydrazide linker to 
the resin, the first amino acid was coupled manually using a fritted single use syringe. The 
loading was checked using Fmoc quantification as following: approx. 1 mg of dry resin was 
added to 1.5 mL of 20% piperidine in DMF and shaken for 15 min. The slurry was 
centrifuged and the supernatant was diluted 1:1 in 20% piperidine in DMF. UV absorption 
was measured at 290 nm in a quartz cuvette against 20% piperidine in DMF. The substitution 
grade of the resin was determined using equation 2 (considering an ε=5253 M-1cm-1 for the 












According to the substitution grade the amount needed was calculated for the other reagents. 
The resin was then transferred to the synthesizer and the synthesis was run using 1 M Oxyma 
with 0.1 M DIPEA in DMA as activator base and 0.5 M DIC in DMF as activator. Fmoc 




deprotection was performed with 20% piperidine in DMF after each coupling step. Coupling 
conditions are listed in Table 2.2.  
 
Table 2.2: Coupling and deprotection cycles for different amino acids. 
Amino Acids Coupling  Deprotection 
2
nd
 amino acid single coupling (90°C for 2 min) double deprotection 
Argo double coupling (25°C for 25 min, 
75°C for 2 min) 
double deprotection 
His & Cys double coupling (25°C for 2 min, 
50°C for 10 min) 
double deprotection 
Ile & Glu double coupling (25°C for 25 min, 
75°C for 2 min) 
single deprotection 
all other amino acids two minutes single coupling 90°C single deprotection 
 
The peptide was cleaved from the resin by treatment with a TFA/TIPS/water mixture 
(90:5:5) 90 min at RT under shaking. The peptide was precipitated and washed with ice-cold 
ether three times. Peptide samples were analyzed in RP-HPLC (C18 Hydrosphere column 3 x 
50 mm, YMC) using a 30-minute gradient of 5 – 70% acetonitrile in water with 0.1% TFA. 
The sample was analyzed by MALDI-TOF-MS using DHB as matrix and a reflector method 
in positive ion mode. The peptides were purified using a Knauer Azura HPLC system with a 
Phenomenex Synergi RP-fusion preparative column (21.1 x 250 mm). Fractions were 
collected, lyophilized and analyzed in analytical RP-HPLC and MALDI-TOF-MS following 





respectively, were combined, lyophilized and weighed.  
 
Generation of Peptide Thioesters 
Peptide thioesters were generated using a protocol adapted from Zheng at al. (2013).
136
 The 
purified NpuC-hydrazide was dissolved in diazotation buffer at a concentration of 1.5 mM at 
pH 3 and stirred at -10°C for 20 minutes to form the peptide azide. To induce thioester 
formation, the solution was warmed to room temperature, 100 eq. thiol (i.e. MMBA, MPAA, 
MMP) were added and the pH was carefully adjusted to 7.0 using 6 M NaOH. After stirring at 
RT for 20 minutes, the thioester was immediately purified and analyzed using RP-HPLC as 
described above.  





Native Chemical Ligation of Peptide Thioesters to GPI Molecules and Model 
Compounds 
The purified peptide thioester was dissolved to a concentration of 1.5 mM in NCL buffer 
containing 100 eq. thiol and 5 eq. TCEP per Cys residue in the sequence. Cys-biotin or Cys-
GPI (10 eq. or 0.9 eq., respectively) was added and the mixture was incubated at 37°C, 
shaking vigorously. The ligation reaction was monitored by RP-HPLC (C18-Hydrosphere, 
YMC, 3 x 50 mm for biotin ligations or Jupiter C4, Phenomenex, 2.1 x 50 mm for GPI 
ligations) and LC-MS (C18 or Protein C4 BEH, Waters, 2.1 x 50 mm). Ligations with Cys-
biotin were typically completed after 1 – 2 days while ligations to Cys-GPI needed longer 
incubation (one week). The ligation products were purified using RP-HPLC on a Phenomenex 
Synergi RP-Fusion column (4.6 x 250 mm) for Npu
C
-biotin, and a Phenomenex Jupiter C4 




 Protein Ligation Methods 2.8.5
Expressed Protein Ligation 
Fusion proteins of a protein of interest (POI) and the Gyrase A mini intein from 
Mycobacterium xenopi (MxeGyrA)
123
 were expressed in E. coli. After obtaining the respective 
protein α-thioesters a solution of 1 mg/mL thioester in Ligation buffer (20 mM Tris/HCl pH 
7.0, 150 mM NaCl), TCEP (up to 0.5 mM) and the thiol reagent (MMBA, MPAA, MESNA 
or MMP) at a final concentration of 50 – 200 mM was prepared. The molecule to be ligated 
was added to the thioester mixture. Cys-biotin (5 eq.), Cys-dimannose (2 eq.) or Cys-GPI (0.9 
– 1.1 eq.), respectively. The pH was readjusted to 7.0 with 1 M NaOH, if necessary. The 
ligation mixture was incubated shaking at room temperature. Reaction progress was 
monitored using RP-HPLC, SDS-PAGE and western blotting.  
 
Protein Trans-Splicing 
For protein trans-splicing (PTS), the purified proteins were dialyzed in splicing buffer 
adapted from Zettler et al.
155
 (50 mM Tris/HCl pH 7.0, 300 mM NaCl, optional 6 M urea,). 
Proteins were combined at a final concentration of 15 – 20 µM with 0.7 – 1.5 eq. of NpuC-
biotin or Npu
C
-mGPI. TCEP was added to a final concentration up to 0.5 mM and it was 
optimized for each POI separately. The reaction mixture was incubated shaking at a 




temperature optimized for the respective protein. The reaction progress was monitored using 
RP-HPLC, SDS-PAGE and western blotting.  
 
One-Pot Ligation 
A modified ligation strategy was developed in this work: One-Pot Ligation (OPL) 
circumvents the necessity to purify a generated peptide or protein thioester ligating it to the 
target molecule (biotin, dimannose or GPI, respectively) using NCL/EPL in situ after 
formation. Instead, a modified C-terminal intein peptide (Npu
C
(AA)) was designed and 
synthesized in automated SPPS simply as peptide hydrazide (see chapter 2.8.4).  
For OPL reactions, the same basic setup as for PTS reactions could be adopted: To a 
solution of 15 – 20 µM fusion protein in splicing buffer 1.2 eq. of the modified NpuC(AA) 
peptide was added together with up to 0.5 mM TCEP (optimized for each protein) and the 
anchoring molecule (Cys-biotin (5 eq.), Cys-dimannose (2 eq.) or Cys-GPI (0.9 eq.), 
respectively). Additionally, the thiol reagent (MMP, MMBA or MPAA) was added to a final 
concentration between 50 and 200 mM. The reaction mixture was then incubated shaking at 
an optimized temperature between 16°C and 37°C. The reaction progress was monitored in 
RP-HPLC, SDS-PAGE and western blotting.  
 
 Purification of Reaction Products 2.8.6
Purification of the reaction products was carried out using the same chromatography 
methods that were used for fusion protein purification, such as his-tag or strep-tag affinity 
chromatography and RP-HPLC.  
Furthermore, a phase-separation method using Triton X-114 was tested for the separation of 
reaction products containing lipidated GPIs from unreacted reaction partners. 
156
 The method 
was performed as specified in the protocol.
157
 One part of sample solution was mixed with 
three parts of ice-cold PBS buffer and 1.5 parts pretreated Triton X-114, vortexed vigorously 
and then the phases were separated using a Pasteur pipette.  
 





Figure 2.3. Triton X-114 separation of lipidated protein. Proteins carrying a lipidation (or a glypiation) are 
expected to incorporate into Triton X-114 micelles and by this can be separated from proteins without lipidation 
by phase separation.  
 
 Product Characterization 2.8.7
In order to follow the purification of fusion proteins, synthesis of peptides and progress of 
ligation reactions, following analytical methods were used.  
 
SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a commonly 
used technique for the separation of proteins or other biomolecules by their molecular weight. 
Gels are generated from polyacrylamide and placed in a buffer filled tank between a cathode 
and an anode. SDS is a strong detergent masking the charge of the proteins so by applying a 
voltage they migrate in the polyacrylamide gel according to their size.
158
 To achieve this, the 
protein samples are treated with a solution of 1% SDS and a reductant (often DTT or β-
mercaptoethanol) and heated for 5 minutes at 100°C in order to completely denature them. In 
1970, an improved discontinuous system was developed by U. Laemmli in which the proteins 
are first focused in a stacking gel with low polyacrylamide before migrating at different 
speeds according to their molecular weight in a separation gel with a polyacrylamide 
concentration of 8 – 20%, depending on the protein sizes to be separated.159  
In this work, gels with 15% polyacrylamide were mainly used, if not stated otherwise, 
which are best suitable for small proteins in the range of 15 – 50 kDa. Gels were prepared in a 
gel casting chamber (Bio-Rad, Hercules, USA) according to the following protocol and 
placed in a Mini-PROTEAN Tetra cell (Bio-Rad) with SDS-PAGE running buffer:  
 




- Stacking gels for SDS-PAGE (4%): 125 mM Tris/HCl pH 6.8, 4% acrylamide / 
bisacrylamide (29:1 mixture), 1% APS, 1% TEMED 
- Separation gels for SDS-PAGE (15%): 250 mM Tris/HCl pH 8.8, 15 % acrylamide / 
bisacrylamide (29:1 mixture), 1% APS, 1% TEMED 
 
In some cases precast gels (Mini-PROTEAN® TGX™ Precast Gels, Any kD, Bio-Rad) 
were also used for a slightly different separation pattern. The samples were mixed 4:1 with 4x 
reducing SDS sample buffer, boiled at 99°C for 5 minutes and loaded into the gel. A voltage 
of 200 V was then applied and the electrophoresis was run until the dye front reached the 
bottom of the gel (ca. 30 – 45 minutes).  
Following electrophoresis, the gels were stained with Coomassie Brilliant Blue using 
InstantBlue Stain (Expedeon, Cambridgeshire, UK). ImageJ Software was used for relative 
quantification of calculation of splicing yields in coomassie-stained gels.  
Proteins available in very small amounts were detected using silver staining according to the 
following protocol:  
- Fixation of the proteins in the gel by incubation at room temperature for two hours in a 
solution of 40% ethanol and 10% acetic acid in dH2O 
- Rinsing of the gel to remove excess acetic acid by incubation of the gel in 50% ethanol 
in dH2O three times for ten minutes 
- Sensitization by incubation in a solution of 0.02% (w/v) sodium thiosulfate (NaaS2O3) 
for 1 – 2 minutes 
- Washing in water three times for 20 seconds 
- Staining by incubation in a cold solution of 0.2% (w/v) silver nitrate (AgNO3) and 
0.075% (v/v 37 % CH2O) formalin in dH2O in the dark 
- Following another washing step (2 x 20 sec), the gel was developed by incubation in a 
solution of 6% (w/v) sodium carbonate (Na2CO3), 0.05% (v/v 37 % CH2O) formalin and 
2% (v/v) sensitizing solution in dH2O for up to five minutes, until bands were visible 
- The gel was washed in water again (2 x 20 sec) and the staining was stopped by the 
addition of 5% acetic acid in dH2O 
- The gel can be stored in 1% acetic acid in dH2O 
Sensitizer, staining solution and developer need to be prepared freshly before use.  
 





Native PAGE is a modification of SDS-PAGE in which proteins can be analyzed in 
polyacrylamide gels in non-denaturing conditions. In this case the proteins will still have their 
natural net charges as those are not masked by SDS and their natural conformation. This leads 
to a separation of the proteins by charge, shape and size rather than only by molecular weight. 
In the pH of the running buffer (ca. 8.8), most proteins are negatively charged and will 
migrate towards the anode. This can give insights about the folding of a protein.  
The gels were prepared in the same way as described for SDS-PAGE, placed in the gel 
chamber with Native PAGE running buffer, which does not contain any SDS. The samples 
were prepared by mixing 1:2 with Native PAGE Sample buffer 2x (no reducing agents) and 
loaded directly into the wells of the gel without heat treatment. A voltage of 200 V was 
applied and the proteins were allowed to migrate for 45 minutes.  
The gels were stained using coomassie staining as described for SDS-PAGE.  
 
Western Blot 
In western blotting, proteins separated using SDS-PAGE are transferred to a nitrocellulose 
or PVDF (polyvinylidene difluoride) membrane by applying an electric field orthogonally to 
the gel. The proteins are negatively charged since they are covered in SDS, and migrate 
towards the anode and the membrane. Following the electrophoretic transfer, the membrane is 
blocked using BSA to prevent unspecific binding of the antibodies used for detection of the 
proteins of interest.  
The gel with separated proteins by SDS-PAGE was placed in the blotting chamber filled 
with Western Blot Transfer Buffer together with the prewetted PVDF membrane in between 
four sheets of blotting paper. The proteins were blotted onto the membrane by applying a 
current of 350 mA for 1 h. Heating of the buffer was prevented by placing an ice pack in the 
blotting tank. The proteins on the membrane were stained by placing the membrane in a 
Ponceau S staining solution for five minutes; excess staining was removed by washing with 
dH2O. The membrane was blocked by incubation with 5 % BSA in PBST or TBST 
(depending on the antibody to be used) for 1 – 2 h.  
Following blocking, the membrane was incubated with the respective antibody or lectin 
using the manufacturer’s conditions, or using own optimized conditions. Either the primary 
antibody was already equipped with an HRP-conjugate, or a secondary antibody-HRP-
conjugate was used for chemiluminescence detection using ECL substrate together with a 
chemiluminescence imager (Imager G:Box Chemi-XXX6, Syngene, Cambridge, UK).  





Matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry
160
 is an MS 
technology widely applied for the analysis of large biomolecules such as proteins or lipids. It 
is a soft ionization method that enables big bio-molecules to be transferred into the gas phase. 
A matrix substance with strong UV absorbance is co-crystallized with the analyte in a ration 
of ca. 5000:1 (mol/mol). Commonly used matrix compounds are shown in Figure 2.4. The 
theory of ionization in MALDI is not completely understood but the commonly accepted 
model is the following as described by Karas & Krüger (2003)
161
: the co-crystals are desorbed 
from the sample carrier by high-energy laser pulses of few nanoseconds; the high excess of 
matrix molecules is taking the analyte molecules with them and by a dense plume consisting 
of neutral matrix molecules, reactive species such as matrix radicals, electrons and hydrogen 
atoms, and a small but sufficient amount of sample ions. This plume expands into the vacuum 
of the mass spectrometer source and accelerated according to its mass-to-charge ratio (m/z). 
Therefore, the MALDI technique is most commonly used in combination with a TOF mass 
detector due to the pulsed generation of ions. In MALDI, generally the singly charged ion 
[M+H]
+
 is the most frequently observed species,
161













Sinapinic acid (SA) 
Figure 2.4: Commonly used matrix compounds in MALDI of biomolecules: 2,5-dihydroxybenzoic acid (DB), 
dihydroxyacetonphosphate (DHAP) and sinapinic acid (SA).  
 
For analysis in MALDI-TOF-MS, samples were desalted using C18 or C4 ZipTip
®
 pipette 
tips. Prior to use, the tips were conditioned with 0.1% TFA in acetonitrile and equilibrated 
with 0.1% TFA in dH2O. The sample was washed with 0.1% TFA in dH2O and eluted in 30 – 
70% acetonitrile, 0.1% TFA in dH2O, depending on the sample properties. The salt-free 
samples were mixed in a 1:1 ratio with a DHB matrix solution, spotted onto a MALDI target 
plate (AnchorChip™ 400/384, Bruker Daltonics, Bremen, Germany) and dried under ambient 
conditions at room temperature. If a good ionization could not achieved using these 




conditions, a different matrix type (DHAP, SA) as well as different matrix-sample ratios were 
tested.  
Preparations of matrix solutions and sample spotting as described in the Bruker MALDI 
sample preparation protocols:  
- DHB: 20 mg/mL 2,5-dihydroxybenzoic acid in TA30 (30% acetonitrile, 0.1% TFA in 
dH2O). Use of dried droplet method, as described above 
- DHAP:  7.6 mg 2,5-dihydroxyacetophenone is dissolved in 375 µL ethanol. Then 
125 µL of a solution of 18 mg/mL DAC (diammonium hydrogen citrate) is added. The 
sample solution, matrix solution and a solution of 2% TFA in dH2O were premixed in a 
ratio of 1:1:1 and pipetted up and down until crystallization started, then 1 µL of the 
mixture was spotted onto the target plate and dried 
- SA: Matrix solution I: sinapinic acid saturated in ethanol, matrix solution II: sinapinic 
acid saturated in TA30. For SA, the double layer method was applied: firstly, a drop of 
matrix solution I is spotted onto the target plate, then 1 µL of a 1:1 mixture of sample 
solution and matrix solution II are spotted on top and dried 
 
Protein and peptide standards (Peptide Standard IV, Protein Standard I and II, Bruker 
Daltonics, Bremen, Germany) were also prepared and used for calibration of methods at 
regular intervals. Following drying, the samples were subjected to MALDI analysis in a 
Bruker Autoflex™ Speed instrument using Flex Control Software (Bruker Daltonics, Bremen, 
Germany).  
Peptides were generally analyzed in reflector positive ion mode, if not stated otherwise. 
Mass spectra were acquired in the mass range between 500 m/z to 6,000 m/z. Proteins were 
analyzed in linear positive ion mode and mass spectra were recorded in the mass range 
between 10,000 m/z and 50,000 m/z, or as required. Synthetic GPI molecules were analyzed 
in linear mode, positive as well as negative ion mode; spectra were recorded in the range 
between 500 m/z and 4,000 m/z. Spectra were analyzed using Flex analysis software (Bruker 
Daltonics, Bremen, Germany).    
 
RP-HPLC 
Analytical RP-HPLC was performed on an Agilent 1100 System with a G1315B DAD 
detector. Water with 0.1% TFA and acetonitrile were used as mobile phase. All samples were 
centrifuged and / or filtered prior to injection. 




Peptide samples were analyzed using a YMC Hydrosphere C18 column (50 x 3 mm, 3 µm 
particle size, 12 nm pore size). Protein samples were analyzed using a Phenomenex Jupiter C4 
column (50 x 2.1 mm, 5 µm particle size, 300 nm pore size). Generally, 5 – 10 µg peptide or 
protein dissolved in 1 – 10 µL 20% acetonitrile, 0.1% TFA in dH2O were injected into the 
column. As a starting point, a gradient of 5 – 70% acetonitrile in 30 minutes was used for 
peptide samples. If required, other gradients were also used, for example 10 – 30% 




LC-MS is a valuable tool in the analysis of biomolecules that combines a separation by RP-
HPLC with mass spectrometry. In LC-MS, an HPLC instrument with a UV/VIS or DAD 
detector is coupled to a mass spectrometer and the compounds separated by HPLC are 
analyzed in mass spectrometry according to their retention time. ESI (electrospray ionization) 
is most commonly used for LC-MS due to the low energy required for ionization and analysis 
of large molecules such as proteins without a high degree of fragmentation.
162
 However, it 





 are commonly observed while in case of large proteins ions such as [M+30H]
30+
 
are commonly observed. Adduction of counter ions (e.g. sodium, potassium, ammonium ions 
in pos. mode, formate or acetate in neg. mode) is also observed if salts are present in the 
sample.
162
 In LC-ESI-MS, the solvent coming from the LC part is sprayed through a capillary 
that is placed orthogonally or off-axis from the mass spectrometer entrance with the help of 
an inert gas (often nitrogen). At the capillary, a voltage of 3 – 5 kV is present, nebulizing the 
liquid to form small charged droplets which are then rapidly evaporated by applying heat and 
nitrogen flow.
162
 This reduces the droplet size which following repeated disintegration 
(Coulomb fissions) yields very highly charged droplets capable of eventually generating gas 
phase ions. In case of proteins, it is reported to be likely that small droplets containing just 
one protein molecule are formed and by evaporation of the solvent, the charges of the droplet 
are transferred to the protein, thereby generating a multiply charged ion. This theory is called 
Charged Residue Model (CRM). Some of these ions enter the actual mass spectrometer via 
the interface (either a tiny hole or a capillary at the MS entrance).
163
  
In this work, a Waters Xevo G2-XS with an Acquity H-class UPLC was used. In this 
instrument, the ESI source is coupled to a quadrupole-time-of flight (QTOF) mass analyzer. A 
quadrupole consists of four parallel metal rods. The two opposite rod pairs are connected 




electrically. The quadrupole is used to generate an oscillating electric field which can be used 
to filter ions of specific m/z ratios. In the TOF mass analyzer, the ions are further separated.  
 
Tryptic Digestions of Proteins 
Additional to the before mentioned top-down approach an analyzing the intact proteins and 
protein conjugates, the classical bottom-up approach was also applied. Proteins in gel pieces 
were digested by proteolytic enzymes such as trypsin and the peptide fragments were 
subsequently analyzed in MS.  
For tryptic digestions the protocol described in Kolarich et al.
164
 was followed in a slightly 
modified way. The digestions were carried out for only 20 min to 1.5 h at 37°C instead of 
16 h as over-digestion was observed using the long incubation time, yielding too short 
fragments. Furthermore, instead of analyzing the fragments in ESI-MS, they were analyzed in 
MALDI-TOF-MS.  
The expected peptide fragments were calculated by the web tool ExPASy PeptideMass
165
 
for the respective protease and modifications. The peptide fragments found in MALDI-TOF-
MS analysis were then compared to the expected fragments and the coverage of the protein 
sequence was assessed.  
 
Circular Dichroism (CD)  
Circular dichroism utilized circularly polarized light to determine the optical properties of 
chiral compounds. This is also a commonly used technique to study the secondary structure of 
proteins.
166
 To utilize this effect, plane polarized light made up of two components of equal 
magnitude, one rotating counter-clockwise (L), the other rotating clockwise (R) is passed 
through a sample containing the protein in solution (ideally in water). The sample will exhibit 
absorbance of the L and R light components, and if absorbance of both components is 
different, a CD signal will be observed, indicating chiral nature of the sample compound. In 
proteins, many chromophores are present, including the peptide bond (absorbance < 240 nm), 
aromatic amino acid residues (260-320 nm) and disulphide bonds (around 260 nm). By 
measuring signals below 240 nm, information about protein secondary structure can be 
obtained, as α-helices, β-sheets and turn regions each exhibit certain absorbance patterns that 
are specific for the respective structures. This information can be used to determine the 
percentage of each structure, or simply to identify the predominant structural features of a 
protein.  




For CD measurements, protein samples were prepared in PBS buffer at concentrations 
ranging from 0.1 – 1 mg/mL, depending on the amounts available. The protein solution was 
then filled into a High Precision Cell Quartz cuvette (light path 1 mm) and placed in the 
Chirascan Circular Dichroism Spectrometer. Circular dichroism was measured between 190 
and 260 nm against PBS buffer as a reference and measurements were performed in 
triplicates. The averages of these measurements were plotted over the wavelength.  










 Establishing the Analytical Conditions for Proteins 3.1
In order to be able to follow the progress of protein purification as well as for monitoring 
the different reactions and for quality control, it was essential to establish a suitable analytical 
environment with the respective methods. Standard techniques were used such as SDS-
PAGE, Western Blotting, MALDI-TOF-MS, RP-HPLC and tryptic digestions. In the case of 
HPLC, suitable RP-columns had to be identified for the analysis of the protein-glycolipid 
conjugates to be analyzed. Furthermore, methods were developed for the analysis of intact 
proteins using a Waters Xevo G2-XS QTOF which was set up at the MPIKG during the 
period of this thesis.  
 
 HPLC for Glypiated Proteins 3.1.1
Initially, a YMC-Pack PROTEIN-RP column (50 x 3 mm, 200 Å) was used for analytical 
HPLC. However, the resolving power of this column was not sufficient, and the peak shape 
was not good enough to detect products eluting with close retention times, Figure 3.1. A new 
column (Phenomenex Jupiter C4, 50 x 2.1 mm, 300 Å) was used instead, giving peaks of 





Figure 3.1. HPLC analysis of (a) eGFP-Npu
N
 and eGFP-mGPI and (b) eGFP-SR / EPL reaction with biotin 
using YMC-Pack PROTEIN-RP column.  
 





Figure 3.2. HPLC analysis of GFP-Npu
N
 using Phenomenex Jupiter C4 column.  
 
 Establishing LC-ESI-MS Analysis for Intact Glycolipoprotein 3.1.2
Analysis 
A mass spectrometer suitable for LC-ESI-MS analysis was set up in the department during 
the course of this dissertation project. As part of this project the analysis of intact proteins has 
been established, and especially the analysis of modified proteins was optimized. Initial 
measurements turned out to yield mass spectra of low resolution not suitable for the 
determination of the protein mass, see Figure 3.3 a. Optimization of the gradients and the 
ionization parameters lead to hugely improved mass spectra, see Figure 3.3 b. Fine-tuning of 
the machine parameters and improved sample preparation delivered more easily deconvoluted 










Figure 3.3. ESI-MS spectra of LC-ESI-MS analysis of eGFP-Npu
N
 fusion protein. a) Initial analysis using 
a Waters BEH C4 UPLC column (50 x 2.1 mm, 1,7 µm particle size), gradient 40-60% ACN in water with 0.1% 
FA in 5 min. b), c) Improved LC-ESI-MS mass spectra of eGFP-Npu
N
 fusion protein. 




 Generation of IL-2 Expression Vectors 3.2
 Subcloning of IL-2-NpuN 3.2.1
The Interleukin-2-NpuDnaEN fusion gene in a pUC57Kan vector ordered from GenScript 
(Piscataway, USA) was subcloned into the pET30a expression vector by digesting both 
vectors with NdeI and HindIII (simultaneous digestion 4 h at 37°C for the fragment; 
subsequent digestion, each enzyme 1.5 h at 37°C for linearizing pET30a vector). Linearized 
pET30a and the 828 bp fragment were purified using agarose gel electrophoresis (1% 
agarose) and ligated using T4 Ligase and 3:1 and 5:1 vector:insert ratios, incubating at 16°C 
overnight. Ligated pET30a-IL-2-Npu
N
 was transformed into TOP10 cells and streaked onto 
LB-agar plates containing kanamycin. Colonies were observed for both ratios after incubation 
at 37°C overnight. Colony PCR was performed with all obtained colonies using T7 fw primer 
and T7 Term rev primer, Figure 3.4. Ligation was only successful for the 3:1 ratio, but not for 
the 5:1 ratio. Since the bands were very heterogeneous, DNA of all clones was sent for 
sequencing, revealing that only clone 13 carried the correct sequence.  
 
 
Figure 3.4. Colony PCR of ligations of IL-2-Npu
N
 in pET30a. Very heterogeneous bands were observed 
from the different clones obtained and all clones were sequenced.  
 
 Cloning of IL-2 Gene Into pTXB1 Vector for EPL Studies 3.2.2
Generation of an IL-2 Fragment for Ligation into pTXB1 Vector 
In order to fuse the IL-2 gene to the MxeGyrA mini intein, the IL-2 gene was excised from 
the pUC57Kan vector by PCR using the following primers: The T7 Universal Primer was 
used as forward primer (sequence: 5’ TAA TAC GAC TCA CTA TAG GG (20 bp)). As 
reverse primer the following primer was designed complementary to the gene’s end: 5’ CCA 




GTC AGT GTT GAG ATG ATG C (22 bp). For addition of a 3’-terminal SapI recognition 
and restriction site, a second PCR was carried out using the purified PCR product as template 
and again the T7 Universal primer as forward primer. The reverse primer for this PCR was 
designed to be complementary to the end of the IL-2 gene, with an additional sequence for the 
SapI site, followed by several bp as spacer, as recommended in Green and Sambrook
167
 
(protocol 6, chapter 8. Primer sequence: 5’ GGT GGT TGC TCT TCC GCA AGT CAG TGT 
TGA GAT GAT GC (38 bp). The resulting PCR product was analyzed in agarose gel 
electrophoresis which showed the expected fragment size of 566 bp (Figure 3.5). As only one 
sharp band was observed, the fragment was used without further purification.  
 
 
Figure 3.5. Analysis of excised IL-2-fragment (a) and of IL-2 fragment with added SapI restriction site 




Direct ligation into the linearized and dephosphorylated pTXB1 vector did not deliver any 
viable colonies in transformation, thus the fragment was ligated into EcoRV-linearized 
pBluescript (pBS) vector using a 3:1 ratio (vector:insert) at 16°C overnight as an intermediate 
step. Undigested pBS vector (#1) as well as unpurified (#2) and purified (#3) samples of the 
ligations were transformed into TOP10 cells and streaked on LB-agar plates containing 
ampicillin, IPTG and X-Gal for blue-white-screening. Many blue colonies were observed 
after overnight incubation at 37°C for the undigested pBS vector, which was the expected 
result. Unpurified and purified pBS-IL-2 delivered one quarter (90/400) and one third 
(100/300) white colonies, respectively, indicating successful ligation.  




Colony PCR was performed with five white colonies of each screening to verify insertion of 
the correct fragment using M13 uni primer as the fw primer and pUC19/M13 rev primer 
(Figure 3.6 a). The expected fragment size of 810 bp was identified in all colonies with 
unpurified vector and some colonies with purified vector. Clone #2.1 was selected for further 
experiments and plasmid DNA pBS-IL-2 was prepared from an overnight culture using 
Miniprep Kit. The correct insertion of IL-2 was confirmed by sequencing.  
 
Ligation of IL-2 Fragment into pTXB1 Vector 
pBS-IL-2 from clone #2.1 was digested with SapI and NdeI for 1 h at 37°C. pTXB1 vector 
was digested with SapI for 1 h at 37°. After heat inactivation of SapI the vector was further 
digested with NdeI at 37°C for 45 min plus 15 min with addition of fresh NdeI. Subsequently, 
the linearized vector was dephosphorylated with Antarctic Phosphatase for 15 min at 37°C to 
prevent self-ligation. Fragment and linearized vector were excised from a 2% agarose gel and 
purified. Ligation of the fragment into the linearized vector was set up using T4 Ligase and a 
5:1 ratio. Following incubation at 16°C overnight, 5 µL of the ligation was transformed into 
TOP10 cells yielding two colonies after overnight incubation at 37°C. Colony PCR verified 
the correct fragment size of 719 bp for both colonies (Figure 3.6 b). DNA sequencing which 
revealed that both clones carried the correct sequence including start codon, IL-2 sequence 




Figure 3.6. a) Colony PCR of IL-2 in pBluescript vector to ensure insertion of the correct fragment (1% 
agarose gel), #2 – unpurified vector, #3 – purified vector. Clone #2.1 was selected. b) Colony PCR of IL-2 in 
pTXB1 vector (1% agarose gel), #1 – clone 1, #2 – clone 2. Both clones have a more or less strong band at the 
expected size (719 bp) and both were confirmed to carry the correct sequence by DNA sequencing.  
 




 Quality Control of Synthetic GPI molecules 3.3
In order to ensure the integrity of the synthetic GPI anchor molecules after storage, they 
were analyzed by MALDI-TOF-MS and LC-ESI-MS. MALDI-TOF-MS was performed using 
DHB as matrix. Generally, GPI molecules were more efficiently ionized using linear negative 















Da. Both spectra were acquired in linear negative mode.  
 
 




For LC-ESI-MS analyses, GPI molecules were separated on a YMC C8 Pro-Pack column 
(50 x 3 mm, 3 µm) using a gradient of 5 – 70% ACN in water (0.1 % FA in 30 min). 
Similarly to MALDI-TOF-MS analysis, GPI molecules were easier to analyze in negative ion 
mode (ES
-
 mode), although ES
+
 mode worked as well. LC-ESI-MS analysis of mGPI is 





Figure 3.8: LC-ESI-MS analysis of mGPI. a) Total ion chromatogram (TIC) of mGPI analysis (C8), b) 




calc=1,460.5 .  
 




obs=789.2821,580.5 Da.  




Bilipidated GPI was analyzed in ESI-MS via direct injection without using an HPLC 
column, with methanol + 0.1% FA as eluent. In ES
+
 mode, a double adduct of bGPI was 
detected (Figure 3.10 a), whereas in ES
-
 mode, two species were detected that are very close 
in mass to bGPI ([M-H]
-






Figure 3.10. ESI-MS spectra of bilipidated, biphosphorylated GPI, [M+H]
+





obs=1773.6470 m/z, which corresponds to a double ammonium adduct, b) 




obs=1,728.8020 Da and 1,744.7869 Da, both of which cannot clearly 












(AA) Peptides and 3.4
Native Chemical Ligation of Npu
C
(WT)-Thioester 
Peptide synthesis was performed by Fmoc-SPPS (Solid Phase Peptide Synthesis) using a 
CEM Microwave Peptide Synthesizer (Liberty Blue) in collaboration with GPI-group 
members Dr. Dana Michel and Antonella Rella.  
 
 Synthesis of NpuC(WT) and Thioester Generation 3.4.1
The C-terminal fragment of the naturally split intein from N. punctiforme (Npu
C
) was 
synthesized as a peptide hydrazide using the conditions described in chapter 2.8.4. The 




 hydrazide.  
  
 
To obtain the peptide, 250 mg of NovaPEG Wang resin were swollen in DCM for 2 h. After 
introducing a hydrazide linker to the resin, the first amino acid (Fmoc-alanine) was coupled 
manually using a fritted syringe. The loading of the resin was determined by quantification of 
Fmoc removal and was found to be 0.31 mmol/g.  The resin was transferred to a reaction 
vessel and the sequence was elongated on a microwave peptide synthesizer using the 
optimized conditions (2.8.4). Due to the complexity and the length of the peptide (39 amino 
acids) the synthesis was split into two parts. First, the first 30 amino acids were coupled using 
five equivalents of amino acids, DIC and Oxyma. A test cleavage was carried out and the 
product was checked for major deletion sequences by HPLC. Subsequently, the peptide was 
elongated with the remaining nine amino acids using six equivalents of amino acids, DIC and 
Oxyma. The coupling cycles used for every amino acid are listed in Table 2.2. The cycles 
were optimized according to observed side products occurring during earlier syntheses. Fmoc 
deprotection was done with 20% piperidine in DMF after each coupling step. 
In order to check the completion of the synthesis, a test cleavage was performed using 
TFA/TIPS/water (90:5:5, v/v/v) solution. The peptide was cleaved from the resin using the 
same cleavage mixture and purified in several batches using HPLC (C18). A gradient of 10 – 




30% acetonitrile in water with 0.1% TFA in 45 minutes was used for purification of Npu
C
 
hydrazide. Fractions containing the pure desired peptide were combined and lyophilized 
again. Typically, around 10 mg purified peptide were achieved. The purified peptide was 
analyzed in RP-HPLC, MALDI-TOF and LC-ESI-QTOF. The respective chromatograms and 







Figure 3.11. Characterization of Npu
C
 hydrazide. a) RP-HPLC (C18) chromatogram of purified Npu
C
 





obs: 741.5617   4,442.36 Da, [M+H]
+
calc: 4,442.32 Da.  
 
Peptide thioester formation (Scheme 3.2) was carried out using a modification of the 
protocol in Zheng et al. (2013)
136
. Thioester formation was completed after 20 minutes, 
monitored by HPLC (C18). The formed Npu
C
 thioester was immediately purified in HPLC 
(C18). Pure Npu
C 
MMP thioester could be obtained in 45% yield, and was characterized in 












Scheme 3.2. Formation of Npu
C










Figure 3.12. Characterization of Npu
C
 MMP thioester. a) RP-HPLC chromatogram (C18) of purified Npu
C
 





calc: 4,529.31. c) Spectrum from LC-ESI-MS analysis of purified Npu
C
 MMP thioester. 
[M+6H]
6+
obs: 755.8969   4,529.38 Da, [M+H]
+














 Native Chemical Ligation of NpuC(WT)-Thioester 3.4.2
NCL of Npu
C
 thioester with Cys-biotin 
Native Chemical Ligation (NCL) conditions were evaluated with a model compound before 
the ligation of more complex GPI molecules. Thus, NCL test reactions to obtain a ligation 
product with Cys-biotin were completed first. Cys-biotin was ligated to Npu
C
 thioester to 
form Npu
C
-biotin (see Scheme 3.3).  
 
Scheme 3.3. NCL of Npu
C
 MMP thioester with Cys-biotin. 
 
For ligation, the Npu
C
 thioester was dissolved at a concentration of 1.5 mM in ligation 
buffer (pH 7.0) as described in 2.8.4, with 5 eq. Cys-biotin. Reaction progress was monitored 
by LC-ESI-MS (conditions as described in chapter 2.8.7). After three days reaction at 37°C 
the Npu
C
 thioester was consumed. The product Npu
C
-biotin was purified by HPLC (C18). The 
fraction containing pure Npu
C
-biotin was analyzed in RP-HPLC, MALDI-TOF-MS (Figure 
7.3) and LC-ESI-MS, Figure 3.13, and was kept at -20°C for PTS reactions.  
 
 
Figure 3.13. Characterization of Npu
C





obs= 800.9292   4,799.57 Da, [M+H]
+




 thioester and the monolipidated GPI (mGPI)  
By using the optimized conditions with Cys-biotin, the ligation between Npu
C
 thioester and 











Scheme 3.4. NCL of Npu
C
 MMP thioester with Cys-mGPI including side reactions.  
 
 




After seven days of ligation at room temperature barely any product could be detected by 
LC-ESI-MS. Mainly the starting material (Npu
C
 thioester) and disulphides of the Npu
C
 
peptide and the thiols (x’’), hydrolyzed thioester (NpuC-OH, x’’’) and the formation of a and a 
cyclized thiolactame side product of Npu
C 
 (x’) side products were observed, Figure 3.14, 
Table 3.1.  
 
 
Figure 3.14. Characterization of ligation product Npu
C
-mGPI. Spectrum from LC-ESI-MS analysis of 
NCL reaction Npu
C
-mGPI (tR=18.4 min), [M-3H]
3-
obs: 1,930.4391   5,794.3173 Da, [M-H]
-
calc: 5,793.8 Da.  
 
To overcome these side reactions, especially oxidations of the cysteine residues, the ligation 
was performed under Argon atmosphere. After one day of ligation the product Npu
C
-mGPI 
was detected in LC-ESI-MS, Figure 3.15, Table 3.1. Additionally, an adduct (+200 Da) was 
observed, which probably corresponds to a mercury adduct resulting from the deprotection 
procedure of Cys-mGPI. The reaction mixture was analyzed in LC-ESI-MS on several days 
and this adduct was decreasing in comparison to the peak corresponding to the exact mass, 
indicating the exchange of Hg for Na counter ions from the NCL buffer.  
 
Table 3.1. Calculated and observed masses of products and side products of NCL between Npu
C
-MMP 
thioester and Cys-mGPI. The respective mass spectra are given in Figure 3.15 







-thiolactame (b) 10.9 4,410.29 Da   735.9197 *6  4,410.52 
Npu
C
-OH (c) 11.6 4,427.30 Da   738.9243 *6  4,427.54 
Npu
C
-MMP (d)  12.6 4,529.31 Da   756.0955 *6  4,530.57 
Npu
C
-MMP-MMP (e) 13.6 4,647.32 Da   775.7636  *6  4,648.58 
Npu
C
-mGPI (f) 19.7 5,793.8 Da 1,159.6219 *5  5,793.1 
1,199.4110 *5  5,992.05, Δ 200 
















Figure 3.15. LC-ESI-MS analysis of NCL between Npu
C
-MMP thioester and Cys-mGPI. a) 
chromatogram (C4, 10-70% ACN in 30 min) with four peaks, b) mass spectrum of tR=10.9 min – Npu
C
-
thiolactame, c) mass spectrum of tR=11.6 min – Npu
C
-OH, d) mass spectrum of tR=12.6 min – Npu
C
-MMP, e) 
mass spectrum of tR=13.7 min – Npu
C
-MMP-MMP, f) mass spectrum (5x charged ion) of tR=18.6 min – Npu
C
-
mGPI. Calculated and observed masses can be found in Table 3.1.  




During seven days reaction, the pH was repeatedly re-adjusted to 7.0 using 1 M NaOH or 
1 M HCl, and after one day and four days, one more eq. TCEP was added to the reaction as 
some oxidation of Npu
C
-MMP was observed (not shown). After seven days the reaction was 
purified in HPLC (C4, Figure 3.17) since barely any unreacted, non-oxidized peptide thioester 
was observed anymore and a cleaner mass spectrum was obtained, Figure 3.16 b. The product 
is expected in the smaller peak at tR=24.5 min, however could not be detected after 






Figure 3.16. LC-ESI-MS analysis of NCL between Npu
C
-MMP after seven days. a) Chromatogram (C4, 
10-70% ACN in 30 min), b) mass spectrum acquired at tR=19.1 min – Npu
C
-mGPI: 1,159.7755 m/z, 5x charged 
 5,793.8775. Masses at other tR correlate with Npu
C
-OH (11 min) and an oxidized Npu
C
-thioester (Δ+16, 12.5 
min). 
 





Figure 3.17. Chromatogram including gradient (10 – 70% ACN in 30 min) of the purification of the 
NCL reaction between Npu
C
-MMP-thioester and Cys-mGPI. The main peak corresponds to thioester 





 Synthesis of the Mutated NpuC(AA) Peptide 3.4.3
The mutated Npu
C




 exchanged for Ala residues 
(Scheme 3.5) was synthesized using Rink Amide PEGA Resin (Novabiochem, loading 0.35 
mmol/g) under the same conditions as for Npu
C
(WT), 3.4.1. The synthesis of this peptide 
showed the formation of less side products and better crude yield of the product compared to 
the synthesis of the WT peptide. The peptide was purified using RP-HPLC (C18) and 





   
 
  




 Expressed Protein Ligation 3.5
To obtain C-terminally modified proteins by Expressed Protein Ligation (EPL), α-protein 
thioesters and cysteine tagged molecules were needed: Cys-Biotin and Cys-Dimannose used 
for method development and Cys-GPIs.  
 
 
Figure 3.18. Schematic depiction of Expressed Protein Ligation (EPL). The protein of interest (POI) is 
expressed as a fusion protein with the GyrA intein from M. xenopi. Thioester formation is achieved by intein 
cleavage induced by thiol addition. This is followed by the ligation to a Cys-containing peptide or other fragment 
(Cys-GPI).  
 
 Expression, Purification and Protein-Thioester formation 3.5.1
Expression of eGFP-Mxe-CDB and thioester formation 
The plasmid pET30a-eGFP-Mxe-CBD was obtained from GenScript (Piscataway, USA) 
with the sequence given in Appendix 7.1.1. To overcome the inefficient intein cleavage with 
proline as adjacent residue, a mutation in the C-terminus of eGFP was introduced (Pro was 
exchanged for Ala).
123,168
 The plasmid was transformed in E. coli BL21 (DE3) and Rosetta 
cells. Expression was optimized by testing 20°C and 30°C as expression temperatures, 0.2, 
0.4 and 1 mM IPTG concentration and induction for 1, 2, 3 and 24 h. E. coli BL21 (DE3) Star 
and Rosetta cells were tested for the expression. As shown in Figure 3.19, the Rosetta cells 
grew slightly better; they reached the late exponential phase after 3 h whereas the BL21 clone 
could be induced only after 5 h. Also post-induction the Rosetta clone continued to grow 
better.  






Figure 3.19. Growth curves of the test expression of eGFP-Mxe-CDB fusion protein in E. coli BL21 
(DE3) Star and Rosetta cells. All cells were inoculated to a starting OD600 of 0.05. OD was measured 
frequently until late exponential phase was reached (OD 0.6-0.8). At this point the temperature was changed to 
20°C or 30°C, respectively, and this time corresponds to t=0 (induction time, indicated by the vertical line).  
 
To analyze the expression of the eGFP-Mxe-CBD fusion protein, samples were taken 1 h, 2 
h, 3 h and 24 h post-induction (Figure 3.20). The amount of sample for each lane in the gel 
was normalized according to the respective OD600. Overall, the overexpression of the fusion 
protein is good under all tested conditions; however, the best expression of the fusion protein 
(assessed by band size using Fiji software) was observed using Rosetta cells induced with 
0.4 mM IPTG for 24 h at 20°C or 30°C.  
In order to assess the expression temperature yielding a higher portion of soluble fusion 
protein, samples were taken after 24 h from the cultures induced with 0.4 mM IPTG and the 
soluble fraction was separated from the insoluble fraction by centrifugation. Lysate samples 
and samples of the pellet resuspended in PBS buffer were analyzed in SDS-PAGE, see Figure 
3.21. At both expression temperatures the fusion protein was distributed over the soluble and 
insoluble fractions, however, better results were obtained at 20°C with ca. 60% of the fusion 
protein present in the soluble fraction compared to ca. 30% soluble protein observed at 30°C 
(calculated using Fiji software). Therefore induction with 0.4 mM IPTG and expression at 






















BL21 (DE3) Star, 30°C
Rosetta, 30°C
BL21 (DE3) Star, 20°C
Rosetta, 20°C




a – BL21 (DE3) Star 
 
b - Rosetta 
 
  
Figure 3.20. SDS-PAGE analysis of the test expressions of eGFP-Mxe-CBD. The fusion protein was 
expressed in E. coli BL21 (DE3) Star (a) and Rosetta cells (b). Cells were grown to late exponential phase and 
induced with different IPTG concentrations. Induction temperatures tested were 20°C and 30°C. M – Molecular 
Weight Marker, 1 – pre induction, 2 – 5 – 0.2 mM IPTG induction 1/2/3/24 h, 6 – 9 – 0.4 mM IPTG induction 
1/2/3/24 h, 10 – 13 – 1 mM IPTG induction 1/2/3/24 h.  
  
Figure 3.21. Solubility check of the eGFP-Mxe-CBD fusion protein using SDS-PAGE. Expression samples 
induced with 0.4 mM IPTG at 20°C or 30°C, respectively, were lysed and separated. M – Molecular weight 
marker, 1 – 20°C, insoluble fraction, 2 – 20°C, soluble fraction, 3 – 30°C, insoluble fraction, 4 – 30°C, soluble 
fraction.  
 
For preparative expression of the eGFP-Mxe-CBD fusion protein, the Rosetta clone 
containing the pET30a-eGFP-Mxe-CDB plasmid was plated onto an LB agar plate with 100 
µg/mL kanamycin and grown at 37°C overnight. The next day, a culture of 100 mL LB 
medium with 100 µg/mL kanamycin was inoculated to a starting OD600 of 0.05 with the 
starter culture and grown at 37°C until the late exponential growth phase was reached (OD600 
0.6 – 0.8). Protein expression was induced by addition of 0.4 mM IPTG, the temperature was 
decreased to 20°C and shaking speed was reduced from 220 to 180 rpm. After 24 h induction 




the cells were harvested by centrifugation. Cells were lysed using lysozyme and sonication. 
Lysates were cleared by centrifugation and filtrated through a 0.22 µm syringe filter.  
Purification of the protein was performed in one single chromatographic step with 
simultaneous formation of the protein thioester as described in 2.8.3. Following completion of 
the cleavage, the pure eGFP-thioester with either MMP (Scheme 3.6), MESNA, MMBA or 
MPAA was eluted with 6 x 0.5 CV buffer W (pH 7.0). The fractions (flow-through, wash, 
resin and elution samples) were analyzed in SDS-PAGE. The green elution fractions 
containing the fusion protein were combined and the pH was adjusted to ca. 6.5 in order to 
prevent thioester hydrolysis.  
Scheme 3.6. eGFP-MMP-thioester  
 
Thiol reagents with different properties regarding reactivity and stability were tested for 
thioester formation. Thioester formation on-column with the different thiols is shown for 
eGFP, Figure 3.22. In the presence of the commonly used MESNA thiol (200 mM), intein 
cleavage reached ca. 80% after 40 h incubation with cleavage buffer at room temperature, 
Figure 3.22 a. In contrast, using 50 mM MPAA in the cleavage buffer, only ca. 50% intein 
cleavage was achieved after 24 h incubation at RT (Figure 3.22 b). Excellent results were also 
obtained by using MMBA and MMP (both 50 mM in cleavage buffer): 80% and 90% 
cleavage were obtained, respectively, Figure 3.22 c.  
a  b c 
   
Figure 3.22. Thioester formation on chitin resin using Sodium 2-Mercaptoethanesulfonate (MESNA), 4-
Mercaptophenylacetic acid (MPAA), 4-(Mercaptomethyl)benzoic acid (MMBA) and Methyl 3-
mercaptopropionate (MMP). a) Thioester formation using MESNA. M – Molecular weight marker, 1 – lysate, 
2 – FT chitin resin, 3 – wash fraction, 4 – resin t=0 (MESNA), 5 – resin 40 h (MESNA), 6 – elution (MESNA). 
b) Thioester formation using MPAA. Molecular weight marker, 1 – lysate, 2 – FT chitin resin, 3 – wash fraction, 
4 – resin t=0, 5 – resin 2 h (MPAA), 6 – resin 4 h (MPAA), 7 – resin 6 h (MPAA), 8 – resin 24 h (MPAA), c) 
Thioester formation using MMBA and MMP. M – Molecular weight marker, 1 – lysate, 2 – FT chitin resin, 3 – 
wash fraction, 4 – resin t=0 (MMBA), 5 – resin 1 h (MMBA), 6 – resin 16 h (MMBA), 7 – elution pooled 
(MMBA), 8 – resin after elution (MMBA), 9 – resin t=0 (MMP), 10 – resin 1 h (MMP), 11 – resin 16 h (MMP), 
12 – elution pooled (MMP), 13 – resin after elution (MMP).  




An analysis of the protein bound to the chitin column showed that the lysozyme used for 
cell lysis binds to the chitin resin as well, Figure 3.22 c. This is in well correspondence with 
literature reports describing chitin as a substrate of lysozyme.
169
 Therefore, the protein 
thioesters were re-purified using SEC (Superdex peptide 30/10 GL in EPL buffer) to remove 
lysozyme and remaining thiol reagent, giving 8 mg pure eGFP-MMP-thioester from 100 mL 
culture in 81% purity (Figure 3.23).  
 
 
Figure 3.23. Purification and thioester formation of eGFP. The overexpressed fusion protein eGFP-Mxe is 
loaded to a chitin resin, washed and thioester formation is induced by addition of thiol-containing buffer (MMP). 
Lastly, the thioester is purified using SEC. M – Molecular weight maker, 1 – Lysate, 2 – Flow-through chitin 
resin, 3 – was fraction chitin resin, 4 – resin sample t=0, 5 – pooled elution fractions, 6, 7 – SEC-purified eGFP-
MMP-thioester.   
 
Based on the results of the intein cleavage with MMBA and MMP, these two protein 
thioesters were selected for ligations with cysteine-containing molecules and analysis in 
MALDI-TOF-MS (Figure 7.4) and LC-ESI-MS (Figure 3.24 and Figure 7.5).  
 
 
Figure 3.24. Raw and deconvoluted ESI mass spectra for eGFP-MMP-thioester. [M+H]
+
calc = 27,097.29, 
[M+H]
+
obs = 27,093.88. The eGFP-thioester eluted from chitin resin was analyzed using a gradient from 10 – 
70% acetonitrile in water (0.1% FA in both eluents) in 30 min. The sample was analyzed using ESI-QTOF. At 




calc=27,097.29 Da,  [M+H]
+
obs=27,093.88 Da 




Following the production of the protein thioesters, their stability was assessed by HPLC 
(C4). The thioester was analyzed immediately following its generation and elution from the 
chitin resin (i.e. “fresh thioester”). The sample was incubated for one week at 4°C in the 
elution buffer (pH 6.5-7.0) containing some remaining thiol reagent and subsequently 
analyzed by HPLC. The chromatogram of the MMBA thioester sample (Figure 3.25 a) 
showed peaks before tR=18 min which were assigned to buffer components (mainly MMBA 
and its disulphides). A peak at tR=19.5 min corresponds to the lysozyme that was co-purified 
using the chitin resin (as described before) and the peak at tR=22.7 min corresponds to the 
eGFP-thioester. A small shoulder observed besides the eGFP-thioester in the fresh sample 
increases in size to about 70% of the size of the thioester peak during one week of incubation. 
LC-MS analysis showed that this shoulder corresponds to the hydrolyzed side product eGFP-
OH. In comparison, the chromatogram of the MMP thioester samples were cleaner since 
MMP and its disulphides do not absorb at the wavelength used for detection (214 nm), Figure 





Figure 3.25. Stability test of eGFP-thioesters. Fresh thioesters (with MMBA and MMP) as well as samples 
stored at 4°C for one week have been analyzed in RP-HPLC (C4, gradient 10 – 70% acetonitrile in water with 
0.1% TFA in 30 min). Both thioesters were degraded substantially over one week.  
from MMBA  
eGFP-SR 
eGFP-OH 




Two peaks corresponding to lysozyme (tR=19.5 min) and the eGFP-MMP-thioester (tR=22.7 
min) together with a small shoulder were present in the fresh thioester sample. After one week 
incubation, the thioester peak decreases to about 30% in size compared to the starting sample 
and the shoulder increases to represent ca. 70% of the eGFP present in the sample. These 
results showed that both thioesters are not stable enough to be stored for extended periods of 
time in the ligation buffer. It was therefore decided to always generate the eGFP-thioester 
freshly before use in EPL reactions. 
 
Expression of Thy-1-Mxe-CDB and thioester formation 
Plasmid pET29a-Thy1-Mxe (Appendix 7.1.2) (GenScript, Piscataway, USA) was 
transformed into E. coli BL21 (DE3) Star and Rosetta cells. Protein expression was tested 
with both clones at 15°C and 30°C, and induction with IPTG concentrations of 0.2 mM, 
0.4 mM and 1 mM.  
Expression tests were performed as described for the eGFP-Mxe-CBD fusion protein: 
cultures were grown to late exponential phase (OD600 0.6-0.8) at 37°C before reducing 
temperature and shaking speed, and induction via IPTG addition. The expression of the fusion 
protein (expected size = 41.2 kDa) was analyzed in SDS-PAGE. The Rosetta clone showed 
better growth before and after induction (Figure 7.7). However, almost no fusion protein was 
expressed (Figure 7.8 b). The best expression was observed with BL21 (DE3) Star cells at 
15°C with 0.4 mM IPTG and 30°C with 0.2 mM ITPG. These conditions were also tested to 
evaluate the portion of soluble protein (Figure 7.9). Unfortunately, under both conditions the 
fusion protein was expressed only in insoluble form. Therefore, expression at 15°C with 
0.4 mM IPTG was selected for larger scale expression.  
Preparative expression of Thy-1-Mxe-CBD was performed in 100 mL LB medium 
supplemented with 100 µg/mL kanamycin. The cells were lysed as described before, 
repeating the sonication and centrifugation steps once. The lysates were discarded and the 
pellet containing insoluble Thy-1-Mxe-CBD was resuspended in HisTrap equilibration buffer 
containing 8 M urea. Vortexing, ultrasonic bath and shaking overnight at room temperature 
was necessary to solubilize the protein. The next day, the solubilized inclusion bodies were 
centrifuged to remove cell debris and the protein was purified via his-tag (HisTrap HP 1mL 
column). The supernatant was loaded to the column, washed with equilibration buffer for 10 
CV and the fusion protein was eluted by a gradient over 5 CV from 30 mM to 500 mM 
imidazole, Figure 3.26 a. Samples containing the fusion protein were combined and dialyzed 




against EPL buffer containing 6 M urea, exchanging the buffer several times over 24 h. 
10.5 mg Thy-1-Mxe were obtained from 100 mL culture.  
Purification with simultaneous thioester formation on-column was not possible for Thy-1-
Mxe-CBD since the CDB fusion does not bind under denaturing conditions required for 
solubilization. Therefore, in order to form the thioester, MMP was added to a solution 
containing purified Thy-1-Mxe-CBD in 6 M urea. Unfortunately, no intein cleavage could be 
observed (not shown). To favor the folding of the intein, thioester formation was tested with 
MMP and MESNA (Scheme 3.7) in 3 M urea (obtained by slowly diluting the 6 M urea 
solution with EPL buffer 1:1). After one day incubation at room temperature, some cleavage 
was observed with both thiols MMP and with MESNA, Figure 3.26 b. However, even with 
MESNA the cleavage efficiency is very low (12% cleavage by band intensity).  
Characterization of the fusion protein and the Thy-1-thioester by HPLC and LC-ESI-MS 
was challenging, and no mass spectra could be acquired.  
 
Scheme 3.7. Thy-1-MMP-thioester & Thy-1-MESNA-thioester.  





Figure 3.26. a) Expression and His-tag purification of Thy1-Mxe. M – Molecular weight marker, 1 – 
lysate 1, 2 – lysate 2, 3 – solubilized inclusion bodies, 4 – flow-through HisTrap column, 5 – wash HisTrap 
column, 6 – 14 – Elution fractions. b) Thioester formation of Thy-1 in 3 M urea with MMP and MESNA 
and EPL with Cys-biotin. Some cleavage is observed with both thiols, however with 100 mM MESNA it is 
better (ca. 12% by band intensity). M – Molecular weight marker, 1 – Thy-1-Mxe in 6 M urea, 2 – thioester in 3 








Expression of IL-2-Mxe-CDB and thioester formation tests 
The plasmid pTXB1-IL-2 generated by cloning (see 3.2.2) was transformed into BL21 
(DE3) Star and Origami cells for expression tests. The Origami cells were tested because it 
was expected that the intracellular redox conditions they confer could be more suitable for 
expression of this cysteine-containing protein. Expression was tested at 37, 25, 19 and 12°C. 
Ampicillin (100 µg/mL) was used for pTXB1 vector in BL21 (DE3) Star cells, tetracycline 
(12.5 µg/mL) and kanamycin (15 µg/mL) were used additionally for Origami cells. Fresh 
transformants were always used for expression. BL21 cells were induced after 2.5 h with 
0.4 mM IPTG for 3 h (37 and 25°C) and 24 h (other temperatures). Origami cells grew very 
slowly and were induced after 4.5 h with 0.4 mM IPTG for 3 or 24 h, respectively. Cells were 
harvested by centrifugation and lysed by sonication.  
The 47 kDa protein was observed only in BL21 cells and mostly in insoluble form. Only at 
12°C a portion of the protein was found in the soluble fraction, Figure 3.27 a. In Origami 
cells, no expression was observed (Figure 3.27 b). Expression at 12°C in BL21 (DE3) Star 
cells was used for further experiments.  
 
a BL21 (DE3) Star         b - Origami 
  
Figure 3.27. Expression test of IL-2-Mxe-CBD in BL21 cells. M – Molecular weight marker, 1 – pre 
induction, 2 – insoluble fraction 37°C, 3 – soluble fraction 37°C, 4 – insoluble fraction 25°C, 5 – soluble fraction 
25°C, 6 – insoluble fraction 19°C, 7 – soluble fraction 19°C, 8 – insoluble fraction 12°C, 9 – soluble fraction 
12°C.  
 
For the formation of the protein thioester, the lysate of IL-2-Mxe-CBD was slowly loaded 
onto chitin resin and flushed with cleavage buffer containing 100 mM MESNA following 
washing with 20 CV buffer W and incubation at room temperature for 40 h. Only a small 
portion of the protein bound to the resin and intein cleavage could not be observed, Figure 
3.28 a. Thioester formation was also tested with 100 mM MMBA in the cleavage buffer. 
However, also under these conditions only a very minor band of the IL-2-thioester could be 
observed by western blot with an anti-strep antibody-HRP, Figure 3.28 b.  




a           b  
   
Figure 3.28. Thioester formation with IL-2-Mxe-GyrA. a) M – Molecular weight marker, 1 – lysate, 2 – 
flow-through, 3 – wash 1, 4 – wash 2, 5 – resin t=0, 6 – resin 40 h, b) M – Molecular weight marker, 1 – lysate, 
2 – flow-through, 3 – resin t=0, 4 – resin 16 h. Gel was stained using silver staining, blot was detected with anti-
strep antibody-HRP conjugate.  
 
In order to evaluate thioester formation in solution as described for Thy-1, pure protein was 
needed. However, any attempt to purify IL-2-Mxe-CBD via StrepTactin resin failed due to 
unsuccessful binding of the protein to the resin (not shown). This strategy was not further 
pursued for this protein.  
 
 Optimization of the Ligation Conditions using eGFP 3.5.2
To test the reactivity of the protein thioesters in EPL reactions, Cys-biotin was used for 
optimization of the reaction conditions. Initially, purified eGFP-thioester in EPL buffer was 
mixed with 0.5 mM TCEP, 50 mM thiol (MMP) and 5 eq. Cys-biotin to give the product 
eGFP-biotin (Scheme 3.8). After one day incubation a sample was analyzed in SDS-PAGE 
and western blot (Figure 3.29) and LC-ESI-MS (Figure 3.30). A strong signal was observed at 
the expected size of ~27.3 kDa in the EPL lane (lane 2).  
 
Scheme 3.8. eGFP-biotin.  
 
 





Figure 3.29. EPL of eGFP-MMP-thioester with Cys-biotin. The ligation product eGFP-biotin xx was 
detected in western blot using an anti-biotin antibody-HRP conjugate (1:250 dilution in 5% BSA in PBS-T). M – 
Molecular weight marker, 1 – eGFP-MMP, 2 – EPL reaction eGFP-biotin 1 day.  
 
LC-ESI-MS analysis of the ligation reaction after one day using a C4 column (Figure 3.30) 
showed the formation of the product eGFP-biotin as a minor product (tR=19.2 min, 
corresponding to the main peak’s tailing); however the main peak was still the eGFP-MMP-
thioester (tR=18.9 min). Additionally, a portion of hydrolyzed thioester eGFP-OH was also 
observed (tR=18.6 min, shoulder of the main peak).  
 
 
     
Figure 3.30. Characterization of eGFP-biotin from EPL xx by LC-ESI-MS (after 1 d reaction). a) LC 
chromatogram  (C4, 10 – 70% ACN with 0.1% FA in water with 0.1% FA in 30 min. b) Raw and deconvoluted 
mass spectrum (acquired in ES
+
 mode with 1.5 kV capillary voltage), tR=19.2 min. [M+H]
+
calc= 27,366.7, obs. 
[M+H]
+
obs= 27,368.31. Some hydrolyzed side product GFP-OH is found at tR=18.6 min. eGFP-MMP-thioester is 
also observed at tR=18.9min ([M+H]
+
calc= 27,097.29, obs. [M+H]
+







calc=27,366.7 Da,  [M+H]
+
obs=27,368.31 Da 




 Kinetic Study of the EPL reaction 3.5.3
The EPL reaction of eGFP-MMP with Cys-biotin after 24 h incubation delivered only a 
small portion of the product eGFP-biotin while the starting product thioester was still the 
main species. Therefore, a kinetic study was performed to gain more insights into the 
correlation between stability and reactivity of the MMP-thioester. Samples of an EPL reaction 
were taken at different reaction times and analyzed by HPLC (on a C4 column), Figure 3.31 
a. The data from the chromatograms (percentage of peak areas of each compound) is plotted 
in Figure 3.31 b. Under these conditions, the protein thioester did not hydrolyze and that the 
ligation reaction proceeds with a linear first order to ca. 47% conversion after seven days. To 
facilitate trans-thioesterification and faster reaction rates, the more reactive thiol MPAA 








Figure 3.31. Kinetic Study of the EPL reaction of eGFP-MMP with Cys-biotin. Samples of the EPL 
reaction were taken after 1, 2, 4 and 7 days and analyzed in RP-HPLC (C4), 10 – 70% ACN in water with 0.1% 
TFA in 30 min. a) LC-chromatogram of the different reaction times (zoom to the retention times where the 
reaction products eluted). At the starting point, some hydrolyzed side product eGFP-OH was already present 
(tR=22.5 min), together with the starting material eGFP-MMP (tR=23 min). Over the time a new peak emerges 
and increases at tR=23.5 min: the product eGFP-biotin.  b) Plot of the peak area in percentage of eGFP-MMP 
(educt), eGFP-biotin (product) and eGFP-OH (side product). This plot shows that the side product eGFP-OH 
remains constant over the course of the reaction whereas product formation proceeds with a linear slope until 






























 EPL for Glypiation 3.5.4
To evaluate the reactivity of a cysteine attached to a phosphoethanolamine as observed in 
GPIs in a similar environment, the EPL reaction was performed first with Cys-dimannose. 
The EPL reaction was set up as described before with 50 mM MMP, 0.5 mM TCEP and 2 eq. 
Cys-dimannose at pH 7.0 and was incubated at room temperature. The reaction mixture was 
analyzed in LC-ESI-MS, Figure 3.32. The desired product eGFP-dimannose could be detected 
together with the hydrolyzed side product eGFP-OH. Analysis of the eGFP-thioester showed 
that significant thioester hydrolysis had already taken place prior to this EPL reaction. This 






Figure 3.32. Characterization of eGFP-dimannose from EPL. a) LC chromatogram (C4)). b) Raw and 
deconvoluted mass spectra of tR=18.7 min (acquired in ES
+ 
mode, 1.5 kV capillary voltage): 
[M+H]
+







calc=27,584.52 Da,  [M+H]
+
obs=27,587.69 Da 




The next step was the transfer of the EPL reaction to ligate the Cys-mGPI to eGFP. The 
reaction was performed using the reaction conditions optimized for Cys-biotin and Cys-
dimannose. After one day incubation at room temperature, SDS-PAGE and western blot 
analysis of the reaction mixture using an in-house generated monoclonal anti-GPI antibody 
(clone MTG4) showed the formation of the product eGFP-mGPI at the expected size 
(28.3 kDa, Figure 3.33 a). The sample was also analyzed in MALDI-TOF-MS following 
desalting using ZipTip (Figure 3.33 b).  The size difference found here (1,384 Da) 




Figure 3.33. EPL reaction of eGFP-MESNA-thioester with Cys-mGPI. a) The product eGFP-mGPI was 
detected in western blot using an anti-GPI antibody (MTG4) in 1:1,000 dilution in 5% BSA in TBS-T 
(incubation 1.5 h at room temperature) and a secondary anti-mouse IgG antibody-HRP conjugate in 1:10.000 
dilution in 5% BSA in TBS-T for 30 min at room temperature. Lanes: 1 – GFP-MESNA-thioester, 2 – eGFP-
mGPI from EPL (1 d). b) MALDI Spectrum of EPL reaction of eGFP-thioester (MESNA) and mGPI. It can 





obs=29,749.504 (old clone, not shown). The size difference of 1,384 Da exactly corresponds to the 
addition of mGPI to eGFP.  
 
 EPL for Glypiation of the Naturally GPI-anchored Thy-1 & Prion 3.5.5
Protein 
EPL with Thy-1 Protein 
After the EPL method was successfully established to ligate the model protein eGFP to 
biotin, dimannose and a monolipidated GPI-anchor, the next step was the application of these 
conditions to ligate also more relevant proteins, such as the naturally GPI-anchored protein 
Thy-1 to natural GPIs.  
Although thioester formation with this insolubly expressed mammalian protein was 
inefficient, Figure 3.26 b, an EPL reaction was tested with Cys-biotin.  Cys-biotin (5 eq.) was 




added to the freshly formed Thy-1-thioesters of MESNA and MMP. The thiols were present 
in 100 mM and 50 mM, respectively. MESNA is commonly used in concentrations of 100-
200 mM in literature whereas MMP exhibited solubility problems at concentrations above 50 
mM. As both thiols are rather unreactive, 1 mM MPAA was added in both cases. After 7 days 
incubation at room temperature the reactions were analyzed in SDS-PAGE, western blot and 
LC-ESI-MS. While analysis in mass spectrometry did not reveal the reaction product Thy-1-
biotin, it was detected in western blot using anti-biotin antibody-HRP conjugate (Figure 3.34). 
However, in the blot other unspecific signals were also observed at the sizes of the fusion 
protein, the cleaved Mxe intein as well as in the very top of the gel.  
 
  
Figure 3.34. Analysis of EPL reaction of Thy-1 thioesters (MESNA or MMP, respectively) with Cys-biotin 
in western blot using an anti-biotin antibody-HRP conjugate (1:250 dilution in 5% BSA in PBS-T overnight).  
 
As thioester formation was difficult and yields are low, it was decided that the EPL strategy 
is not well suitable for Thy-1 protein.  
 
EPL with Prion Protein 
Another naturally glypiated protein is the infamous Prion Protein (PrP). His-tag purified 
PrP-Mxe fusion protein (~ 51 kDa) in 6 M urea was kindly provided by Prof. Joaquín Castilla 
from BioGUNE, Bilbao, Spain. Similar to the results with denatured Thy-1 protein, thioester 
formation of PrP was not possible on-column using chitin resin (not shown). Instead, thioester 
was formed in solution using 100 mM MMBA and was detected using SDS-PAGE with silver 
staining and MALDI-TOF-MS, Figure 3.35 a and b. EPL reaction of PrP with Cys-biotin was 
carried out using the mixture of PrP-MMBA thioester (23 kDa), uncleaved PrP-Mxe and 
cleaved Mxe (27 kDa), using 2 mM TCEP and 100 mM MMBA. The ligation product PrP-




biotin was identified in western blot, Figure 3.35 b. To compare the reactivity of the thioester 
in pure form with the protein mixture, the formed PrP-thioester was purified by HPLC using a 
C4 column and was directly submitted to EPL with Cys-biotin xx. A stronger signal in 
western blot using anti-biotin antibody-HRP was observed for EPL using MPAA, Figure 3.35 
c. The EPL reactions with PrP-thioester and Cys-biotin were furthermore analyzed by HPLC 
(C4) and MALDI-TOF-MS, Figure 3.36 a and b. By using MPAA as thiol in the reaction, a 
new peak with earlier tR was observed in HPLC and MALDI-TOF-MS analysis showed a 






Figure 3.35. Analysis of PrP thioester formation a) analysis in SDS-PAGE with silver staining, b) 





calc=23,081.81 Da. M – Molecular weight marker, 1 – PrP-Mxe, 2 – PrP-MMBA thioester, 3 – EPL PrP-
biotin, 4 – EPL with MMBA after C4 purification, 5 – EPL with MPAA after C4 purification. Detection in 
western blot using anti-biotin antibody-HRP.  
 








Figure 3.36. EPL of PrP-thioester and biotin with MMBA and MPAA, respectively, analysis in HPLC 





EPL reactions of PrP-thioester were also performed with Cys-dimannose and Cys-mGPI. 
The detection of both products was attempted using ConA-HRP in western blot, due to the 
lack of the anti-GPI antibody at this time (not shown). Unfortunately, only PrP-dimannose 
was detected. PrP-mGPI was however detected by HPLC (C4) and MALDI-TOF-MS, Figure 















a b  
 
Figure 3.37. EPL of PrP-thioester and mGPI, a) analysis in HPLC (C4, gradient 10 – 50 % in 30 min), b) 





mGPI)=24,330.30 Da.  
 
 Purification of EPL Products 3.5.6
EPL reactions with 1 mg eGFP-MMP were carried out with Cys-biotin, Cys-dimannose, 
Cys-mGPI and Cys-bGPI for three days at RT and purified by SEC using a Superdex 75 
column in PBS buffer).  
The separation of the product eGFP-biotin from eGFP-MMP thioester and the side product 
eGFP-OH was not possible on this column (Figure 3.38 a) and they could not be distinguished 
in SDS-PAGE analysis (not shown). However, analysis of the fractions from different parts of 
peak #2 from SEC purification in LC-ESI-MS revealed that the shoulder of the peak mainly 
contains eGFP-OH and eGFP-MMP (not shown) whereas the main peak (later part of the 
peak) mainly contains eGFP-biotin and a MMP-disulphide of eGFP-biotin, Figure 3.38 c.  
eGFP-MMP, EPL reaction mixture and purified eGFP-biotin were also analyzed in SDS-
PAGE and western blot, Figure 3.38 b.  
Similar results were obtained also for the purification of the EPL reaction between eGFP-
MMP and Cys-dimannose (not shown). The ligation products of EPL between eGFP and Cys-
mGPI and Cys-bGPI were purified in the same way on the Superdex 75 column. However, 
characterization by LC-ESI-MS was challenging and the anti-GPI antibody was not available 
at this moment. Fractions expected to contain the products were nevertheless combined and 
concentrated for CD measurement. Unfortunately, they precipitated during concentration.  
 
 








Figure 3.38. SEC purification of eGFP-biotin. a) SEC Chromatogram on a Superdex 75 column of the EPL 
reaction eGFP-biotin. b) SDS-PAGE and western blot analysis of EPL eGFP-biotin as well as purification of the 
product by SEC. M – Molecular weight marker, 1 – GFP-thioester, 2 – EPL reaction GFP-biotin, 3 – eGFP-
biotin purified vie SEC. Blot – anti-biotin antibody-HRP (1:250 in 5% BSA-PBST). c) Raw and deconvoluted 
spectra from LC-ESI-MS analysis of SEC fraction #33 (late in peak #2). eGFP-biotin from EPL: 
[M+H]
+
calc=27,366.7 Da. The observed mass [M+H]
+
obs=27,481.49 Da corresponds well to the MMP disulphide 




































calc=27,366.7 Da,  [M+H]
+
obs=27,481.49 Da 




 Protein Trans-Splicing 3.6
The second strategy evaluated to obtain glypiated proteins was Protein Trans-Splicing 
(PTS) using split inteins. For this strategy two units were needed: fusion proteins of the 
proteins of interest with the N-terminal fragment of the naturally split intein NpuDnaE from 
Nostoc punctiforme and the C-terminal intein fragment, which was chemically synthesized 
and ligated to the anchor of interest by NCL.  
 
 
Figure 3.39. Protein Trans-Splicing. The protein of interest (POI) is expressed as a fusion protein with the N-
terminal fragment of the DnaE intein from N. punctiforme. Protein trans-splicing is induced upon contact with 
the C-terminal intein fragment and begins with an N-to-S acyl shift giving a thioester intermediate. This is 
followed by an intramolecular transthioesterification and asparagine cyclization. The last step is a spontaneous 
S-to-N acyl shift, resulting in the ligation of both extein fragments via a native peptide bond.  
 
 Expression and Purification of Fusion Proteins 3.6.1
Expression and purification of eGFP-Npu
N 
A plasmid containing the sequence of an eGFP-Npu
N
 split intein fusion protein (pVS07
145
) 
was kindly provided by Prof. Henning Mootz from University Münster. The plasmid was 
transformed into E. coli BL21 (DE3) Star cells and expressed in 2 L LB-medium with 
100 µg/mL kanamycin with overnight induction (0.4 mM IPTG) at 18°C. Purification was 
performed via the N-terminal strep-tag II using a Strep-Tactin
® 
resin. As shown in Figure 
3.40, this protocol delivered a very good purification of the 40.8 kDa fusion protein. Cell lysis 
was performed as described for eGFP-Mxe using lysozyme and sonication (see chapter 3.5.1). 
Cleared lysates were loaded very slowly onto StrepTactin
®
 columns equilibrated with buffer 




W (pH 7.5, CV = 2 mL). Fractions were analyzed using SDS-PAGE. Fractions containing  the 
fusion protein were combined for further purification using SEC using a Superdex 75 column. 
The fractions containing the fusion protein concentrated using centricons to deliver 30 mg of 
pure fusion protein from 2 L culture volume. The protein solution was dialyzed against PTS 
buffer and stored at max. 2.5 mg/mL at 4°C in order to prevent dimerization.  
Figure 3.40 a shows a typical SEC chromatogram of the strep-tag purified fusion protein 
eGFP-Npu
N
 containing two peaks that were analyzed in SDS-PAGE and Native PAGE to get 
insights into the molecular size and shape of the proteins in the respective fractions (Figure 
3.40 b). The comparison of the two peaks from SEC in SDS-PAGE revealed that peak #1 is 
significantly less clean than peak #2. In Native PAGE most of the protein of peak #1 did not 
even migrate into the separating gel but remained in the stacking gel, indicating that the 
proteins are in fact much bigger than expected from their molecular weight, probably due to 
protein aggregation. Peak #2 showed a main protein band that migrated until ca. the middle of 
the gel, indicating that this is a properly folded, compact protein. The protein from the first 
peak was therefore discarded and only the protein eluting in the second peak was kept for PTS 







Figure 3.40. SEC purification of GFP-Npu
N
. a) SEC chromatogram from a typical run of strep-tag purified 
eGFP-Npu
N 
fusion protein using Superdex 75 16/600 column on Knauer Azura FPLC. b) Analysis of two SEC 
peaks of eGFP-Npu
N
 in SDS-PAGE and Native PAGE. The first peak contains various protein bands, possibly 




 was also characterized by HPLC on a C4 column, MALDI-TOF-MS as 
well as LC-ESI-MS, see Figure 3.41 b and Figure 7.10. The mass observed 
([M+H]
+
obs=40,674.92) corresponds well with the calculated mass of eGFP-Npu
N






























calc=40,669.16). This is common and well known in literature 







Figure 3.41. Analysis of the expression and complete purification of eGFP-Npu
N
. a) SDS-PAGE: 92 % 
pure (calculated with Fiji Software). M – Molecular weight marker, 1 – lysate, 2 – flow-through StrepTactin® 
resin, 3 – wash fraction StrepTactin® resin, 4 – pooled elution from StrepTactin® resin, 5 – SEC-purified GFP-
Npu
N









 was ordered from GenScript (Piscataway, USA) and 
transformed into E. coli BL21 (DE3) Star and Rosetta cells. Expression was tested with both 
strains and at different induction conditions (IPTG concentration and temperature, see Figure 
7.15). Under the conditions tested the fusion protein was expressed insolubly (see Figure 
7.16). However, expression using the Rosetta clone with induction at 30°C and 0.5 mM IPTG 
for 24 h was found to give the highest expression.  
For preparative protein expression, 1 L LB medium were inoculated to OD600 = 0.05, grown 
to late exponential phase (OD600 of 0.6 – 0.8) at 37°C, 220 rpm. Protein expression was 
induced by addition of 0.5 mM IPTG at 30°C, 180 rpm for 24 h. Cells were lysed after 
resuspension in 25 mL lysis buffer (20 mM Tris pH 8.0, 500 mM NaCl, 10 mM Imidazole) + 
0.25 mg/mL lysozyme + protease inhibitors and treated as described before, repeating 
sonication and centrifugation once. The supernatant was discarded and the inclusion body 
pellet was solubilized in 20 mL HisTrap equilibration buffer + 8 M urea by vortexing, 
ultrasonic bath and incubation for 2 h at room temperature (120 rpm). The solubilized 
inclusion bodies were centrifuged for 1,5 h (24,400 x g, 4°C) and filtered through a 0.2 µm 
syringe filter prior his-tag purification under denaturing conditions (8 M urea). For this, 8 mL 










equilibration buffer + 8 M urea. The column was washed with 10 CV equilibration buffer + 8 
M urea following elution of unbound host proteins, and the fusion protein was eluted using a 
gradient from 30 mM to 1 M imidazole over 5 CV. The collected fractions were analyzed in 
SDS-PAGE (see Figure 3.42) and fractions containing the fusion protein were combined and 
dialyzed into PTS buffer + 6 M urea to give 40 mg fusion protein from 1 L culture volume.  
 
 
Figure 3.42. Affinity purification of Thy-1-Npu
N
 via His-Tag. a) Chromatogram of the purification on a 
HisTrap column (FF crude, 5 mL), the fusion protein was eluted by a gradient from 30 mM to 1 M imidazole 
over 5 CV. b) Analysis of the HisTrap purification in SDS-PAGE. M- Molecular weight marker, 1 –  pre 
induction, 2 – lysate 1, 3 – lysate 2, 4 – solubilized inclusion bodies (load) 5 – flow-through HisTrap column, 6 – 




 fusion protein was characterized by MALDI-TOF-MS and LC-
ESI-MS (Figure 7.17). The mass observed ([M+H]
+
obs=25,356.21 m/z) corresponds well with 
the calculated mass ([M+H]
+
calc=25,226.5 Da), this time with the N-terminal methionine in 
place, which is also in agreement with literature as here the adjacent residue is a glutamine 





 was also analyzed using tryptic digestion as described in 2.8.7. The coverage of 
the protein sequence is given in Figure 3.43. Using this protocol a big part of the protein 
sequence was verified.  
 
Figure 3.43. Analysis of Thy-1-Npu
N
 fusion protein by tryptic digestion. Underlined sections were 

























MQKVTSLTAC   LVDQSLRLDC   RHENTSSSPI    QYEFSLTRET   KKHVLFGTVG   
VPEHTYRSRT   NFTSKYNMKV   LYLSAFTSKD   EGTYTCALHH   SGHSPPISSQ   
NVTVLRDKLV   K-CLSYETEIL   TVEYGLLPIG   KIVEKRIECT   VYSVDNNGNI   
YTQPVAQWHD   RGEQEVFEYC   LEDGSLIRAT   KDHKFMTVDG   QMLPIDEIFE   
RELDLMRVDN   LPNHHHHHH 
 
 








 was prepared by subcloning (3.2.1) and was transformed 
into BL21 (DE3) Star cells for expression tests. Under all conditions tested the 31.5 kDa 
protein was expressed only in insoluble form (expression at 37, 25 and 12°C, induction with 1 
and 0.4 mM IPTG), Figure 3.44. Since the expression did not deliver soluble protein with any 
induction temperature, protein production was accomplished at 37°C for 5 h with 0.4 mM 
IPTG.  
 
a      b 
  
Figure 3.44. Expression test of IL-2-Npu
N
 fusion protein. M –Molecular weight marker, 1 – insoluble 
fraction, 37°C, 1 mM IPTG, 2 – insoluble fraction, 25°C, 1 mM IPTG, 3 – insoluble fraction, 37°C, 0.4 mM 
IPTG, 4 – insoluble fraction, 25°C, 0.4 mM IPTG, 5 – soluble fraction, 37°C, 1 mM IPTG, 6 – soluble fraction, 
25°C, 1 mM IPTG, 7 – soluble fraction, 37°C, 0.4 mM IPTG, 8 – soluble fraction, 25°C, 0.4 mM IPTG.  
 
The inclusion bodies were solubilized using 8 M urea as described for Thy-1 protein. 
Refolding of the denatured protein was attempted by dialysis in buffer W, dialysis in buffer W 
+ 0.2 M L-arginine as additive (not shown), rapid dilution in buffer W and slow dilution in 
buffer W. These refolding experiments showed high precipitation during dialysis. In dilution, 
most of the protein remained soluble, Figure 3.45 a. Therefore, the supernatant from rapid 
dilution was slowly loaded to StrepTactin
®
 resin for purification via strep-tag. Under these 
conditions the protein was not separated and coeluted with host proteins, possibly chaperones 










a      b 
  
Figure 3.45. Refolding Optimization and Strep-tag purification of IL-2-Npu
N
 fusion protein. a) M – 
Molecular weight marker, 1 – rapid dilution (pellet), 2 – rapid dilution (supernatant), 3 – slow dilution (pellet), 4 
– slow dilution (supernatant), 5 – dialysis (pellet), 6 – dialysis (supernatant). b) M – Molecular weight marker, 1 
– supernatant from rapid dilution, 2 – flow-through StrepTactin® resin, 3 – wash fraction, 4 – 9 – elution 
fractions.  
 
To overcome the limitation in the purification, a different approach was investigated for IL-
2-Npu
N
 fusion protein: the inclusion bodies were prepared and reduced using a multi-step 
washing procedure adapted from Piontek (2007).
146
  By this method, protein purity could be 
improved from 43% to 51% and the insoluble fusion protein was solubilized in 6 M GdmCl, 
Figure 3.46. Purification by SEC and HPLC (on a C4 column) was also tested for this protein, 
but these methods did not result in improved purity (not shown). Therefore, the protein was 
used for PTS experiments as it was after the washing procedure.  
 
 
Figure 3.46. Inclusion Body washing procedure. M – Molecular weight marker, 2 – supernatant lysis, 2 – 
pellet lysozyme wash, 3 – pellet deoxycholate wash, 4 – supernatant deoxycholate wash, 5 – pellet 
deoxycholate removal, 6 – supernatant deoxycholate removal, 7 – pellet wash with water, 8 – supernatant 
wash with water, 9 – supernatant reduction with 100 mM DTT, 10 – pellet DTT removal, 11 – supernatant 
DTT removal, 12 – denatured protein sample in 6 M GdmCl.  
 




 PTS of eGFP-NpuN with NpuC hydrazide and NpuC-biotin  3.6.2
In a first attempt, the protein trans-splicing reaction was tested using only the eGFP-Npu
N
 
fusion protein and the Npu
C 
peptide hydrazide with 5 mM TCEP under the conditions 
specified in 2.8.5.
110
 Incubation at room temperature and 37°C resulted in 60% and 69% 





 peptide hydrazide was investigated at different 
concentrations of TCEP (1, 5 and 10 mM TCEP) and different ratios of peptide to protein 
(1.1, 1.5 and 2.3 eq. of peptide). The highest splicing yields were obtained using 1 mM TCEP, 
1.5 eq. of peptide and incubating overnight at 37°C, Figure 7.11 and Figure 7.12.  
Next, the PTS reaction between eGFP-Npu
N
 fusion protein and Npu
C
-biotin was 
investigated using the optimized conditions. After 3 days, only 50% conversion was achieved, 
however the product of the PTS reaction was purified via strep-tag (CV=0.5 mL) to evaluate 
the success of the ligation. Since eGFP-Npu
N
 carries an N-terminal strep-tag, this purification 
step separates the cleaved intein fragments from the product while unreacted fusion protein 
co-elutes with the product, Figure 3.47 b. This step should facilitate the characterization of the 
product as fewer contaminants are present.  An analysis of the purified sample by RP-HPLC 
is given in Figure 7.13. It contains eGFP-biotin as the main product, but another peak is 











 hydrazide, 5 mM 
TCEP. M – Molecular weight marker, 1– GFP-NpuN, 2 – NpuC hydrazide, 3 – PTS 16 h, room temperature, 4 – 




-biotin and purification of eGFP-biotin by SEC. 
eGFP-biotin was detected in western blot by anti-biotin antibody (1:250 in 5% BSA in PBS-T, o/n). M – 
Molecular weight marker, 1 – GFP-NpuN, 2 – PTS reaction GFP-biotin 3 d, 3 – GFP-biotin purified via strep-
tag. 
 













Figure 3.48. Characterization of eGFP-biotin by LC-ESI-MS. Raw and deconvoluted mass spectra are 
shown: tR=10.4 min corresponds to the Npu
C


































calc=3,992.14 Da,  
[M+6H]
6+
obs=666.3334 m/z  3,992.00 Da 




The product eGFP-biotin was detected in LC-ESI-MS with an observed mass of 
[M+H]
+
obs=29,643.91 Da. This corresponded with the calculated mass of the desired product 
[M+H]
+
calc=29,644.68 Da (see Figure 3.48 for raw and deconvoluted mass spectra) and is the 
main product according to the chromatogram (tR=18.1 min). The chromatogram also contains 
a peak at tR=10.4 min, corresponding to the Npu
C







obs=666.3334 m/z  3,992.00 Da). At tR=20.4 
min, cleaved Npu
N 







 Kinetic Studies of the PTS Reaction 3.6.3
The NpuDnaE split intein is the fastest known split intein.
145
 Although these observations 
always involved reactions with peptides and proteins as the C-extein, it was anticipated that 
the reactions in this work including a GPI-anchor as extein will also be very fast. To 




-biotin was performed similarly as 
described for the EPL reaction, 3.5.3. Reaction samples were starting after a shorter time 
(5 min, 10 min, 30 min, 1 h, 2 h, 4 h, 6 h, 24 h and after five days) due to the expected faster 
reaction rates. The samples were analyzed in SDS-PAGE, western blot and HPLC, Figure 
3.49. After five minutes, a weak band was already visible in the blot that increases in intensity 
over the following hours, but not any more after several days (detected using anti-biotin 
antibody-HRP). However, from the SDS-PAGE the yield still seems to increase over the time, 
Figure 3.49 a. A high reaction rate at the beginning that stopped after the first day can also be 
seen in the plot of percentage of conversion over time (Figure 3.49 b). Analysis in HPLC 























-biotin. a) Analysis in SDS-PAGE 
and western blot. M – Molecular weight marker, 1 – eGFP-NpuN, 2 – PTS reaction eGFP-biotin 5 min, 3 – 10 
min, 4 – 30 min, 5 – 1 h, 6 – 2 h, 7 – 4 h, 8 – 6 h, 9 – 24 h, 10 – 5 d. b) Conversion (in percent, calculated using 
ImageJ software) plotted over the time. c) Analysis in HPLC (C4). The fusion protein eGFP-Npu
N
 elutes at 
tR=25 min. This peak varies in shape over the course of the study as cleaved Npu
N
 has a very similar retention 
time. A new peak emerges and increases at tR=22.5 min. It corresponds to the product eGFP-biotin, as was 
confirmed by LC-MS analysis. The flat peak at tR~16 min corresponds to reacted and unreacted Npu
C
-biotin and 
the increasing peak just before it (tR=15 min) corresponds to Npu
C






















 PTS of eGFP-NpuN with NpuC-mGPI 3.6.4
 
Figure 3.50. Scheme of PTS between a POI and Int
C
-GPI. The splicing product will carry some extra 
amino acids at the splice junction.  
 
Based on the good results obtained in the PTS reaction for the biotinylation of eGFP which 





-mGPI. The reaction was set up using the conditions used for 
PTS with Npu
C
-biotin. PTS was tested with 1 mM and 75 µM (5 eq.) TCEP. Better results 
were obtained using 1 mM TCEP (not shown), when Npu
C
-mGPI was used in 1.5-fold excess. 
To evaluate the progress of the reaction, samples were also taken at frequent intervals. The 
product eGFP-mGPI was detected in western blot using an anti-GPI antibody (MTG4) already 
after 10 minutes reaction at 37°C, Figure 3.51.  However, even with prolonged reaction the 
signal in western blot did not increase in intensity, indicating a similar behavior as described 
above. The PTS reaction with Npu
C
-mGPI is very fast in the beginning and slows down 
already after a few hours.  
 
 




-mGPI. Analysis in SDS-PAGE and western blot. 
The product eGFP-mGPI was detected using an anti-GPI antibody (MTG4). M – Molecular weight marker, 1 – 
eGFP-Npu
N
, 2 – PTS 10 min, 3 – PTS 30 min, 4 – PTS 1 h, 5 – PTS 2 h, 6 – PTS 8 h, 7 – PTS 24 h.  
 
 The product of the PTS reaction to obtain eGFP-mGPI was purified after one day reaction 
using SEC on a Superdex 75 column. SDS-PAGE analysis and the SEC chromatogram 
showed a low yield of the reaction, Figure 3.52 a and b. Nevertheless, the fractions collected 
in SEC purification were analyzed in SDS-PAGE with silver staining and by analytical SEC 
using Yarra SEC-2000 column, Figure 3.52 b and c. Both methods indicated that the product 
eGFP-mGPI was present in fraction 4. The purified eGFP-mGPI, the fusion protein eGFP-






 and the reaction mixture were analyzed in western blot using anti-GPI antibody 
(MTG4), Figure 3.52 e. The product was detected at the expected size (ca. 30 kDa) in the 












-mGPI. a) Analysis in SDS-PAGE 
showed that the conversion was not very good. b) Purification of the PTS reaction in SEC (Superdex75). The 
collected fractions are numbered. c) Analysis of the fractions in SDS-PAGE with silver staining (M – Molecular 
weight marker, 1 – eGFP-NpuN, 2 – PTS o/n, 3 – SEC fraction 1, 4 – SEC fraction 2, 5 – SEC fraction 3, 6 – 
SEC fraction 4, 7 – SEC fraction 5) and d) analytical SEC (Yarra Bio-SEC 2000). e) Western blot analysis of 
purified eGFP-mGPI using anti-GPI antibody (MTG4). M – Molecular weight marker, 1 – eGFP-NpuN, 2 – PTS 
reaction prior to purification, 3 – fraction 3 – containing eGFP-NpuN, 4 – fraction 4 – containing eGFP-mGPI. A 
faint signal is observed at the expected size (~30 kDa) in the lanes of the PTS reaction as well as fraction 4.  
 
Unfortunately, LC-ESI-MS analysis of eGFP-mGPI was not successful, although the 
cleaved Npu
C
 fragment (mass 3,992.14 Da) was observed, indicating that some PTS reaction 
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 Application of PTS for the Semi-Synthesis of Naturally Glypiated 3.6.5
Proteins 
PTS with Thy-1 Protein 





-biotin was performed at room temperature and 37°C using 0.5 mM TCEP. 
Thy-1-Npu
N
 fusion protein was purified by HPLC (C4) after his-tag purification. Reaction 
samples were taken after one day and after five days incubation and analyzed in SDS-PAGE 
and western blot, see Figure 3.53. All reaction partners were found in the gel, i.e. Thy-1-Npu
N
 
fusion protein (25.2 kDa), Npu
C
-biotin (~5 kDa), cleaved Npu
N
-His6 (12.6 kDa) and the 
product Thy-1-biotin (12.9 kDa). However, Thy-1-biotin and Npu
N
 are not well separated due 
to their small MW difference and they appeared as a double band. In western blot, the biotin 
moiety was detected using an anti-biotin antibody-HRP. Signals were obtained for Thy-1-
biotin and Npu
C
-biotin at the expected positions in the blot; however they are not very strong. 
Conversion was calculated to be 20 and 23% at room temperature and 37°C after one day, and 
28 and 23% after five days. Therefore, incubation at room temperature was selected for 
further experiments as it furthermore decreases the risk of proteolysis or other protein 
degradation during the incubation compared to incubation at 37°C.  
 
 




-biotin. M – 
Molecular weight marker, 1 – Thy-1-NpuN, 2 – PTS Thy-1-biotin RT, 1 d, 3 – PTS RT, 5 d, 4 – PTS 37°C, 1 d, 5 
– PTS 37°C, 5 d. The fusion protein is found at the expected position (ca. 25 kDa) as is unreacted NpuC-biotin 
(below 10 kDa). Cleaved Npu
N
 and the product are very similar in size (12.6 kDa and 12.9 kDa, respectively), so 
a separation in SDS-PAGE is not expected. The biotin moiety was detected using an anti-biotin antibody-HRP 
(1:250 dilution in 5% BSA-PBST).  
 
Due to the low yields of the PTS reaction, characterization of Thy-1-biotin was not possible 
by LC-ESI-MS. The purification of the Thy-1 fusion protein by HPLC using acetonitrile and 




TFA as well as lyophilization might impact the folding of the protein. Although Thy-1-Npu
N
 
was already present in denatured form, this purification could have an effect in the reaction 
and hamper intein activity. Therefore, PTS reaction was also tested using Thy-1-Npu
N
 fusion 
protein which was only purified via his-tag and kept in solution all the time prior to PTS. 
However, under these changes the reaction yield was very low and after one week the product 
was not visible in SDS-PAGE but was only detected in western blot using anti-biotin 
antibody-HRP, Figure 3.54. The reaction was initially performed in buffer containing 6 M 
urea. As this slows down the reaction, the reaction was diluted to 3 M urea after one week of 
incubation, without any improvement of the yield (not shown).  
 




-biotin using fusion protein only purified via 
his-tag. Detection in western blot using anti-biotin antibody-HRP. M – Molecular weight marker, 1 – Thy-1-
Npu
N
, 2 – PTS Thy-1-biotin 7 days.  
 




-mGPI, however the product could 
not be detected unambiguously due to difficulties in LC-ESI-MS analysis and lacking 
availability of the MTG4 antibody. LC-ESI-MS analysis revealed that some PTS reaction was 
happening as the Post-PTS Npu
C
 fragment lacking the extein residues CFNA and mGPI (mass 
3,992.14 Da) was detected (not shown).  
 
PTS with Prion Protein 
PrP-Npu
N
His6 fusion protein (refolded) was kindly provided by Prof. Christian Becker from 
University of Vienna, Figure 7.21. CD analysis of the refolded protein showed a profile 
corresponding to an α-helical structure, indicating the PrPc form of the prion protein.  




-biotin was carried out without urea and with 
2.5 M urea. After three days incubation at room temperature the reactions were analyzed in 
SDS-PAGE and western blot (anti-biotin antibody-HRP). The PTS reaction worked in both 
cases tested, however reaction in 2.5 M urea resulted in a more intense signal in western blot. 
However, the conversion was overall very low, ca. 10% in both cases.  









-biotin. Detection in western blot using anti-biotin 
antibody-HRP. M – Molecular weight marker, 1 – PrP-NpuN, 2 – PTS reaction w/o urea, 3 d, 3 – PTS reaction 
in 2.5 M urea, 3 d.  
 
 Preliminary Results for PTS with IL-2 3.6.6
To test PTS also for IL-2, a reaction was set up using IL-2-Npu
N
 fusion protein (31.5 kDa, 
denatured as well as refolded) and Npu
C
 peptide hydrazide with 1 and 5 mM TCEP. The 
expected size of cleaved IL-2 is 19.7 kDa. However, at this size no significant new band was 





-mGPI, in this case using intermediate urea concentrations (3 and 4 M) as 
well as refolded protein without urea. Unfortunately, the result was the same as for Npu
C
 
hydrazide, Figure 3.56 b. Samples were analyzed in analytical SEC without success. 
Unfortunately, western blot analysis (using anti-GPI antibody, MTG4) resulted in no signal 
since this antibody generated in-house was losing activity and could not successfully be 
reproduced during the period of this thesis. Further experiments are still required to evaluate 
the outcome of this ligation.  
a b 
  




 hydrazide. M – Molecular weight marker, 1 – 
Npu
C
, 2 – IL-2-NpuN, 3 – PTS without urea, 1 mM TCEP, 4 – PTS without urea, 5 mM TCEP, 5 – PTS with 6 
M urea, 1 mM TCEP, 6 – PTS with 6 M urea, 5 mM TCEP. b)  PTS reaction between IL-2-NpuN and NpuC-
mGPI. M – Molecular weight marker, 1 – PTS without urea, 2 – t=0, 3 – PTS in 3 M urea, 4 – PTS in 4 M urea. 
Detection in western blot using anti-GPI antibody (MTG4).  




 One-Pot Ligation 3.7
A new semi-synthetic strategy for generation of GPI-APs was investigated in this work, 
combining features of both EPL and PTS, which can be conducted in a one-pot manner and 
was therefore named One-Pot-Ligation. Experiments with EPL and PTS revealed that while 
EPL was well suitable for soluble proteins, such as eGFP, it mostly failed for insoluble 
proteins prepared by denaturing conditions by solubilization. PTS on the other hand 
performed relatively well for both soluble and insoluble proteins, however it suffers from a 
high technical complexity as the required building blocks are not trivial to obtain (especially 
glypiated Npu
C
). Therefore, we aimed at the development of a novel strategy that helps avoid 
the bottleneck of the PTS reaction (the tedious generation of peptides ligated to GPIs) while 
maintaining its superior robustness.  
For this new strategy, a modified C-terminal intein fragment was designed, Npu
C
(AA), in 




) are exchanged for Ala residues, de-
functionalizing the C-terminus of the fragment for the trans-splicing process. Identical to the 
wildtype Npu
C
, this modified intein fragment can associate with the N-terminal fragment, 
bringing the POI’s C-terminus in close proximity to that of NpuC(AA). In order to replace the 




, a thiol reagent such as MESNA, 
MPAA or MMP can be added to form a protein thioester in situ. This process is followed by 
an EPL reaction of the formed protein thioester with the Cys-tagged anchor also present in the 
reaction mixture.  
 
 
Figure 3.57. One-Pot Ligation. The same fusion proteins as for PTS are combined with a mutated Npu
C
 




 have been replaced by Ala residues. In a one-pot 
reaction, a protein thioester is formed in situ, followed by Native Chemical Ligation of Cys-GPI to the C-
terminus of the POI. Only one extra cysteine residue is introduced using this strategy.  
 




 Establishing the OPL Method and Optimization of the Thiol 3.7.1
Reagent 





(AA), Cys-biotin and 50 mM MMBA as thiol reagent. Samples for analysis 
in SDS-PAGE were taken after 2 h, 24 h, 48 h and 72 h reaction. Formation of the product 
was detected in western blot using anti-biotin antibody-HRP. Under these conditions an 
efficient intein splicing was observed giving 86% conversion (Figure 3.58).  
 
 





biotin. M – Molecular weight marker, 1 – GFP-NpuN, 2 – OPL 2 h, 3 – 24 h, 4 – 48 h, 72 h.  
 
The OPL reaction mixture was analyzed in LC-ESI-MS. This analysis showed a mixture of 
products, when using MMBA as thiol reagent, in which only the intermediate product eGFP-
MMBA-thioester and the hydrolyzed side product eGFP-OH were detected, but not the 
product eGFP-biotin, Figure 3.59.  This might indicate that although some product was 
formed and detected in western blot, the amount was too small for detection in LC-MS.  
The high efficiency in the formation of the thioester and the poor product formation using 
MMBA as a thiol suggested that possibly the use of other thiols could help improve the 
yields. Several thiol reagents with different properties regarding stability and reactivity were 
tested for OPL reaction, see Scheme 3.9.  
 
 













Figure 3.59. Analysis of OPL of eGFP-Npu
N
 and mGPI. 50 mM MMBA, 1 d. a) Chromatogram (Waters 





obs=871.4858  4,353.43 Da, [M+H]
+
calc=4,353.3 Da. c) Raw and deconvoluted spectra acquired at 









calc=28,988.4 Da). tR=7 min is the fusion protein eGFP-
Npu
N
 (no clean spectrum was obtained, not shown). d) Raw and deconvoluted spectra acquired at tR=7.2 min: 
cleaved Npu
N










































Three different thiols (MESNA, MMP and MMBA) and the selenol compound (4-
selenomercaptomethyl)benzoic acid (SeMBA) were tested for OPL. SeMBA (10 eq.) was 
found to be not well suitable for OPL, it generated the selenoester and following reactions in 
low yield (only 14% after three days, Figure 3.60 a). The comparison of MESNA, MMP and 
MMBA for OPL showed that MESNA and MMP, but not MMBA are suitable for the ligation 
reaction and give good yields (ca. 25% after one hour and ca. 40% after one day for both 
MESNA and MMP, compared to 11% after one hour and 25% obtained after one day using 
MMBA), Figure 3.60 b.  
a               b 
        
Figure 3.60. Investigation of OPL reaction using three different thiols and one selenol compound 
(SeMBA). a) Comparison of MMBA and SeMBA: M – Molecular weight marker, 1 – GFP-NpuN, 2 – OPL with 
MMBA, 1 d, 3 – OPL with SeMBA, 1 d, 4 – OPL with MMBA, 3 d, 5 – OPL with SeMBA, 3 d. b) Comparison 
of OPL with MESNA, MMP and MMBA: M – Molecular weight marker, 1 – GFP-NpuN, 2 – OPL with 
MESNA, 1 h , 3 – OPL with MMP, 1 h, 4 – OPL with MMBA, 1 h, 5 – OPL with MESNA, 1 d, 6 – OPL with 
MMP, 1 d, 7 – OPL with MMBA, 1 d.  
Using MMP and MESNA similar results were obtained. However, due to the easier 
handling of MMP in OPL, this thiol was used for further studies. An OPL reaction was set up 
with eGFP-Npu
N
 and Cys-biotin. Analysis by LC-ESI-MS after one day incubation at room 
temperature showed the formation of the product. eGFP-biotin was detected at tR=13.8 min, 
Figure 3.61 b. However, this product could not be separated from the intermediate product 
eGFP-thioester and the side product eGFP-OH which was detected as well. Additional to 
these products, the Npu
C
(AA) peptide (Figure 3.61 a), the fusion protein and the cleaved Npu
N
 
(not shown) were also identified in the chromatogram analysis.  












Figure 3.61. LC-ESI-MS analysis of OPL reaction between eGFP-Npu
N
 and Cys-biotin. a) TIC profile of 
the OPL reaction between eGFP-Npu
N
 and Cys-biotin, b) mass spectrum acquired at tR=5.3 min Npu
C
(AA) 
1,089.3006x5 4,353.20 calc=4,353.3, c) Raw and deconvoluted spectrum acquired at tR=13.8 min. It contains 
eGFP-OH, eGFP-MMP and eGFP-biotin. d) Detailed view of the products from c).  
[M+5H]
5+

































 Kinetic Studies of One-Pot Ligation 3.7.2
In order to learn about the reaction mechanism as well as the reaction kinetics, One-Pot 
Ligation reactions were set up and samples were taken at regular intervals (t=0, 1 h, 2 h, 6 h, 
24 h, 2 d, 3 d and 6 d). The samples were analyzed in HPLC and SDS-PAGE (Figure 3.62 a 
and b). The reaction yields at each time point (calculated from the SDS gel using ImageJ 
software) were plotted over the time, Figure 3.62 c. These results showed that in the 
beginning the reaction is similarly fast as PTS, however is proceeds longer at intermediate 
rates, as the yields are still improving after incubation over several days which was not the 
case for conventional PTS. This in in good agreement with our expectation regarding the 







Figure 3.62. Kinetic Study of OPL Ligation between eGFP-Npu
N
 and Cys-biotin. a) Analysis in HPLC 
(C4). The peak of eGFP-Npu
N
 (tR=22 min) decreases with time and changes its shape as the cleaved Npu
N
 intein 
fragment has a similar retention time. The peak of Npu
C
(AA), tR=14.5 min, decreases as well. A new peak 
emerges and increases at tR=19.5 min, corresponding to either eGFP-OH or the product eGFP-biotin. b) Analysis 
in SDS-PAGEM – Molecular weight marker, 1 – eGFP-NpuN, 2 – NpuC(AA), 3 – OPL 1 h, 4 – OPL 2 h, 5 – 
OPL 6 h, 6 – OPL 24 h, 7 – OPL 48 h, 8 – OPL 72 h. c) Plot of the conversion from SDS-PAGE analysis 























 OPL for Protein Glypiation 3.7.3
Ligation of eGFP to a GPI Mimic by OPL 
Before OPL was used for protein glypiation, the reaction was evaluated using eGFP-Npu
N
 
and Cys-dimannose as a better GPI mimic than biotin; it is a carbohydrate attached to the 
cysteine via phosphoethanolamine unit, Scheme 2.2. The reaction was set up under the 
optimized conditions using 0.5 mM TCEP and 50 mM MMP and it was analyzed by LC-ESI-
MS. Contrary to observations made with biotin, after ten minutes reaction only the side 
product eGFP-OH was detected. After one day reaction, the product eGFP-dimannose was 







Figure 3.63. OPL reaction between eGFP-Npu
N
 and Cys-dimannose, analysis in LC-ESI-MS. a) 
Chromatogram of the analysis of OPL reaction after 1 day (Waters C4 BEH, gradient 10-70% in 15 min). b) 
raw spectra acquired at tR=18.3 min from the samples after 10 min and 1 day incubation, zoomed in to the 22+ 
ion. It shows a small peak corresponding do eGFP-dimannose additionally to the ones of eGFP-OH and eGFP-





















calc=29,430.6 Da)  
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Figure 3.64. Kinetic Study of OPL using Cys-dimannose. Analysis in SDS-PAGE and western blot. 200 
mM MMP, 2 mM MPAA. Detection was performed using ConA lectin-HRP. The signals obtained are 
unspecific, however, and present mainly at the fusion protein size for unknown reasons.  M – Molecular weight 
marker, 1 – eGFP-NpuN, 2 – OPL 1 min, 3 – 10 min, 4 – 1 h, 5 – 2 h, 6 – 4 h, 7 – 6 h, 8 – 24 h.  
 
eGFP-dimannose obtained by OPL was purified by SEC on a Superdex 75 column in PBS 
for characterization and Circular dichroism analysis. Three peaks corresponding to unreacted 
fusion protein eGFP-Npu
N
 (peak 1), the product eGFP-dimannose (peak 2) and cleaved Npu
N
 
fragment (peak 3), Figure 3.65.  
 
 
Figure 3.65. Purification of eGFP-dimannose obtained by OPL via SEC (Superdex 75 column, PBS 
buffer). Peak #2 contains the product eGFP-dimannose.  
 
Glypiation of eGFP by OPL 
Next, OPL was performed with Cys-mGPI. The reaction (containing 1 mM TCEP and 
50 mM MMP) was incubated at 37°C for six days, taking samples after 1 h, 1 day and two 
days. The samples were analyzed in western blot and by analytical SEC using Yarra SEC-
2000 column, Figure 3.66 a and b. Similarly to previous OPL test reactions with Cys-biotin 
and Cys-dimannose, the reactions required prolonged incubation time for the formation of the 
product. eGFP-mGPI from OPL was purified by SEC on a Superdex peptide column, Figure 






































Figure 3.66. OPL reaction between eGFP-Npu
N
 and Cys-mGPI. a) Analysis in SDS-PAGE and western 
blot (detection using anti-GPI antibody MTG4). A signal is already visible after 1 day incubation, but splicing 
yield increases over the prolonged incubation time. M – Molecular weight marker, 1 – eGFP-NpuN, 2 – OPL 
eGFP-mGPI 1 day, 3 – OPL eGFP-mGPI 2 days, 4 – OPL eGFP-mGPI six days. b) Analysis in analytical SEC 
(Yarra SEC-2000) and comparison with eGFP-Npu
N
 fusion protein. After 1 h two new peaks emerge, one of 
which is increasing over longer incubation time (eGFP-mGPI). c) SEC chromatogram of purification of eGFP-
mGPI from OPL. Peak #1 contains the product, whereas peak #2 contains product as well as Npu
C
(AA). d) SDS-
PAGE analysis of the fraction from SEC purification. M – Molecular weight marker, 1 – OPL reaction eGFP-
mGPI (Load fraction), 2 – 4 – peak #1, 5 – peak #2, 6 – 12 – peak #3. 
 
   The product eGFP-mGPI was also detected in LC-MS, measured on a SYNAP HRMS 62-
S mass spectrometer at the mass facility of FU Berlin), Figure 3.67. However the peak 
observed represents only a minor part of the sample. In order to confirm the attachment of the 
mGPI to the C-terminus, a tryptic digestion of the product separated by SDS-PAGE was 
performed following the protocol described in 2.8.7. Analysis of the peptide fragments by 

































Figure 3.67. a) Deconvoluted mass spectrum of eGFP-mGPI (measured on a SYNAP 62-S mass 




calc=30,336.0 Da with N-
terminal Met (in this protein batch with and without Met was found). b) Tryptic digestion of eGFP-mGPI from 
OPL: underlined parts of the sequence have been identified in MALDI-TOF-MS analysis.  This does not include 
the C-terminus of the protein bearing the GPI, this method does not give any information about glypiation.  
 
Finally, OPL was also evaluated for the ligation of a bilipidated GPI-anchor to eGFP. The 
reaction was carried out using the same conditions as for OPL with mGPI. The product, 
eGFP-bGPI, was also detected in western blot using anti-GPI antibody (MTG4), Figure 3.68. 




Figure 3.68. Western blot analysis (anti-GPI antibody MTG4) of OPL reaction between eGFP-Npu
N
 and 
Cys-bGPI. M – Molecular weight marker, 1 – eGFP-NpuN, 2 – OPL eGFP-bGPI 1 day, 3 – OPL eGFP-bGPI 2 
days, 4 – OPL eGFP-bGPI six days.  
MASWSHPQFE KASGTVSKGE ELFTGVVPIL VELDGDVNGH KFSVSGEGEG 
DATYGKLTLK FICTTGKLPV PWPTLVTTLT YGVQCFSRYP DHMKQHDFFK 
SAMPEGYVQE RTIFFKDDGN YKTRAEVKFE GDTLVNRIEL KGIDFKEDGN 
ILGHKLEYNY NSHNVYIMAD KQKNGIKVNF KIRHNIEDGS VQLADHYQQN 
TPIGDGPVLL PDNHYLSTQS ALSKDPNEKR DHMVLLEFVT  
AAGITLGMDE LYKGSRSGSC-mGPI 
 




Additionally to chromatographic methods, detergent extraction was evaluated for the 
purification of glypiated proteins. This method should result in less dilution of the samples 
and separation of lipidated (glypiated) from unlipidated proteins by phase separation using 
Triton X-114.
156
 This method was tested for eGFP-mGPI and eGFP-bGPI. Unfortunately, due 
to the lack of an anti-GPI antibody of correct specificity, detection of the extraction was 
difficult. MTG5 antibody was used for detection, however this antibody gave a signal for 
glypiated eGFP, but also for eGFP-Npu
N
 fusion protein, Figure 7.14. As this result was 
inconclusive, this separation method was not further investigated.  
 
 OPL for the Semi-Synthesis of Naturally Glypiated Proteins 3.7.4
OPL for Thy-1 Protein 
After EPL and PTS, OPL was also used to introduce a C-terminal modification to the Thy-1 
protein. First, biotinylation of Thy-1 was optimized in buffer containing 6 M urea at room 
temperature and 37°C and TCEP concentrations of 1 mM, 5 mM and 10 mM. In this case, 
higher TCEP concentrations than for eGFP were tested as Thy-1 protein was already present 
in denatured form. The reaction samples were analyzed in SDS-PAGE and western blot after 
one day incubation, Figure 3.69 a. Reaction at room temperature with 5 mM TCEP gave the 
highest yield (66% conversion after one day). Longer reaction did not improve the yield, 
Figure 7.20. The product Thy-1-biotin was analyzed using LC-ESI-MS and MALDI-TOF-MS 
after tryptic digestion. In tryptic digestion, most of the sequence was covered, however the C-
terminal fragment was not found in MALDI-TOF-MS analysis, Figure 3.69 b. LC-ESI-MS 
analysis did not show the presence of the desired product.  
OPL was also performed between Thy-1-Npu
N
 and Cys-mGPI. After six days reaction, the 
mixture was analyzed in LC-ESI-MS, Figure 3.70. The expected mass of Thy-1-mGPI 
[M+H]
+
calc=13,939.9 Da was not observed, however, the mass that was found 
[M+H]
+
obs=13,590.58, corresponded very well with a delipidated and dephosphorylated 
species of Thy-1 ([M+H]
+
calc(Thy-1-GPIdelipidated)=13,590.63. Therefore, utilizing the fact that 
unreacted fusion protein and cleaved Npu
N
 carry a his-tag, Thy-1-mGPI from OPL was 
purified using his-tag affinity chromatography (HisTrap HP 1 mL column) under denaturing 
conditions (6 M urea), Figure 3.71 a. As expected, Thy-1-mGPI (lacking the his-tag) was 




 bound to the column and were only found 
in the elution fractions, Figure 3.71 b. Npu
C
(AA) was mainly found in the flow-through 




fraction, but also in the same fraction as the product. However, due to its small size it can 






Figure 3.69. OPL Thy-1-biotin. a) Detection in Western blot with anti-biotin antibody-HRP. M – 
Molecular weight marker, 1 –  OPL RT, 10 mM TCEP, 2 – OPL RT, 5 mM TCEP, 3 – OPL RT, 1 mM TCEP, 4 
– Thy-1-NpuN, 5 – OPL 37°C, 1 mM TCEP, 6 – OPL 37°C, 5 mM TCEP, 7 – OPL 37°C, 10 mM TCEP. b) 




Figure 3.70. LC-ESI-MS analysis of Thy-1-mGPI from OPL. The deconvoluted mass spectrum shows a 
main peak at [M+H]
+
obs=13,590.58 Da, which does not correspond to the full Thy-1-mGPI ([M+H]
+
calc=13,939.9 
Da), but instead to a delipidated, dephosphorylated species ([M+H]
+
calc=13,590.63 Da).  
 
MQKVTSLTAC   LVDQSLRLDC   RHENTSSSPI    QYEFSLTRET   KKHVLFGTVG   
VPEHTYRSRT   NFTSKYNMKV   LYLSAFTSKD   EGTYTCALHH   SGHSPPISSQ   
NVTVLRDKLV   KC-biotin  
 







Figure 3.71. Purification of Thy-1-mGPI from OPL using his-tag. a) Strategy. b) SDS-PAGE analysis, M 
– Molecular weight marker, 1 – OPL reaction Thy-1-mGPI 6 d, 2 – flow-through his-tag purification, 3 – wash 
fraction, 4 – 8 – elution fractions.  
 
OPL for Prion Protein 
OPL reaction between PrP-Npu
N
 and Cys-biotin was carried out without urea and with 
2.5 M urea. After three days incubation at room temperature the reactions were analyzed in 
SDS-PAGE and western blot using anti-biotin antibody-HRP. In order to compare the 
efficiency of the OPL, the reaction was performed in parallel with a PTS reaction under the 
previously mentioned reaction conditions with PrP. In comparison, it can be seen that OPL 
gave a better intein cleavage than PTS (15% and 13% w/o and with urea, respectively). 
However, the formation of the product was less efficient giving only a very weak signal in 
western blot, Figure 3.72.  
 
 
Figure 3.72. OPL between PrP-Npu
N
 and Cys-biotin. M – Molecular weight marker, 1 – PrP-NpuN, 2 – PTS 
reaction w/o urea, 3 d,  3 – PTS reaction 2.5 M urea, 3 d, 4 – OPL reaction w/o urea, 3 d, 5 – OPL reaction 2.5 M 
urea, 3 d.  
 




 Modification of IL-2 by OPL 3.7.5
Based on the negative results obtained in the PTS for modification of IL-2 protein, OPL was 
investigated as an alternative strategy. Reaction of IL-2-Npu
N
 and Cys-biotin was investigated 
at room temperature and 37°C. Samples were taken after 2 h, 24 h, 48 h and seven days, and 
were analyzed in SDS-PAGE and western blot (using anti-biotin antibody-HRP), Figure 3.73 
a. Splicing yields were comparable at both temperatures tested (up to 39% and 35%, at RT 
and 37°C, respectively). However the signal in western blot was stronger in the samples 
incubated at room temperature, and intensity increased over the whole incubation time (seven 
days).  
Similarly, OPL was performed between IL-2-Npu
N
 and Cys-mGPI under the conditions 
optimized for Cys-biotin. A new band is observed in SDS-PAGE analysis approximately at 
the expected size (21 kDa), most likely corresponding to the product IL-2-mGPI. However, 
more extensive characterization was not possible due to lack of anti-GPI antibody and LC-
ESI-MS availability. After one day reaction, 20% conversion was obtained, and after seven 




Figure 3.73. OPL IL-2-Npu
N
 and a) Cys-biotin and b) mGPI. a) M – Molecular weight marker, 1 – IL-2-
Npu
N
, 2 – OPL RT 2 h, 3 – RT 24 h, 4 – RT 48 h, 5 – RT 7 d, 6 – OPL 37°C 2 h, 7 – 37°C 24 h, 8 – 37°C 48 h, 9 
– 37°C 7 d. b) 1 – NpuC(AA), 2 – IL-2-NpuN, 3 – OPL RT 24 h, 4 – OPL RT 7 d.  
 
  




 Investigation of the Effect of C-terminal Modification and 3.8
Glypiation on Protein Structure Using Circular 
Dichroism 
Circular dichroism (CD) was used to investigate the effect of C-terminal modifications 
(biotinylation, dimannosylation and glypiation) on the structure of eGFP. In its native fold, 
eGFP possesses a β-barrel structure.171 This structure was confirmed in CD measurements for 
eGFP-MMP thioester and eGFP-OH (made with Npu
C
(AA)), Figure 3.74, which showed a 










Figure 3.74. CD spectra of eGFP-MMP-thioester (a) and eGFP-OH (b) in comparison to sample far UV 
CD spectra of different types pf protein secondary structure (c, taken from 
166
). The long dotted lone the 
sample spectrum corresponds to anti-parallel β-sheet structure with a minimum between 210 and 220 nm, which 








The purified samples from EPL (eGFP-MMP, eGFP-biotin, eGFP-dimannose, eGFP-mGPI 
and eGFP-bGPI) and from OPL (eGFP-OH, eGFP-biotin, eGFP-mGPI and eGFP-bGPI) were 
also analyzed in circular dichroism. PTS did not yield sufficient sample amounts of any 
proteins for analysis in CD. For the samples from both EPL and OPL the β-sheet structure 
was not affected by C-terminal modification, Figure 3.75, Figure 3.76. For biotinylation and 
dimannosylation, the spectra are entirely unchanged in comparison to those of eGFP-thioester 
and eGFP-OH, respectively. In the case of modification with mGPI, the minimum at ca. 216 
nm is less pronounced for both EPL and OPL samples in comparison to unmodified eGFP, 
however this is likely to be due to a lower protein concentration as concentrating the samples 
was risky regarding possible precipitation. For modification with bGPI however, for the EPL 
sample not spectrum could be obtained and for the OPL sample of eGFP-bGPI, almost no 






Figure 3.75. CD spectra taken of samples from EPL (eGFP-biotin, eGFP-dimannose and eGFP-mGPI) 
in comparison with eGFP-MMP thioester. The β-sheet structure of eGFP is not compromised by C-terminal 
modification with biotin, dimannose or mGPI.  









Figure 3.76. CD spectra taken of samples from OPL (eGFP-biotin, eGFP-mGPI and eGFP-bGPI) in 
comparison to eGFP-OH.  
 
  





In this section, the findings of this work will be discussed and evaluated in relation to the 
obtained improvements, advances and disadvantages, and the potential among the different 
reported methods for the semi-synthesis of GPI-APs. Section 4.1 deals with the peptide 
synthesis, thioester formation and NCL reactions. A discussion of the different strategies for 
the generation of homogeneous GPI-anchored proteins is provided in sections 4.2– 4.4. 
Additionally, challenges regarding synthesis, generation or characterization of different 
compounds is addressed in section 4.5. As a general remark it should be noted here that the 
big challenges resulted from the difficult handling (low solubility) and impaired stability of 
the highly complex synthetic GPI structures.  
 
 Peptide Synthesis and Native Chemical Ligation 4.1
As part of this project, two peptides corresponding to the C-terminal fragment of the DnaE 
split intein from Nostoc punctiforme (Npu) were synthesized to investigate the semi-synthesis 
of GPI-APs. The Npu
C
 fragment was synthesized as a peptide thioester for a Native Chemical 
Ligation with the cysteine-containing biotin and GPI. Although this C-terminal fragment is 
only a 39 amino acid peptide, its synthesis was not trivial and several challenges were 
encountered during the process. The sequence contains nearly all proteinogenic amino acids, 
and for many of them, the coupling and deprotection conditions required separate 
optimization, Table 2.2. Therefore, the availability of this fragment unexpectedly turned out 
to represent a significant bottleneck in the establishment and optimization of the PTS method 
to obtain GPI-APs. After various syntheses and optimization of the process, this peptide was 
obtained in 10 mg scale under optimized conditions using a resin that released the peptide as a 
peptide hydrazide as a thioester precursor.  
Having the Npu
C





 This conversion was executed following the report of Zheng et al. 
(2013). Different thiols were used for the formation of this thioester, however only when 
MMP was used, the reaction proceeded in quantitative yield within 20 minutes and without 
the formation of side products, such as cyclic thio-lactame between the C-terminus and the 
side chain of a cysteine residue, or the product of the hydrolysis of the thioester. Although 




some material was lost during this conversion, mainly during purification by HPLC, the main 
constraint was the difficult synthesis of the peptide hydrazide with low yields.  
Following the preparation of the thioester, a native chemical ligation reaction between the 
Npu
C
 thioester and the different cysteine-containing molecules was performed. The yields and 
reaction rates of this process were strongly dependent on the ligated molecule. In the case of 
Cys-biotin, NCL was almost completed after three days reaction at 37°C, whereas NCL of 
Npu
C
-MMP with Cys-mGPI was not successful under the same conditions. In order to avoid 
the oxidation of the cysteine during the NCL with the GPI, the reaction was performed under 
argon. However, even under these conditions, the reaction was by far not as successful as 
ligation to Cys-biotin. After one week incubation under argon at 37°C with freshly added 
TCEP every one to two days, and re-adjusting the pH to 7.0 frequently, the product could be 
observed in LC-ESI-MS analysis. Unfortunately, together with the ligated product, also the 
hydrolyzed peptide and some oxidized side products were detected. After different efforts for 
the optimization of the reaction, the product of the ligation (Npu
C
-mGPI) was obtained in 
sufficient amounts to investigate the PTS process.  
The modified peptide Npu
C
(AA) on the other hand was much easier to synthesize, possibly 
due to the lack of the two critical amino acids in the sequence, the cysteine and the asparagine 
residues participating in the PTS, which were replaced by alanines. Additionally, this peptide 
does not require any modification post-synthesis, avoiding the loss of material after 
purification. The easy accessibility to the mutated Npu
C
 peptide represented a significant 
advantage for the application of the OPL method over the PTS method in a slightly different 
way than anticipated: it was assumed that this method would mainly be more convenient 
because no peptide thioesters had to be generated and ligated to a GPI or GPI analogues.   
 
 EPL is a Suitable Strategy for Soluble Proteins 4.2
The first method evaluated for the ligation of proteins and GPIs was Expressed protein 
ligation. This method has been largely used to ligate proteins with a C-terminal thioester with 
other molecules. In this case, EPL was found to be an excellent strategy for the semi-synthesis 
of C-terminally modified proteins, if the proteins of interest are present in soluble form. The 
process was usually hampered by the reactivity and stability of the active protein thioesters. 
However, using an appropriate thiol and a freshly prepared protein thioester in the reaction, a 
faster ligation with the cysteine-bound molecules ensured little to no hydrolysis. 




Unfortunately, even with the use of more stable thiols such as MMP, the protein thioester was 
not very stable (< 1 week), which was not expected in this short time. Fortunately, expression 
of the eGFP-Mxe fusion protein was straightforward and high-yielding and the protein could 
be used in molar excess to the ligation partners. The EPL strategy represents a very versatile 
method for the generation of libraries of proteins carrying different GPI-anchors for 
comparative studies, as no extra ligation step is required for the generation of the GPI-APs. 
The production of the thioester requires relatively little synthetic effort, so that the main 
limitation was the difficult access to sufficient amounts of GPI molecules, the synthesis of 
which is still a challenge, and the low solubility of the GPI molecules.   
In addition to the problems associated with protein solubility, the main limitation of EPL 
was the relatively slow reaction rates as was shown in the kinetic study in section 3.5.3. It is 
likely that the slow reaction rates were due to low concentration or reactivity of the GPI-
anchors, namely by deactivation of the reactive cysteine by the connecting this residue to the 
GPI, which is involved in the ligation reaction, as it was observed by Guo et al. (2009)
81
 for 
the Sortase A reaction. In contrast to previous reports involving GPI mimics in EPL reactions, 
the GPIs are structurally far away from these mimics so that this problem would not be 
observed,
37
 especially when peptide-based mimics were applied.
132
 
This method could be efficiently used for the semi-synthesis of eGFP-biotin and eGFP-
mGPI, in which all the components are soluble. However, an additional limitation of this 
strategy was the difficult purification of the reaction products, which do not have large size 
difference. Generally, unreacted protein thioester and the desired product present a fairly 
small difference in molecular weight in the case of GPI-APs (i.e. only the size of the GPI) and 
standard purification methods, such as SEC, IEX or affinity purification could not be applied. 
Only a separation by HPLC was possible, however this involved a denaturation of the folded 
eGFP, which is not desirable.  
The EPL was an inefficient strategy for ligations involving insoluble proteins. Although the 
ligation reaction should work well under denaturing conditions, as it is done with peptides in 
NCL, the conditions required for solubilizing the protein of interest are not always compatible 
with the conditions required to obtain a proper folding of the Mxe intein, which was not 
capable of performing the intein cleavage reactions 6 M GdmCl, and only to a little extent in 
6 M urea, which is a weaker denaturing agent. To overcome this limitation, the formation of 
the thioesters from the insoluble proteins Thy-1, IL-2 and PrP was completed in solution until 
a certain level, using a dilution process. However, even when the formation of the protein 
thioesters was achieved, isolation of pure thioesters was difficult as the chitin binding domain 




present in the fusion proteins does not bind to the chitin resin under these conditions. 
Furthermore, the cleavable Mxe-CDB domain was relatively close in size to the protein 
thioesters which made size exclusion chromatography difficult (additional to the fact that it is 
not well suited for denatured proteins).  
 
 PTS is a Robust Method Limited by Access to Peptide-4.3
GPI Conjugates 
The second strategy evaluated in this work for the semi-synthesis of GPI-APs was the 
protein trans-splicing (PTS). PTS has scarcely been used for the generation of GPI-APs, and 
in the few reports described in literature, the products were generally not purified but used in 
situ, mostly to demonstrate the localization of the glypiated proteins, for example on the cell 
membrane in live cells.
138
 Therefore, no full characterization of such products is available to 
date. Since PTS is very robust and reliable, exhibiting nearly no hydrolysis, it can be assumed 
that these products have been obtained as reported. Based on these results, one of the aims of 
this work was to expand the application of this strategy to obtain glypiated proteins in 
amounts that can be further characterized and used in studies to understand the role of this 
modification of proteins.  
In contrast to EPL, the PTS strategy was successful for both native and denatured proteins. 
This strategy is characterized by high reaction rates, especially under native conditions, which 
is in well agreement with literature.
145
 Although the kinetic studies carried out here did not 
reach the results of the literature reports where the observed t1/2 is < 1 min,
138,172
 it is the 
fastest of the strategies investigated in this work. This is possibly due to the use of exteins that 
are structurally very different from the native ones (i.e. Cys-GPI instead of peptides).  As it is 
the case for the Npu split intein, a strong extein dependency has also been described as a main 
drawback of the PTS reaction by Shah et al. (2013).
118
 Mutations in the non-essential residues 
close to essential ones was investigated by Stevens et al. (2017)
172
 to generate more 
promiscuous split inteins with some success. Most of the mutations slowed down the splicing 
reaction, but some of them, especially the presence of a GXP motif close to the penultimate 
His125) did result in a wider spectrum of accepted exteins.  
One advantage of PTS over EPL pointed out in Shah & Muir (2011)
117
 is its independence 
on protein concentration. The initial step, association of the two intein fragments, does not 
rely on random collision of the fragments in the reaction solution but can utilize the strong 




affinity of both split intein fragments to each other. This strong affinity is probably the reason 
for the high robustness of the PTS reaction towards chaotropic agents such as urea and can be 
attributed to: the big difference in pI of the two split intein fragments, which makes the 
complex very stable and therefore independent of salt concentration.
115
 
Due to the nature of the PTS reaction involving the cleavage of a relatively large protein 
domain, the Npu
N
 fragment, from the fusion protein and its replacement by the rather small 
GPI-anchors, that starting fusion protein and the product possess a large difference in 
molecular weight that offers good opportunity for purification via SEC for native proteins. 
Furthermore, in this a good option is the introduction of C-terminal tags, because this 
facilitates easy separation of the products from the cleaved intein fragments. These 
advantages were demonstrated in the formation of glypiated Thy-1 and Prion proteins, 
although full conversion was not achieved.  
 The main drawbacks of the use of the PTS strategy were the high synthetic effort needed to 
obtain the synthetic fragments and the loss of material in the numerous purification steps after 
reach reaction. As already discussed, especially the generation of Npu
C
-mGPI in sufficient 
amounts represented a major challenge during this work. Furthermore, the need of multiple 
steps makes this strategy less versatile to investigate the effect of a GPI structure on a specific 
protein and for the generation of GPI-AP libraries with different GPI-anchors or other C-
terminal modifications, which will require the synthesis of each single structure attached to 
the Npu
C
 fragment, involving also purification.  
In this context and due to these difficulties, PTS was successfully applied for the generation 
of eGFP-biotin, Thy-1-biotin and also IL-2-biotin in small amounts, but generation of POI-
mGPI was mainly limited by access to Npu
C
-mGPI. PTS with other exteins than biotin and 
the monolipidated GPI-anchor was not achieved so far.  
 
 OPL Represents a Promising Strategy for GPI-AP Semi-4.4
Synthesis 
Considering the problems and disadvantages observed in the EPL and PTS strategies, as 
described in section 3.7, a third strategy (One-Pot Ligation) was considered for the ligation of 
the GPIs to proteins. The OPL was envisioned as a new strategy overcoming the drawbacks of 
both EPL and PTS by circumventing the tedious process of peptide thioester formation and 
purification, as well as NCL to GPI-anchors.  The strategy is similar to the one reported in 




Vila-Perello et al. (2013),
100
 where a mutated Npu
C
 peptide was employed for protein 
thioester generation from cell lysate, and ligation of this thioester to a small fluorescent 
peptide marker was also investigated. This method has not been investigated towards the 
generation of GPI-APs.  
The mutated Npu
C





 which were replaced by Ala residues. By using this 
peptide, the intein fragments undergo the association and the splicing process is arrested 
following the initial N-to-S acyl shift to form a protein thioester, because the 
transthioesterification is impeded due to the lack of the thiol group from the cysteine at the C-
terminus of the mutated Npu
C
 peptide, Figure 4.1. This formed thioester intermediate between 
the C-terminus of the protein and the cysteine at the N-terminus of the Npu
N 
fragment can be 
captured in the following reaction by adding a reactive thiol which will induce formation of a 
protein thioester in situ. There is no need, however, to purify this protein thioester, which was 
found to be unstable during EPL investigations, see section 3.5.2. In contrast, the formed 
thioester can be reacted in situ, avoiding its manipulation and preventing its hydrolysis. 
Protein thioester formation is followed by a transthioesterification with the external thiol 
reagent and the S-to-N acyl shift with formation of a peptide bond between the extein’s C-
terminus and the cysteine residue of Cys-GPI. The reaction can proceed over different 
pathways, i.e. it is also conceivable that Cys-GPI might directly attack the thioester 
intermediate after the N-to-S acyl shift, although this route seems less likely since Cys-mGPI 
is not present in excess, other than the thiol reagent and was also less reactive.  
One-Pot Ligation was developed to overcome the respective limitations of the EPL and PTS 
strategies, i.e. slow reaction rates in case of EPL and high synthetic effort in case of PTS. 
Indeed, it offers some advantages such as the easier synthesis of the mutated Npu
C
 peptide 
than for the wildtype peptide, probably due to the exchange of Cys and Asn residues to 
alanines. Only one purification step was required following SPPS and deprotection (HPLC) 
and no further manipulation of the peptide, resulting in significantly easier access to this 
peptide. The OPL reaction also showed reaction rates that were determined to be in between 
the ones of the EPL and PTS processes, reaching ca. 80% conversion after one day in 
comparison to ca. 50% in seven days for EPL.   
In order to understand the progress of the reaction, an analysis of the reaction kinetics was 
carried out using Cys-biotin, see section 3.7.2. This study showed that protein thioester 
formation in situ was very fast, having rates comparable to PTS. This was observed mainly in 
SDS-PAGE analysis. Analysis of the same samples by HPLC and LC-MS, however, revealed 




that this thioester intermediate was present for a long time, indicating that the subsequent in 
situ EPL reaction took places much slower and that indeed the pathway via the thioester 
intermediate was the predominant one, and not the direct attack of the Cys-GPI, Figure 4.1.  
Although OPL did in fact combine advantages of both previously investigated strategies, it 
also showed a high level hydrolysis of the in situ formed protein thioester, which was 
dependent on the thiol used for the reaction. This also became obvious in the kinetic study 
mentioned above, which at the same time revealed the reason for this finding, i.e. the fast 
creation of the protein thioester (which had already been found to be unstable during the PL 
investigations) and the slow following in situ EPL reaction. As in EPL, this might refer to the 
same problem of reactivity as observed by Guo et al. (2009)
81
 who observed activation of the 
peptide but not the ligation to the GPI mimic directly. The easy setup and purification, 
requiring only one purification step at the end of the ligation, makes OPL also as variable as 
EPL regarding its potential for the generation of a library of GPI-APs for further studies.   
The product purification after the OPL reaction was a straightforward process due to a 
sufficient size difference between starting compounds and products. As demonstrated in the 
synthesis foe GFP-mGPI, the products of the reaction can be isolated using SEC or affinity 
chromatography. Moreover, under optimized conditions, this strategy can be used to convert 
all protein thioester into the product, although this was not always the case. Using more stable 
thiols such as MMP, hydrolysis of the thioesters was strongly reduced and the ligation 
products could be obtained.  






Figure 4.1: Proposed mechanism for One-Pot Ligation (OPL). Following intein fragment association and N-S-acyl shift (steps 1 and 2), two routes are suggested for the 
reaction progress: mainly, a protein thioester will be formed in situ by attack of the thiol reagent, which is present in excess. Subsequently, an EPL reaction takes place in the 
same reaction mixture, ligating the anchoring molecule (here a GPI molecule) to the C-terminus of the protein. A possible second route is the direct attack of the thio-group of 
the Cys-GPI, although this seems less likely due to the excess of thiol reagent present.  




 Methodological Challenges 4.5
In order to fully characterize the proteins, peptides, cysteine-containing molecules and the 
expected GPI-APs, various methods were applied in this work. This characterization and 
analysis represented a big challenge, especially for the products, because standard methods to 
characterize intact GPI-APs are not available. Traditionally, the analysis of GPI-APs is 
performed separately for the protein and the glycolipid. The analysis generally starts by 
removing the protein from the cell membrane by cleaving the lipid portion with 
phospholipases C or D. The released protein part is attached to the GPI glycan, which can 
then be analyzed in western blot using antibodies against the protein of interest or by 
proteomic methods.
173,174
 Although partitioning using Triton X-114 has been reported for the 




Digestion by proteases (especially trypsin) with subsequent detection of the peptide 
fragments in mass spectrometry is a commonly used technique for protein identification and 
detection of modifications. This technique was also applied in this work for the detection of 
the generated GPI-APs. However, the C-terminal peptide fragment from the tryptic digestions 
from the generated proteins was too short (two amino acids) in all cases and could not be 
identified in MALDI-TOF-MS analysis (neither with nor without a GPI-anchor attached). 
Significantly shortened digestion duration in comparison to the protocol used was 
investigated to obtain larger fragments due to more missed cleavages, 
164
 however, even with 
this modification the detections of the C-terminus was not possible. This method was 
therefore also considered not suitable for the identification of our GPI-APs. It was useful, 
however, to prove the identity of the fusion proteins.  
As an alternative to detect the glycan modification on the C-terminus, PAS (periodic acid-
Schiff) staining in acrylamide gels was investigated for GPI-AP analysis, anticipating that the 
carbohydrate part of the GPI would result in staining. PAS staining has mainly been applied 
for detection of highly glycosylated proteins and is not very sensitive. Therefore, this assay 
also did not deliver detection of GPIs and it was not possible to stain small amounts of GPI-
APs.  
Another option was detection of the glycan part of the GPI in western blot using an anti-GPI 
antibody. Such an antibody was present in the group, resulting from earlier studies on possible 
anti-malarial therapies on the basis of anti-GPI antibodies.
176
 The MTG4 antibody described 




in this work was known to exhibit the best recognition of various GPI-derivatives while not 
being the most specific antibody. Initially, the MTG4 antibody was successfully used for 
detection of GPI-APs in western blots. However, this antibody showed a low stability and 
quickly lost its activity. After some successful experiments, it was so far not possible to 
generate a new functional batch of it from the existing clones.  
Electrospray-ionization mass spectrometry in combination with HPLC was anticipated to be 
the most suitable method for detection and analysis of the products. This technique would 
allow for monitoring of the reaction progress as well as detection of the final products in an 
unambiguous way. While characterization of intact proteins in LC-ESI-MS is commonly 
performed,
177,178
 detection of glypiated proteins indeed was a substantial challenge. This is 
mainly due different properties of the GPI-APs: the amphiphilic nature of the GPIs and 
presence of different functional groups with different stabilities and with different charges. 
These problems have been reported and recognized by other groups working towards the 
semi-synthesis of GPI-APs. Paulick et al. (2007)
137
 reported problems with ionization of their 
eGFP-GPI product in ESI-MS. The hydrolyzed side product GFP-OH ionized primarily and 
suppressed other ions (such as the desired product). MALDI-TOF was reported to give better 
results, however. Wu et al. (2013)
140
 were not able to acquire mass spectra of their obtained 
eGFP-GPI-products using SrtA, and claimed this was due to the lipid chains and phosphate 
groups present, referring to Harvey (2003).
179
 Generally, characterization of GPIs is a topic 
scarcely addressed so far. Harvey (2017)
180
 reports a few examples of the analysis of 
glycolipids in MALDI-TOF, referring mainly to GIPCs. GPIs were barely mentioned also in 
this extensive review on mass spectrometry of post-translationally modified proteins of all 
kinds.  
Considering the work reported in the field of GPI-AP semi-synthesis (see section 1.2.3), it 
becomes clear that basically none of the groups achieved both successful generation of the 
products and complete characterization, displaying the difficulty of this undertaking. 




This work is no exception in this regard, although significant progress has been made in the 
ionization of the products and the formation of the Npu
C
-mGPI. For this  39 amino acid 
peptide Npu
C
 ligated to a GPI-anchor bearing one lipid chain and two phosphate linkages, 
after long optimization and many efforts, it was possible to obtain decent mass spectra, even 
though this product was not present in very large amounts. Earlier studies performed by other 
groups often involved very small peptides (such as dipeptides) and/or very simple GPI-




mimics (such as dimannose or even peptidomimics). Complete characterization of the 
generated eGFP-GPI constructs still remains elusive, and the final GPI-bearing products, 
could successfully be detected in ESI-MS.  
A big limitation during this work was, however, the availability of the different 
characterization methods at any given time, as the MTG4 antibody was unfortunately never 
available at the same time with an appropriate MS system and therefore both methods could 
not be used for cross-validation.  
 
 Structural Studies 4.6
Only a few studies have evaluated the role of glypiation in the structure of proteins. 
Interestingly, there are various reports in literature claiming both the presence and the absence 
of a structural effect of GPI-anchoring for different proteins. Becker et al. (2008) found no 
structural difference between their generated PrP-mGPI and PrP alone, according to CD 
analysis.
131




Using the ligation products with eGFP obtained by the different strategies, preliminary 
structural studies with and without GPI-anchors were performed using circular dichroism. As 
expected, no structural change was observed for eGFP as it is an intrinsically very stable 
protein having its C-terminus exposed at one end of the typical β-barrel structure and 
therefore easily accessible for manipulation.
171,181
 This was true for both EPL and OPL 
(samples from PTS could not be analyzed due to a lack of sufficient material), demonstrating 
the potential of these two strategies, especially the use of OPL for the modification of folded 
proteins without further manipulation of the ligation products other than purification.  
For the naturally GPI-anchored proteins is was not possible to perform CD-measurements as 
all of them were only obtained in insoluble form, or not in sufficient amounts for its refolding  
and for further structural studies.  









5 Conclusion and Outlook 
 Conclusion  5.1
There is still a lack of methods for the efficient generation of pure, homogeneous GPI-
anchored proteins for structural and functional studies.
34
 Recently, enormous progress has 
been made in the total synthesis of GPIs, however the generation of GPI-anchored peptides 
and proteins is still a big challenge. As revealed in section 1.2.3, there are only a handful of 
groups active in this field and some of them are not using native or complete GPI-anchors for 
attachment to the proteins.  
Generally, purely biological methods have either evolved over a long period of time in 
nature, or utilize such systems in vitro, making them very robust. They are, however, not 
always selective. Chemical Protein Synthesis can offer advantages over these methods 
regarding the site-specific installation of PTMs and has been the method of choice to 
investigate post-translational modifications on proteins because it yields more homogeneous 
products for the analysis of structure-function and activity relationships.
182
 Strategies using 
semi-synthesis are emerging as an excellent possibility to extend the accessibility of all kinds 
of natural or unnatural modifications in a site-specific manner towards large proteins. These 
strategies are derived from pure chemical synthesis with the prospect to access proteins of any 
size, which is only possible by using (recombinant) expression in living systems. There are 
good examples of successful application of these combined methods, but semi-synthesis also 
presents some drawbacks, especially regarding the yields that are obtained.  
The aim of this work was to generate large naturally glypiated protein by semi-synthetic 
methods. For this, initially two strategies were investigated using eGFP as a convenient model 
protein, i.e. Expressed Protein Ligation (EPL) and Protein Trans-Splicing (PTS). Both 
methods were successfully established for eGFP, together with the methods to characterize 
the reaction products. The implementation of the strategies, however, developed to an even 
bigger challenge than the semi-synthetic methods themselves, as direct detection (i.e. mass 
spectrometry and LC-MS) to characterize the highly complex protein-carbohydrate-lipid 
conjugates with additional phosphate linkages is not trivial. When comparing these results to 
reported methods (see sections 1.2.3 and 4.5), different improvements were established 
towards this goal in this work.  
 





When glypiation of other, more relevant proteins was investigated using the EPL and PTS 
strategies (i.e. Thy-1, PrP and IL-2), it became obvious during the expression of the proteins 
and the first attempts to obtain the desired products, that for these insolubly expressed 
proteins, the success from eGFP is not fully transferrable, especially for EPL. The formation 
of protein thioesters was difficult under denaturing conditions and only low yields were 
achieved. After optimizing the conditions to obtain these proteins in solution, purification of 
the protein thioesters was necessary, which turned out to be difficult as well. Additionally, 
protein thioesters were found to be unstable and prone to hydrolysis, making additional steps 
(such as purification) undesirable. PTS represented a more reliable method also for insoluble 
proteins; however this strategy suffered from the high synthetic effort required to obtain the 
precursor of the ligation reaction, especially the glypiated Npu
C
 peptide was a major problem.  
Therefore, OPL was devised to overcome these limitations, combining the easier setup from 
EPL with the superior robustness and speed from PTS. Indeed, the synthetic effort required 
was less than for PTS as the mutated Npu
C
 peptide was easier to synthesize and no thioester 
generation and ligation was required. The reaction rates in OPL were found to be intermediate 
in between those of EPL and PTS. Kinetic studies performed on this strategy revealed that the 
in situ protein thioester formation is indeed a very fast process, resulting from the properties 
of the ultrafast Npu split intein. The following in situ EPL reaction was the rate-limiting step. 
The low rates in this second step resulted in some hydrolysis of the thioesters, even though 
they did not need to be purified or manipulated in any other way. The use of thiols balancing 
reactivity and stability helped in overcoming this limitation. Therefore OPL is a promising 
tool for the semi-synthesis of GPI-anchored proteins for structural and biological studies.  
 
 Outlook  5.2
Two main limitations were observed during this dissertation project: the challenging 
detection of GPI-APs and the generation of these molecules in amounts big enough for further 
studies towards elucidation of the actual function of the GPI-anchor on the proteins. Some 
initial studies in this direction have been performed by comparing the secondary structure of 
the glypiated proteins by circular dichroism. However, this was only possible for eGFP and 
should be pursued for the other proteins, especially for proteins which are naturally glypiated. 
Therefore, it will be necessary to increase the amount of GPI-APs accessible by the presented 




methods and as the next step, to refold the insolubly expressed proteins. Also in this direction 
some initial studies have been performed in this work, but have not been pursued further due 
to a lack of time.  
It was found that the his-tag represents a more reliable means of purification than the strep-
tag at least for the fusion proteins used in the PTS and OPL strategies. Also, the C-terminal 
attachment of the his-tag (on the C-terminus of the intein fusion) is superior over the N-
terminal position, since this facilitates a more elegant and straight-forward possibility to 
separate reacted and unreacted proteins, as well as the cleaved Npu
N
 fragment.  
 
As a next step, further studies can be envisioned in which the generated GPI-APs are 
incubated with cell cultures (i.e. T-cell cultures) to study the effect of the GPI-anchor in their 
activation (for example via cytokine release). Due to their intrinsic fluorescence, the 
generated eGFP-GPI products can also be used for insertion into liposomes to perform 
localization studies and to investigate the behavior of these molecules in their natural 
environment, such as the formation of lipid rafts.   
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Figure 7.1. Plasmid map of commercially available pTXB1 vector (NEB).  
 
 PrP-Mxe-CBD 7.1.4

































































































 Additional Data on Characterization of Peptides and 7.2
Proteins 
 NpuC peptides 7.2.1
a      b 




Figure 7.2. Characterization of Npu
C
(AA). a) RP-HPLC chromatogram of purified Npu
C
(AA). LC 











0.1% TFA in 30 min. Flow rate 0.5 mL/min. b) MALDI-TOF spectrum of Npu
C
(AA) , DHB was used as matrix, 




calc: 4,353.2. c) Chromatogram (Waters BEH C18 1.7 µm, 
50 x 2.1 mm, 5 – 70 % acetonitrile with 0.1%FA in water with 0.1% FA, 0.3 mL/min) and spectrum of the main 









Figure 7.3 MALDI-TOF-MS analysis of  Npu
C
-biotin. DHB was used as matrix, mass spectrum was 








Figure 7.4. MALDI-TOF mass spectrum of eGFP-MMBA-thioester. DHB was used as matrix, mass 
spectrum was acquired in linear positive mode. [M+H]
+
calc = 27,145.5 Da, [M+H]
+
obs = 27,068.141 m/z.  






Figure 7.5. Raw and deconvoluted ESI mass spectra for eGFP-MMBA-thioester. [M+H]
+
calc = 27,145.5 
Da, [M+H]+obs = 27,142.46 m/z The eGFP-thioester eluted from chitin resin was analyzed using a Phenomenex 
Jupiter C4 column (50 x 2.1 mm) with a gradient from 10 – 70% acetonitrile in water (0.1% FA in both eluents) 
in 30 min. The sample was analyzed using ESI-QTOF. At tR=19.6 min, the given mass spectrum was recorded. 
This spectrum was deconvoluted using Biopharmalynx software. The resulting deconvoluted mass is 













Figure 7.6. Additional data on EPL eGFP-dimannose: hydrolyzed side product Raw and deconvoluted 
mass spectra of tR=18.1 min: [M+H]
+
obs=26,974.17, corresponding to the hydrolyzed  side product eGFP-OH, 
[M+H]
+





Figure 7.7. Growth curves of the test expression of Thy-1-Mxe-CDB fusion protein in E. coli BL21 (DE3) 
Star and Rosetta cells. All cells were inoculated to a starting OD600 of 0.05. OD was measured frequently until 
late exponential phase was reached (OD 0.6-0.8). At this point the temperature was changed to 15°C or 30°C, 
















BL21 (DE3) Star, 30°C
Rosetta, 30°C












a – BL21 (DE3) Star    b - Rosetta 
      
Figure 7.8. Expression test for Thy-1-Mxe-CBD fusion protein in E. coli BL21 (DE3) Star (a) and 
Rosetta cells (b). The expression was checked using SDS-PAGE. M – Molecular weight marker, 1 – pre 
induction, 2 – 5 – 0.2 mM IPTG induction 1/2/3/24 h, 6 – 9 – 0.4 mM IPTG induction 1/2/3/24 h, 10 – 13 – 1 
mM IPTG induction 1/2/3/24 h. Expected size = 41.2 kDa.  
 
 
Figure 7.9. Solubility check of the Thy-1-Mxe-CDB fusion protein using SDS-PAGE. Samples from 
expression tests at 15°C, 0.4 mM IPTG and 30°C, 0.2 mM IPTG were lysed and centrifuged. M – Molecular 
weight marker, 1 – 15°C, 0.4 mM IPTG, insoluble fraction, 2 – 15°C, 0.4 mM IPTG, soluble fraction, 3 – 30°C, 
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Figure 7.10. Characterization of eGFP-Npu
N
 fusion protein. a) RP-HPLC, b) LC-ESI-MS, raw and 












 hydrazide. M – Molecular weight marker, 1 – NpuC hydrazide, 2 – eGFP-NpuN, 3 – 1 mM TCEP, 
RT, 30 min, 4 – 1 mM TCEP, RT, o/n, 5 – 1 mM TCEP, 37°C, 30 min, 6 – 1 mM TCEP, 37°C, o/n, 7 – 2 mM 
TCEP, RT, 30 min, 8 – 2 mM TCEP, RT, o/n, 9 – 2 mM TCEP, 37°C, 30 min, 10 – 2 mM TCEP, 37°C, o/n, 11 
– 5 mM TCEP, RT, 30 min, 12 – 5 mM TCEP, RT, o/n, 13 – 5 mM TCEP, 37°C, 30 min, 14 – 5 mM TCEP. 
37°C, o/n, 15 – 10 mM TCEP, RT, 30 min, 16 – 10 mM TCEP, RT, o/n, 17 – 10 mM TCEP, 37°C, 30 min, 18 – 
10 mM TCEP, 37°C, o/n, 19 - eGFP-Npu
N
, 20 – 75 µM TCEP (i.e. 5 eq.), 37°C, o/n, 21 – 250 µM TCEP (5 eq. 
















. M  - Molecular 
weight marker, 1 – eGFP-NpuN, 2 – NpuC hydrazide, 3 – PTS with 2.3 eq. of peptide, 1 h, 4 – 2.3 eq. peptide, 
o/n, 5 – 1.5 eq. peptide, 1 h, 6 – 1.5 eq. peptide, o/n, 7 – 1.1 eq. peptide, 1 h, 8 – 1.1 eq. peptide, o/n.  
 
Figure 7.13. Analysis of strep-tag purified eGFP-biotin by RP-HPLC (C4).  
a b 
  
Figure 7.14. Triton separation of (a) eGFP-mGPI and (b) eGFP-bGPI. Detection was performed using 
MTG5 anti-GPI antibody, however, this clone gave a signal also for the eGFP fusion protein. A) M – Molecular 
weight marker, 1 – eGFP-NpuN, 2 – OPL eGFP-mGPI 4 d, 3 – aqueous phase, 4 – detergent phase. B) M – 
Molecular weight marker, 1 – separation 1, aqueous phase, 2 – separation 1, detergent phase, 3 – eGFP-bGPI 
SEC purified, 4 – separation 2, aqueous phase, 5 – separation 2, detergent phase.  






a    Rosetta, 30°C                              37°C                b                            BL21 (DE3) Star, 30°C 
 
c         37°C                                               d-Rosetta, 25°C           BL21 (DE3) Star 25°C 
       
Figure 7.15. Expression tests for Thy-1-Npu
N
 analyzed in SDS-PAGE. Sample amounts were normalized 
to the OD600. a) M – Molecular weight marker, 1 – Rosetta 30°C, pre induction, 2, 3, 4 – 0.2 mM IPTG, 1, 2, 24 
h, 5, 6, 7 – 0.5 mM IPTG, 1, 2, 24 h, 8, 9, 10 – 1 mM IPTG, 1, 2, 24 h, 11 – Rosetta 37°C, pre induction, 12, 13, 
14 – 0.2 mM IPTG, 1, 2, 24 h, b) 1, 2, 3 – 0.5 mM IPTG, 1, 2, 24 h, 4, 5, 6 – 1 mM IPTG, 1, 2, 24 h, 7 – BL21 
(DE3) Star 30°C, pre induction, 8, 9, 10 – 0.2 mM IPTG, 1, 2, 24 h, 11, 12, 13 – 0.5 mM IPTG, 1, 2, 24 h, c) 1 – 
BL21 (DE3) Star, 37°C, pre induction, 2, 3 – 0.2 mM IPTG, 2, 24 h, 4, 5 – 0.5 mM IPTG, 2, 24 h, 6, 7 – 1 mM 
IPTG, 2, 24 h, d) 1 – Rosetta, pre induction, 2, 3 – Rosetta 0.2 mM IPTG, 3, 24 h, 4, 5 – Rosetta 0.5 mM IPTG, 
3, 24 h, 6, 7 – Rosetta 1 mM IPTG, 3, 24 h, 8 – BL21 (DE3) Star, pre induction, 9, 10, 0.2 mM IPTG, 3, 24 h, 
11, 12 – 0.5 mM IPTG, 3, 24 h, 13, 14 – 1 mM IPTG, 3, 24 h. Expression in Rosetta clone is better than in BL21 
(DE3) Star clone; at 37°C there is almost no expression, the best expression was found with 30°C, 0.5 mM 
IPTG, 24 h induction; 25°C with 1 mM and 3 – 24 h looks also good.  






Figure 7.16. Solubility check of Thy-1-Npu
N
 fusion protein in Rosetta using SDS-PAGE and western 
blot. For detection an anti-his-tag antibody (mouse) was used in 1:5,000 dilution in 5% BSA in PBS-T 
(incubation 1 h at room temperature) and a secondary antibody anti-mouse IgG-HRP conjugate (1:10,000 in 5% 
BSA in PBS-T, 20 min at room temperature).  The fusion protein was found only in the total fraction but not in 
the soluble fraction, indicating that it was expressed insolubly. M – Molecular weight marker, 1 – 30°C, total 
lysate, 2 – 30°C, soluble fraction, 3 – 25°C, total, 4 – 25°C, soluble fraction.  
 









Figure 7.17. Characterization of Thy-1-Npu
N
 fusion protein by mass spectrometry. a) MALDI-TOF-MS, 




obs=25,222.9 m/z. b) 
Raw and deconvoluted spectra from LC-ESI-MS analysis. Waters BEH C4 UPLC column (50 x 2.1 mm, 1.7 
µm) on Waters Acquity H-Class UPLC with Waters Xevo G2-Xs mass spectrometer, gradient 10 – 70% ACN 
with 0.1% FA in water with 0.1% FA in 30 min, flow rate 0.5 mL/min, ES
+

















Figure 7.18. Solubility test of Thy-1-Npu
N
 in different common buffers for HIC. M – Molecular weight 
marker, 1 – 1.8 M ammonium sulfate, 2 – 1.5 M ammonium sulfate, 3 – 1 M ammonium sulfate, 4 – 4 M NaCl, 
5 – 3 M NaCl, 6 – 1 M sodium sulfate, 7 – sodium sulfate saturated, 8 – PTS buffer + 6 M urea (control). 
Unfortunately, the fusion protein did not remain soluble in any HIC buffer tested. Therefore, HIC could not be 
applied for purification.  
 
 
Figure 7.19. PTS Thy-1-biotin. M – Molecular weight marker, 1 – Thy-1-NpuN, 2 – PTS reaction Thy-1-
biotin (3 days).  
 
 
Figure 7.20. OPL reaction over a prolonged time. M – Marker, 1 – Thy1-NpuN, 2 – OPL 1 d, 3 – OPL 3 d, 
4 – OPL 6 d. 58% after 3 d, no increase after 6 d.  










 fusion protein provided by Prof. Christian Becker, University of Vienna, analysis 




obs=29,297 Da: Arg adduct due to 
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